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General Introduction
LEUKEMIA
The highly coordinated process of blood cell development and homeostasis, termed 
hematopoiesis, is essential for the development and survival of a normal individual. 
Normal hematopoiesis takes place in the bone marrow (BM), where primitive 
hematopoietic stem cells (HSC) are located. HSC usually are in a quiescent stage but 
have the potential to undergo polarized division to form new blood cells belonging to 
different cell lineages. One of the daughter cells retains the lifelong capacity for self-
renewal and the omnipotence of the mother cell. The other daughter cell differentiates 
into a primitive progenitor cell that is able to further divide and differentiate into 
progeny belonging to one of the hematopoietic lineages, including red blood cells, 
platelets, and a variety of lymphoid and myeloid cells (Figure 1.1). 1-3
Ultimately, terminally differentiated cells are produced that cannot divide and undergo 
apoptosis after a period of time ranging from hrs (neutrophils) to years (memory 
B and T lymphocytes). However, if one or more transformations occur at any stage of 
the differentiation process, this may lead to uncontrolled proliferation of a malignant 
cell population that is arrested in its maturation. When these malignant cells 
accumulate in the blood it is known as leukemia. Due to accumulation of leukemic 
cells in the BM, the production of red blood cells, platelets, and normal leukocytes is 
Figure 1.1 Normal human hematopoiesis.
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hampered. If untreated, the surplus leukemic cells overwhelm the bone marrow, enter 
the bloodstream, and eventually invade other parts of the body, such as the lymph 
nodes, spleen, liver, and central nervous system (brain, spinal cord). 
Several types of leukemia exist, depending on the maturation state and the lineage 
commitment of the malignant clone. The most common types of leukemia are acute 
myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid 
leukemia (CML), and chronic lymphocytic leukemia (CLL).
Treatment of leukemia
Because of the different nature of the disease, patients with acute leukemia are 
treated differently from patients with chronic leukemia. Therapy frequently consists 
of a combination of different cytostatic agents. If patients receive high-dose 
chemotherapy and total body irradiation, stem cell transplantation (SCT) is required 
to achieve immunologic reconstitution in these patients. In addition, donor T cells 
from the transplant may cause a beneﬁcial graft-versus-leukemia (GVL) effect. 
Acute leukemia
Acute leukemia is characterized by aggressive outgrowth of immature blasts 
committed to the myeloid (AML) or lymphoid lineage (ALL). Accumulation of these 
cells in the BM, but later on also in the blood compartment, leads to replacement of 
normal hematopoiesis.
Treatment regimens of acute leukemia generally involve separate phases. Induction 
chemotherapy consists of the administration of a combination of chemotherapeutic 
agents, such as anthracyclines (doxorubicin, daunorubicin), methotrexate, and 
cytarabine (Ara-C), 4-6 leading to reduction of proliferating hematopoietic cells (both 
malignant and benign) from BM and blood, and aiming at obtaining a remission. 
Due to their quiescent state, HSC are saved from chemotherapy-induced cell death, 
which allows repopulation of the marrow with normal cells after therapy. A complete 
remission (CR) requires normalization of the BM (<5% marrow blasts) and recovery 
of cell counts in the peripheral blood (neutrophil count of ≥ 1 x 109/L, platelet count 
of ≥ 100 x 109/L). A partial response (PR) is achieved when blood count recovery is 
similar to a CR, but with the persistence of 6% to 25% bone marrow blasts. 
Once remission is achieved, intensive consolidation therapy is required to destroy the 
low levels of remaining leukemic cells, known as minimal residual disease (MRD), 
hence making long-term disease-free survival (DFS) possible. 
Despite aggressive induction and consolidation therapy, the overall 5-year survival 
rates of patients with AML and ALL are low mainly due to the high incidence of relapses 
of the leukemia (50-60%). 7 In AML, long-term survival occurs in approximately 30% 
of younger adults, compared to only 5-15% long-term DFS in adults over the age of 
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60 years. 8-11 In ALL, the cure rate in children is 70-75%,12 whereas only 30-40% long 
term survivors in adults have been reported. 13
Chronic leukemia
Chronic leukemia can be subdivided in CLL and CML, which are two completely 
different disorders. CLL is an indolent malignancy, characterized by slow but 
progressive expansion of a leukemic lymphoid clone with a prolonged life span 
(>1 year) due to decreased apoptosis, resulting in the accumulation of immature 
leukemia cells in bone marrow, blood, spleen, liver and lymph nodes. Because 
of the indolent progression of the disease, the incurability of the disease, and the 
relatively high age of the majority of patients, many CLL patients initially do not 
receive therapy. Currently the decision to treat patients is based on multiple factors 
including advanced clinical staging (Rai-Binet), symptomatic disease, disease activity 
(lymphocyte doubling time), patient age, and probably in the near future the presence 
of unfavorable prognostic factors such as ZAP-70 expression, unmutated variable 
heavy chain immunoglobulin (IgVH) status and some genetic aberrations. 
14-18 Therapy 
regimens frequently consist of different combinations of chlorambucil, ﬂudarabine, 
cyclophosphamide and rituximab. 19-21 Rituxumab is a genetically engineered mouse-
human chimeric monoclonal antibody directed against the human B-cell-restricted 
cell surface antigen CD20, which induces apoptosis by complement-dependent and 
antibody-dependent cell-mediated cytotoxicity. 22-24
CML is caused by a reciprocal t(9;22)(q34;q11) translocation in HSC. In the t(9;22) 
translocation, a major part of the ABL proto-oncogene, including the catalytic domain, 
is translocated onto the BCR region of chromosome 22, giving rise to the oncogenic 
bcr/abl fusion protein. 25 Treatment of CML in chronic phase (CML-CP) is aimed at 
inhibiting the effects of this translocation. Imatinib mesylate (Gleevec) is a compound 
designed to speciﬁcally inhibit the kinase activity of the bcr/abl fusion product. 26 In 
newly-diagnosed CML-CP patients imatinib showed signiﬁcantly higher major and 
complete cytogenetic responses (90 and 82% respectively) when compared with 
the formerly used treatment regimen consisting of IFN-α and Ara-C (35 and 15% 
respectively). 27 
Although chronic phase CML can be relatively indolent, progression to accelerated 
phase CML (CML-AP) or blastic phase (CML-BP) is imminent. CML-BP can be of 
myeloid, lymphoid or other hematopoietic lineage. Clinically, CML-BP progresses 
with similarly aggressive kinetics as AML or ALL. CML-AP and CML-BP are usually 
treated as an acute leukemia, but the results of this treatment are extremely poor.
Allogeneic stem cell transplantation and donor lymphocyte infusions 
SCT can be considered as a rescue procedure to achieve immunologic reconstitution 
in patients of whom both malignant and normal hematopoiesis were destroyed by high-
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dose chemotherapy and total body irradiation. SCT can be classiﬁed as autologous 
or allogeneic, based on the origin of the HSC. Autologous SCT is a procedure in 
which a patient’s own HSC, which were removed from the BM before initiation of 
intensive treatment regimens, are infused. A disadvantage of this type of transplant is 
that it is very difﬁcult to guarantee that normal stem cells have been separated from 
leukemic cells, even after in vitro treatment with drugs, immunologic agents, or other 
methods to kill or remove leukemic cells. 
Allogeneic SCT is a form of transplant in which the stem cells are gathered from a HLA-
identical healthy donor, which may be a relative (brother, sister, child) or a matched 
unrelated donor. Besides causing immunologic reconstitution, allogeneic SCT is also 
an effective anti-leukemic therapy, since donor T cells in the graft may recognize and 
attack the residual leukemic cells resulting in the possible generation of a GVL effect. 
However, besides the beneﬁcial effect of allogeneic SCT, several disadvantages 
of this therapy exist including the potential failure of engraftment, organ toxicities 
caused by graft-versus-host disease (GVHD) and prolonged immunosuppression 
with its concomitant risks of post-SCT infectious complications.
Nonmyeloablative or reduced-intensity SCT relies upon the GVL effect of the allograft 
rather than the direct tumoricidal activity of the conditioning regimen. This regimen 
results in a shortened duration of cytopenia and a minimal mucosal toxicity, providing 
a reasonably safe transplant option for patients 20 years older than the population 
usually treated with traditional fully ablative high-dose chemotherapy regimens.
Many studies showed that the beneﬁcial GVL reactivity observed after allogeneic 
SCT was induced by donor T cells in the graft. 28-30 In patients with a relapse of their 
leukemia after allogeneic SCT, the GVL effect of donor T cells can be utilized by 
administration of single or multiple doses of lymphocytes from the original stem cell 
donor. The curative effect of donor lymphocyte infusions (DLI) was ﬁrst reported in 
patients with relapsed CML. 31  DLI demonstrated to have curative potential in many 
hematopoietic malignancies, but the efﬁcacy of DLI varied depending on the nature 
of the disease. 32 In CML-CP, DLI was highly successful showing complete molecular 
remissions in 70-80% of the treated patients. 32-35 In contrast, DLI was less effective in 
patients with more aggressively proliferating diseases like CML-AP, CML-BP, AML and 
ALL showing remission rates of 33%, 17%, 15-29% and 0-13%, respectively. 32;33;36-38 
Following HLA-identical SCT or DLI, allogeneic T cells recognizing minor 
histocompatibility antigens (mHags) are thought to be mainly responsible for the 
observed clinical immune response. MHags are immunogenic polymorphic peptides 
derived from genetically polymorphic intracellular proteins that may differ between 
donor and recipient. A number of mHags have been identiﬁed till now 39 including 
the hematopoiesis-speciﬁc mHags HA-1 and HA-2. 40 HA-1 and HA-2 speciﬁc T cells 
have been shown to contribute to the clinical response observed after DLI. 41;42
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Mechanisms of action of frequently used therapies 
Chemotherapy and cellular immunotherapy induce different mechanisms in the target 
cell eventually leading to the death of the target cell. 
Chemotherapy
For many cytostatic agents used for the treatment of leukemia speciﬁc mechanisms 
of action have been presumed. The broadly used chemotherapeutic agent Ara-C, a 
pyrimidine analogue of deoxycytidine (dC), enters the cells in its nucleoside form by 
passive diffusion, and is then converted by a series of cellular enzymes to the active 
metabolite Ara-C triphosphate (Ara-CTP). In proliferating cells, Ara-CTP competes 
with the natural nucleoside triphosphate dCTP for incorporation into replicating DNA. 43
This incorporation causes termination of the daughter strand DNA synthesis at 
the sites of drug incorporation. Furthermore, Ara-C inhibits DNA repair by blocking 
topoisomerase I-mediated DNA religation. 44 
Purine analogues like ﬂudarabine (F-Ara-A) and cladribine (2-CdA) have been 
reported to inhibit DNA polymerase and ribonucleotide reductase. 45
One of the expected mechanisms of action of anthracyclines like daunorubicin is 
intercalation of the anthracycline between adjacent base pairs of the double helix of 
DNA causing inhibition of DNA transcription and replication due to the formation of 
DNA breaks. 46 Anthracyclines can also inhibit DNA helicases 47 or interact with DNA 
topisomerase II, 48;49 blocking optimal DNA unwinding and strand segregation during 
DNA transcription and translation. 
All these chemotherapeutic agents are supposed to exert their action preferably 
in cycling cells. 50-52 In line with this, a substantial number of leukemic blasts and 
leukemic precursor cells which are in dormant G0-phase of the cell cycle escape from 
treatment with these drugs. 53 However, also examples can be given that contradict 
this assumption. Firstly, whereas HSC are indeed saved from chemotherapy-induced 
cell death, quiescent (G0) lymphocytes in peripheral blood are easily killed by 
chemotherapeutic treatment. Secondly, although the brains mainly consist of cells in 
resting phase of the cell cycle, which are expected to be insensitive to chemotherapeutic 
treatment, cerebral cytotoxicity is a rare complication of chemotherapy treatment. 
Finally, CLL can be effectively treated with ﬂudarabine, an agent mainly acting by 
inhibiting DNA synthesis, which seems to be an irrelevant mechanism of killing resting 
CLL cells. How all these discrepancies must be explained is not clear.
Most chemotherapeutic agents have been reported to kill leukemic target cells via 
activation of apoptosis pathways. 45;54;55 The apoptotic pathways that are thought to 
be induced after treatment with chemotherapy are described in more detail in the next 
paragraph (Figure 1.4).
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DNA fragmentation became evident in leukemic cells 6 hrs after exposure to 
Ara-C and other anti-cancer agents. 56-59 It seems to be unlikely that inhibition of 
DNA synthesis occurs within 6 hrs of incubation suggesting that other mechanisms 
of action may be involved in Ara-C-induced apoptosis. Conversely, although ﬁrst 
apoptotic signals are already visible after 6 hrs of exposure to Ara-C, in many cells 
eventual cell death can only be observed after 24 to 48 hrs of incubation, which 
corresponds to the time required for incorporation of Ara-C into DNA.
Cellular Immunotherapy
The allogeneic antileukemic activity of DLI and HSCT is mainly caused by donor-
derived natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). These killer 
lymphocytes can mediate target cell death using two different effector mechanisms: 
granule-mediated cell death and death receptor-mediated apoptosis. 60 Cytotoxic 
granules consist of the pore-forming protein perforin (PFN) and various granzymes, of 
which Granzyme B (GrB) is the most prominent member. High concentrations of PFN 
may cause pores in the target cell membrane, which may directly result in target cell 
death independent on an active apoptosis machinery (necrosis). Low concentrations 
of PFN enable the introduction of GrB, which in turn can activate different apoptotic 
cascades in the target cell. The role of the death-receptor pathway in CTL-induced 
tumor cell death remains to be further elucidated, as described in more detail in the 
next paragraph.
APOPTOSIS
Apoptosis is a general mechanism for removal of unwanted cells from the body, 
without causing inﬂammation, and is therefore essential during development and in 
the maintenance of tissue homeostasis. 61 Examples of processes of the immune 
system in which apoptosis plays an important role include the death of cells with 
short half-lives (neutrophils), 62 and the elimination of self-reactive T cells 63 and low 
responsive B cells in the germinal center. 64 Deregulation of apoptotic cell death can 
disrupt the delicate balance between cell proliferation and cell death and contributes 
to the pathogenesis of a number of human diseases including cancer, viral 
infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired 
immunodeﬁciency syndrome). 65-67
Characteristics of apoptosis
Two forms of cell death have been described in vertebrate tissues. 68 When cells 
die from severe and sudden injury, such as ischaemia, sustained hyperthermia 
or physical or chemical trauma, this is called necrosis or accidental cell death. 
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During necrosis there are early changes in mitochondrial shape and function, and 
the cell rapidly becomes unable to maintain homeostasis. The plasma membrane 
probably is the major site of damage: by losing its ability to regulate osmotic pressure, 
the cell swells and ruptures. The cell contents are lost in the surrounding tissue space 
and provoke an inﬂammatory response.
Apoptosis is a more subtle form of cell death, often called programmed cell death. 
Apoptosis refers to a series of morphological changes during cell death that are 
different from those seen in necrosis and which occur when cell death is physiologically 
determined or acceptable. Caspases play an important role in the apoptotic process. 
Initiator caspases are important regulators of apoptosis by inducing a signaling 
cascade, whereas effector caspases cleave various structural proteins resulting in 
an ordered disassembly of the cell. 
Morphology
Although the exact pattern changes from cell type to cell type, in general cells 
undergoing apoptosis are characterized by the morphological changes indicated in 
Figure 1.2 for a lymphocyte (adapted from Cohen 62). The various stages of apoptosis 
are best seen in isolated culture, since in vivo phagocytosis will intervene. 
Figure 1.2. Various stages of apoptosis in a lymphocyte (adapted from Cohen62).
(a) A normal cell has a sparse cytoplasm and heterogeneous nuclear chromatin, and cell volume is 
 about 90 fL.
(b) The cell looses some volume, and its cytoplasmic organelles are now tightly packed. There is clumping 
of chromatin. At this stage, membrane changes that can lead to phagocytosis such as exposure 
of phosphatidylserine at the cell surface are present. 69 Loss of membrane phospholipid asymmetry 
may be caused by changes in energy metabolism, bivalent cation concentrations or cytoskeleton 
organization. 70
(c) The cell exhibits zeiosis: the plasma membrane becomes rufﬂed and blebbed.
(d) The cell and nucleus shrink and the chromatin becomes very dense. The chromatin collapses into 
patches, and subsequently into crescents along the nuclear envelope. Cell volume is now about 
70 fL.
(e) The nucleus has collapsed into a black hole. 
(f) The collapsed nucleus frequently breaks up into several spheres. This change is often accompanied
 by fragmentation of the DNA into a ladder of regular subunits, which is the result of apparently
  random  double-stranded breaks in the linker regions between nucleosomal cores.71 Since there
  may be over a million of such breaks, this never can be repaired and cessation of transcription is
  imminent.
(g) Eventually, the cell fragments into membrane-enclosed apoptotic bodies.
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Regulation of apoptosis
Apoptosis is tightly regulated and orchestrated at the molecular level by pro-
apoptotic members of the caspase family including caspase-3, -6, -7, -8, -9 and -10. 
Caspases are synthesized in the cell as inactive precursors (zymogens) composed 
of three distinct domains: an N-terminal polypeptide or prodomain, a large subunit 
containing the active site cysteine with a conserved QACXG motif, and a C-terminal 
small subunit. Caspases show an unusual and absolute requirement for cleavage after 
aspartic acid (Asp) residues. 72 An aspartate cleavage site separates the prodomain 
from the large subunit, and an interdomain linker containing one or two aspartate 
cleavage sites separates the large and small subunits. 73 The presence of Asp at the 
maturation cleavage sites is consistent with the ability of caspases to auto-activate or 
to be activated by other caspases as a part of an ampliﬁcation cascade.
Caspases are activated to fully functional proteases by two cleavage events (see 
Figure 1.3). The ﬁrst proteolytic cleavage divides the chain into large and small 
caspase subunits via removal of the linker region, and a second cleavage removes 
the N-terminal prodomain. The active caspase is a tetramer of two large and two 
small subunits, with two active sites. 74-76 
Each active site is formed by sequences supplied by both the large and small subunits, 
providing amino acids necessary for substrate recognition and catalysis. Despite their 
shared requirement for cleavage after aspartic acid residues, caspases are highly 
speciﬁc in their substrate preferences. 77;78 Most caspase substrates can be divided 
into two general categories: (1) regulators of apoptosis which are either activated or 
inactivated by cleavage; and (2) housekeeping or structural proteins whose cleavage 
is required for the ordered disassembly of the cell.
The mammalian caspases have been divided into upstream (initiator) and downstream 
(effector) caspases based on their sites of action in the proteolytic caspase cascade. 
Initiator caspases (caspase-8, -9 and -10) function upstream of effector caspases 
Figure 1.3. Formation of an active caspase.
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as signaling molecules, whereas effector caspases (caspase-3, -6 and -7), which 
are mammalian homologues of the C. elegans CED-3 caspase, 79 account for the 
morphological features of apoptosis. 73;80 
In line with their function, initiator and effector caspases have different prodomains. 
Initiator caspases have long prodomains containing structurally related protein 
modules that physically link these proteases to their speciﬁc activators, hence 
enabling oligomerization of procaspases. Two types of interaction modules have 
been detected: death effector domains (DEDs) and caspase recruitment domains 
(CARDs). 80-82 Initiator caspases have substrate speciﬁcities that are similar to 
caspase recognition sites present in their own sequence, 78 implying that these 
caspases can utilize autocatalysis for activation. In contrast, effector caspases have 
small prodomains, and are activated via cleavage by initiator caspases or other, 
already activated, effector caspases.
Therapy and apoptosis
Apoptosis can be initiated by many different stimuli including chemotherapy and 
(cellular) immunotherapy. The different signaling cascades eventually leading to 
apoptosis that may be induced by the different forms of therapy against leukemia 
are summarized in Figure 1.4. Chemotherapy treatment may induce apoptosis via 
activation of the mitochondrial (intrinsic) pathway of apoptosis. In addition to the 
mitochondrial pathway of apoptosis, involvement of the death receptor pathway, 
also called extrinsic apoptotic pathway, in chemotherapy-induced apoptosis has 
been postulated by several investigators, after showing that several anti-cancer 
drugs induce upregulation of Fas receptor (FasR) and Fas ligand (FasL), followed 
by subsequent autocrine or paracrine induction of Fas-mediated apoptosis. 83-87 It is 
unclear whether both pathways are induced simultaneously or whether preferentially 
one of the two is activated. Moreover, the pathway of apoptosis likely depends on the 
nature of the target cells and the cytostatic agent used.
Cytotoxic lymphocytes may induce apoptosis of target cells both via release of 
granules containing perforin and granzyme B, and via activation of the death 
receptor pathway. Granule-mediated cell death has been reported to play an 
important role in the elimination of virus-infected cells and tumor cells. 88;89 In contrast, 
death receptor-mediated cell death has primarily been described to be involved in 
eliminating autoreactive T cells and downsize immune responses after infections. 90-93 
The involvement of the death receptor pathway in the elimination of tumor cells 
remains to be elucidated. 
Mitochondrial pathway
The mitochondria play an important role in the initiation of the intrinsic pathway of 
apoptosis, also called the mitochondrial pathway, by functioning as stress sensors 
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and determining the ‘point of no return’. Upon stress signals, as caused for instance 
by growth factor withdrawal, UV- or γ-irradiation, or chemotherapeutic agents, the 
permeability of the mitochondria is increased. This process is regulated by the B-cell 
lymphoma 2 (Bcl-2) family of proteins, containing both pro-apoptotic members such as 
Bcl-2 associated X protein (Bax) and Bcl-2 antagonist/killer (Bak), and anti-apoptotic 
members such as Bcl-2 and Bcl-XL. 
95;96 Bcl-2 and Bcl-XL reside on the mitochondrial 
outer membrane, while the pro-apoptotic family members may be either cytosolic or 
present on the mitochondrial membrane. 
Mitochondrial outer membrane permeabilization leads to the release of factors such 
as cytochrome C 97;98 from the mitochondrial intermembrane space into the cytosol. 
In the cytosol, cytochrome c binds to and induces oligomerization of apoptotic protease 
activating factor-1 (Apaf-1). 99 In the presence of ATP or dATP, Apaf-1 and procaspase-
9 associate via their CARDs which results in the formation of an “apoptosome” 
consisting of cytochrome c, Apaf-1, and pro-caspase 9.  In this heptameric complex 
caspase 9 is activated. 100;101 The apoptosome can then recruit procaspase-3, which 
is cleaved and activated by the active caspase-9. Active caspase-3 in turn cleaves 
various death substrates, eventually leading to disassembly of the cell. 102,103
Along with cytochrome c, two other proteins are released from the mitochondria during 
apoptosis: SMAC/DIABLO 104;105 and OMI 106. These proteins increase apoptosome 
function by inhibiting the inhibitor of apoptosis protein (IAP) family of caspase inhibitors 
Figure 1.4. Apoptotic pathways induced by chemotherapy or (cellular) immunotherapy (partly 
adapted from Siegel 94).
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and thus promoting caspase activation, as depicted in Figure 1.4.
Besides these relatively well-known pro- and anti-apoptotic proteins, mentioned in 
Figure 1.4, probably many other proteins are involved. Moreover, different apoptotic 
pathways may share similar components and in this way inﬂuence each other making 
the actual apoptotic mechanisms very complex.
Death receptor pathway
One of the alternative or additional pathways that may play a role in chemotherapy-
induced apoptosis is the death receptor pathway. The death receptor pathway is 
initiated when death ligands of the tumor necrosis factor (TNF) superfamily (FasL, 
TNF-α, TNF-related apoptosis inducing ligand (TRAIL)), bind to transmembrane 
proteins called death receptors present at the cell surface of the target cell. 
Upon extracellular triggering, trimerization of the death receptor occurs, and Fas 
Associated Death Domain (FADD) is recruited to the intracellular death domain (DD) 
of the death receptor, 80 followed by binding of pro-caspase 8, also called FADD-
like IL-1 converting enzyme (FLICE), to the DED of FADD. 107 In this complex of 
receptor-bound FADD with pro-caspase- 8, called the Death Inducing Signaling 
Complex (DISC), 108 procaspase-8 is proteolytically cleaved. The active caspase-8 
that is formed either directly cleaves effector caspases resulting in apoptosis without 
mitochondrial depolarization, or cleaves BH3-interacting-domain death agonist (Bid), 
a member of the pro-apoptotic Bcl2 family. Truncated Bid (tBid) relocalizes to the 
mitochondrial outer-membrane and activates the intrinsic pathway of apoptosis 
(see Figure 1.4). 109;110 111;112
Cellular caspase-8 (FLICE)-like inhibitory protein (cFLIP), which contains two DEDs 
and a non-catalytic pseudo-caspase domain, is also recruited to the DISC, where 
at high concentrations it can block caspase-8 activation (Figure 1.4). 113 At lower, 
and probably more physiological, concentrations cFLIP is thought to function as a 
scaffolding molecule that aids caspase-8 oligomerization and activation. 114;115
T-cell induced cell death
T cell receptors (TCR) of cytotoxic CD8+ T cells recognize a complex formed 
between class I Major Histocompatibility Complex (MHC) molecules and antigenic 
peptides, mainly derived from intracellular processing of endogenously synthesized 
proteins. 116;117
Binding of different peptides in different class I alleles is based on the length of the 
speciﬁc peptide and the presence of crucial anchor residues. 118;119 
Upon recognition of target antigen by membrane TCRs, CTLs can mediate target cell 
death potentially using two effector pathways. 60;120 Target cell death either occurs 
via TCR-triggered exocytosis of preformed cytotoxic granules or, alternatively, via 
activation of the death receptor pathway in the target cell. 60;89;121 PFN and granzymes 
are stored in the lytic granules of most CTLs. After speciﬁc interaction and recognition 
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of a target cell these granules are released, resulting in formation of pores in the 
cell membrane of the target cell. These pores themselves may either directly 
cause leakiness of the target cell resulting in necrosis, or enable the introduction of 
granzymes including GrB into the target cell. GrB in turn can activate different apoptotic 
cascades in the target cell (Figure 1.4). It directly cleaves effector caspases such as 
caspase-3, 122 or it activates the mitochondrial pathway via cleavage of Bid. 123 Although 
target cells can internalize GrB in the absence of PFN, sublytic concentrations of 
PFN are required to induce apoptosis. 124 The death receptor pathway is induced 
when apoptosis inducing ligands (FasL, TNF-α, TRAIL), expressed on the membrane 
of TCR-activated T cells, cross-link death receptors expressed on the target 
cells. 120;125 
Many factors likely affect the susceptibility of leukemic target cells to T cell-mediated 
cell death. The cell cycle status of the target cell is important, since resting cells are 
less sensitive to T-cell-mediated apoptosis. Furthermore, the strength of interaction 
between target and effector cell probably affects the kinetics of target cell death but 
may also inﬂuence the efﬁcacy of T-cell treatment, since not all effector mechanisms 
may be induced in case of weak effector-target interactions. The strength of interaction 
between effector and target is largely determined by the afﬁnity of the T cell receptor 
(TCR), the avidity of the MHC/TCR complex, and the expression of adhesion and 
costimulatory molecules on both leukemic and T cells. These and probably also other 
factors should be studied in more detail to improve the effectiveness of T cell-based 
immunotherapeutic interventions in patients with leukemia. 
Resistance to therapy-induced apoptosis
After occurrence of a relapse, many patients are unresponsive to further 
therapy. Moreover, some patients never reach a state of complete remission. 
Different mechanisms may underlie this resistance, including expression of drug 
efﬂux pumps by leukemic cells, 126-129 cell cycle status of the leukemic cell, and 
inability of leukemic cells to undergo apoptosis in response to therapy due to aberrant 
expression of (anti-) apoptosis proteins. Expression levels of proteins involved in the 
induction or inhibition of apoptosis have been described to contribute to the response 
against a variety of drugs used for the treatment of leukemia. 130-132 
The anti-apoptotic protein Bcl-2 133 is overexpressed in many cancers including 
CLL. 134 One of the mechanisms of Bcl-2 to inhibit apoptosis is prevention 
of cytochrome c release from the mitochondria. 135;136 For most cancers, the 
overexpression of Bcl-2 or Bcl-XL correlates with poor survival and progression of 
the disease. 137-141 One approach for targeting anti-apoptotic Bcl-2 proteins is by 
reducing their expression levels using anti-sense oligonucleotides. An antisense 
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oligonucleotide against BCL2, oblimersen, 142 has been in phase III clinical trials 
for melanoma, CLL and multiple myeloma, as well as in phase II clinical trials 
for other cancers. 143-145 So far, the clinical results are not very promising. 144;146 
Another important protein family that regulates apoptosis is the IAP family of proteins 
(see Figure 1.4). 147;148 XIAP, c-IAP1, and c-IAP2 bind to and inhibit active caspase-3 
and -7, and also procaspase-9, but not caspase-1, -6, -8 or -10. The XIAP protein is 
overexpressed in many cancers, and the expression of XIAP correlates with apoptotic 
resistance. Survivin 149 is not present in normal adult tissues but is overexpressed 
in many different tumors, and is important for tumor cell viability. 150 Many different 
strategies to inhibit these IAPs are currently developed.
Also overexpression of anti-apoptotic proteins that speciﬁcally cause resistance to 
immunotherapy like FLICE inhibitory protein (FLIP) and proteinase inhibitor-9 (PI-9) 
have been reported. FLIP is an enzymatically inactive homologue to caspase 8 and 
interacts with FADD, preventing pro-caspase 8 to bind to the death domain of the 
death receptors (see Figure 1.4). 151;152 Overexpression of FLIP by tumor cells was 
demonstrated to be an escape mechanism for malignant cells to survive CTL attack. 
153 PI-9 speciﬁcally binds to GrB and was shown to efﬁciently inhibit GrB-mediated 
apoptosis in both in vitro and in vivo studies. 154 
Besides elevated levels of anti-apoptotic proteins, also defects in pro-apoptotic 
molecules may cause resistance to chemotherapy, since functional blocks in 
caspase activation pathways in patients with leukemia have been correlated with 
poor clinical response to induction chemotherapy. 155 Moreover, downregulation of 
procaspase-8 expression caused resistance to doxorubicin-induced apoptosis in 
several malignancies. 156-158 Finally, recent patient studies showed that absence or 
low expression of FADD in cells from patients with AML is associated with resistance 
to chemotherapy treatment and poor clinical outcome. 159-161 Because both caspase-8
and FADD are involved in death-receptor-induced apoptosis, this suggests that 
at least part of the death-receptor signaling pathway is involved in resistance to 
chemotherapy.
AIM OF THE STUDY
Failure of therapy due to acquired resistance is still a main cause of death of patients 
with leukemia. Aberrations in apoptotic pathways in leukemic cells have been shown 
to contribute to unresponsiveness of leukemic cells to chemotherapy and may also 
be involved in decreased sensitivity of these cells to cellular immunotherapy. Before 
defects can be detected, the apoptotic pathways itself should be unraveled in more 
detail. Although general therapy-induced apoptotic pathways have been described 
(Figure 1.4), still many controversies exist which will be highlighted in this thesis. 
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The general scope of this thesis is to acquire more insight into the complexity of 
the apoptotic pathways that are induced in leukemic cells after treatment with 
conventional cytostatic drugs or with cytotoxic T cells. A better understanding of the 
apoptotic mechanisms itself and the factors that inﬂuence these pathways may help 
to improve treatment outcomes in patients with different types of leukemia. 
Cells in quiescent stage of the cell cycle have been reported to be unsusceptible 
to most chemotherapeutic drugs including Ara-C. However, resting lymphocytes in 
peripheral blood are destroyed by chemotherapeutic treatment. Chapter 2 describes 
a study in which G0 cells from patients with B-CLL were tested for their responsiveness 
to Ara-C, an agent considered to be S-phase-speciﬁc. CFSE-based cytotoxicity 
assays combined with cell cycle analysis were used to perform long-term analysis 
of Ara-C-mediated killing of B-CLL cells. We analyzed the mechanisms that were 
involved in Ara-C-mediated apoptosis of these B-CLL cells, focusing at the effect of 
Ara-C on DNA and RNA synthesis.
Chemotherapy-induced apoptosis leads to activation of the mitochondrial pathway 
of apoptosis, although involvement of the death receptor pathway has also been 
postulated by several investigators (Figure 1.4). In Chapter 3 we investigated 
in more detail the role of the death receptor pathway and caspase-8 activation in 
chemotherapy-induced apoptosis in patient-derived myeloid and lymphoblastic 
leukemia cell lines. For this purpose, we introduced retroviral constructs encoding the 
anti-apoptotic proteins Bcl-2 and FLIP into these leukemia cell lines, and examined 
the effect on chemotherapy-induced apoptosis and caspase-8 activation.
Although T cells often express all prerequisites for death receptor-mediated 
apoptosis, the contribution of this effector mechanism to T-cell-mediated cell death is 
still largely unclear. Chapter 4 addresses the role of the death receptor pathway in 
CTL-mediated cell death of human target cells. Since PFN/GrB-mediated apoptosis 
and death receptor-induced apoptosis differ in time required to eliminate target cells, 
lysis of target cells was analyzed using CTL clones with slow and rapid kinetics of 
killing derived from a patient with chronic myeloid leukemia (CML). To determine the 
involvement of the death receptor pathway, a retroviral construct encoding the anti-
apoptotic gene FLIP was introduced into these target cells, and the inhibitory effect of 
FLIP expression on CTL-induced target cell death was assessed. 
PI-9 is considered to be a speciﬁc inhibitor of granzyme B-induced cell death, and 
should therefore not affect Fas-induced apoptosis. In Chapter 5, a more basic analysis 
of the speciﬁcity of PI-9 is performed in which the inhibitory effect of enhanced PI-9 
expression on Fas-induced apoptosis is evaluated.
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Chapter 6 describes two distinct mechanisms of T-cell-mediated target cell death. 
We studied whether both mechanisms resulted in the production of IFN-γ by the 
T cell. Furthermore it was assessed whether these two forms of CTL-induced target 
cell death were induced via activation of different apoptotic pathways in the target 
cell.
Finally, in Chapter 7 the most important ﬁndings of this thesis are summarized. 
These data are compared with the general existing insights on apoptosis induction 
by chemotherapy and cellular immunotherapy. Finally, some suggestions are done 
on how these results may be applied for clinical applications. 
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ABSTRACT
Background and objective. Cytarabine (Ara-C) is commonly used for the treatment 
of acute leukemia. Incorporation of Ara-C into DNA is a key event in the mechanism 
of killing of proliferating leukemic cells. Previously, we demonstrated cytotoxicity of 
Ara-C to proliferating, but unresponsiveness to resting (G0) malignant cells from 
patients with acute leukemia. In contrast, here we show unexpected apoptosis of G0-
B-CLL cells by Ara-C in a dose dependent manner. In this study we analyzed which 
cellular processes were involved in Ara-C-mediated killing of G0-B-CLL cells. 
Experimental design. Using primary B-CLL cells (>98% in G0), we examined the 
mechanisms of Ara-C-mediated apoptosis in resting G0 cells. CFSE-based cytotoxicity 
assays combined with cell cycle analysis, were used to perform long-term analysis of 
Ara-C-mediated killing of B-CLL cells. The effect of Ara-C on DNA and RNA synthesis 
effects were studied using various 3H-incorporation experiments. 
Results. Ara-C-mediated cell death of B-CLL cells showed the characteristics of 
normal apoptosis, such as phosphatidyl serine exposure and caspase activation. 
The mechanism of killing of quiescent B-CLL cells by Ara-C was shown not to be 
dependent on DNA replication. In contrast, CD40L-activated B-CLL cells showed 
S-phase speciﬁc depletion of proliferating CLL cells. We demonstrated Ara-C to be 
converted into its active triphosphate by G0-B-CLL cells, coinciding with 30% inhibition 
of RNA synthesis. 
Conclusions. In conclusion, our data indicate that Ara-C can induce apoptosis in 
resting G0-B-CLL cells using a mechanism independent of cell proliferation and DNA 
replication but associated with inhibition of RNA synthesis and downregulation of 
Mcl-1.
INTRODUCTION
Ara-C, an analogue of deoxycytidine (dC), has been the most important compound 
in the chemotherapy regimens of patients with acute myeloid leukemia for 40 years. 
The close structural similarity of Ara-C with dC allows it to be metabolized by the 
same metabolic pathways as used for the normal processing of dC. 1 Cytarabine is 
transported into cells in its nucleoside form (Ara-C), and is then converted by a series 
of cellular enzymes to the triphosphate Ara-CTP, the active metabolite of cytarabine. 
In proliferating cells, Ara-CTP competes with the natural nucleoside triphosphate 
dCTP for incorporation into replicating DNA. This incorporation causes termination 
of the daughter strand DNA synthesis at the sites of drug incorporation. Furthermore, 
Ara-C inhibits DNA repair by blocking topoisomerase I-mediated DNA religation. 2 
Since the cytotoxicity of Ara-C is dependent on DNA synthesis, maximal effect of 
Ara-C on cell death is observed during the S-phase of the cell cycle. In line with this, 
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we previously demonstrated selective lysis of leukemic cells from patients with acute 
leukemia in active stage of the cell cycle, whereas G0 cells were unresponsive to 
several cytostatic agents including Ara-C. 3;4 
In contrast, here we show Ara-C-mediated cell death of resting cells derived from 
patients with chronic lymphocytic leukemia (CLL). CLL is an indolent malignancy, 
characterized by progressive expansion of a leukemic lymphoid clone, resulting in 
the accumulation of leukemia cells at the G0 quiescent stage of the cell cycle in bone 
marrow, blood, and other extramedullary sites such as spleen, liver and lymph nodes. 
There is only a small pool of proliferating cells, 5 as determined by the extremely low 
incorporation rate of 3H-thymidine by leukemic lymphocytes, 6 or by ﬂow cytometric 
analysis of newly synthesized DNA. 7 
Recently, nucleotide analogues like ﬂudarabine (F-Ara-A) have been introduced as 
front-line therapy in the treatment of CLL. 8 Since the incorporation of nucleotide 
analogues like ﬂudarabine and cytarabine (Ara-C) into DNA has been considered to 
be a key event in causing cytotoxicity in proliferating leukemic cells, we hypothesized 
that nucleotide analogues induce cell death of B-CLL cells by a different mechanism. 
Some studies already revealed that mechanisms of killing resting cells include 
inhibition of cellular DNA repair, inhibition of RNA synthesis, activation of pro-apoptotic 
proteins (Apaf-1), and downregulation of survival proteins (Bcl-2). 9;10
In this study, we analyzed which cellular processes were involved in Ara-C-mediated 
killing of B-CLL cells. We ﬁrst examined the relation between Ara-C-mediated 
apoptosis and the cell cycle status of the B-CLL cells using both quiescent and 
proliferating (CD40L-activated) B-CLL cells. Since we observed that different 
mechanisms were involved in Ara-C-mediated killing of G0-B-CLL cells compared 
to proliferating B-CLL cells, we studied whether Ara-C could be converted into 
Ara-CTP in quiescent B-CLL cells, a reaction essential for the cytotoxicity of Ara-C 
in proliferating cells. 2;11 Furthermore, the effect of Ara-C on RNA synthesis in G0-B-
CLL cells was investigated.  Finally, we analyzed whether Ara-C-mediated killing of 
G0-B-CLL cells was initiated via downregulation of survival proteins and dependent 
on caspase activation. In contrast to the mechanism of killing by Ara-C of proliferating 
leukemic cells, our results demonstrate that Ara-C-mediated killing of B-CLL cells 
is not dependent on cell proliferation and DNA incorporation, but probably requires 
Ara-CTP formation and may involve inhibition of RNA synthesis.
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MATERIALS AND METHODS
Cells and culture conditions
Peripheral blood was obtained from 4 CLL patients (3 female, 1 male) after informed consent. 
The materials we used were collected at times that patients had not received any form of therapy concerning 
their CLL, except one patient who was mildly treated with chlorambucil 2 years earlier. The percentage 
of CLL cells in peripheral blood samples was in all cases over 90% and these cells showed typical CLL 
characteristics including expression of CD19, CD5 and CD23. Mononuclear cells were separated by 
density centrifugation using Ficoll Isopaque, and either cryopreserved in liquid nitrogen or used directly 
for experiments. Isolated B-CLL cells were cultured at 37°C and 5% CO2 for a maximum of 10 days in 
IMDM supplemented with 3 mM L-glutamine, 50 µg/mL streptomycin, 50 U/mL penicillin (all Cambrex Bio 
Science, Verviers, Belgium), and 10% pooled human serum. To induce proliferation, B-CLL cells were 
cultured for 7 days on irradiated (70 Gy) CD40L-transduced mouse ﬁbroblasts 12 (LTK-CD40L; kindly 
provided by Dr. C. van Kooten, Department of Nephrology, Leiden University Medical Center). Irradiated 
LTK-CD40L cells were cultured overnight at 37°C and 5% CO2 in a 24 wells plate at a concentration of 
2 x 105 cells/well in IMDM supplemented with 10% fetal bovine serum (FBS, Cambrex), 3 mM L-glutamine, 
50 µg/mL streptomycin and 50 U/mL penicillin. After one day, the medium was removed, and B-CLL cells 
were added at a concentration of 1x106/mL/well, and cultured in the medium described for resting B-CLL 
cells, supplemented with 500 IU/mL IL-4 (Schering-Plough, Amsterdam, The Netherlands).
Reagents
Apoptosis was induced with the following agents: cytosine arabinoside (Ara-C), 9-β-D-arabinosyl-2-
ﬂuoradenine (ﬂudarabine) (both from Sigma-Aldrich, St. Louis, MO, USA), camptothecin (Alexis Corp., 
Lausanne, Switzerland), and as a negative control deoxycytidine (Sigma) was used.
Cytotoxicity assays
Cytotoxicity was measured using 24 or 40-hr 51Cr release assays as described previously 3 or using 
carboxyﬂuorescein diacetate succinimidyl ester (CFSE) -based cytotoxicity assays as described by Jedema 
et al., 13 with some alterations. Target cells were labeled with 5 µM CFSE (Molecular Probes Europe, 
Leiden, The Netherlands). For the cytotoxicity assay, 25,000 cells/well (100 µL) were plated in 96-well 
microtiter plates (all in triplicate). Ara-C (10-5 M) was added in a volume of 50 μL/well. After 24, 48, 72 and 
120 hrs, FACS analysis was performed. To exclude dead cells from the analysis, 7-amino-actinomycin D 
(7-AAD) (2 µg/mL ﬁnal concentration) or Propidium Iodide (PI) (1 µg/mL) (both Sigma-Aldrich) was added, 
and samples were mixed properly and directly analyzed on a ﬂowcytometer (Becton Dickinson (BD), 
San Jose, CA, USA). To allow quantitative analysis of the viable cells, the wells were harvested and 
transferred to FACS tubes containing 10,000 Flow-Count Fluorospheres (Coulter Corporation, Miami, FL, 
USA). This was done immediately prior to the analysis to avoid the formation of complexes between the 
cells and the beads. For each sample 5,000 microbeads were acquired, facilitating the calculation of 
absolute numbers of viable (7-AAD-/PI-) CFSE+ target cells. The percentage of speciﬁc lysis was calculated 
as follows: 
 [(mean absolute number of viable CFSE+ target cells in control medium - absolute number of viable CFSE+ 
target cells experimental) / (mean absolute number of viable CFSE+ target cells in control medium)] * 100. 
To determine the role of caspases in the induction of Ara-C-mediated cell death, CFSE-labeled B-CLL cells 
were pre-incubated for 2 hrs with 100 µM of irreversible cell-permeable broad-spectrum caspase inhibitor 
N-benzyloxycarbonyl-Val-Ala-Asp-ﬂuoromethylketone (z-VAD-FMK), caspase-3- (z-DEVD-FMK), caspase-
8 (z-LETD-FMK) or caspase-9 inhibitor (z-LEHD-FMK) (all Alexis) prior to apoptosis induction. After 48 hrs 
of exposure to Ara-C, inhibition of apoptosis was determined using the CFSE-based cytotoxicity assay. 
To speciﬁcally calculate the effect of the caspase-inhibitors on Ara-C-induced apoptosis, caspase-inhibitors 
were also added to the medium control, and a correction was performed for inhibition of spontaneous cell 
death by the caspase-inhibitors. 
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Annexin V / PI staining
Apoptosis was determined by Annexin V and PI staining. Annexin V speciﬁcally binds to phosphatidyl 
serine (PS), a phospholipid that becomes exposed on the surface of cells undergoing apoptosis. 
Dual staining with PI enables the identiﬁcation of early apoptotic cells that have not yet lost their membrane 
integrity. 14 Cells were collected and resuspended in binding buffer 10 mM HEPES/NaOH pH 7.4, 150 mM 
NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2) at a concentration of 10
6 cells/mL. Cells were incubated 
at room temperature for 20 min with 0.1 µg/mL FITC-labeled Annexin V (Bender MedSystems, Vienna, 
Austria), washed, and resuspended in binding buffer. PI was added at a ﬁnal concentration of 1 µg/mL, and 
the cells were directly analyzed on a ﬂowcytometer. 
Cell cycle analysis
For cell cycle analysis, 106 cells were washed with PBS, ﬁxed and permeabilized for 10 min at 4°C using 
a solution of 80 µg/mL L-alpha-lysolecithin (Sigma-Aldrich) in 1% paraformaldehyde, washed with PBS 
containing 0,8 g/L human albumin, and stained for 30 min at 4°C with FITC-conjugated anti-Ki-67 MoAbs 
(clone MIB-1; Immunotech, Marseille, France) or isotype controls. After washing, cells were incubated 
with 20 µg/mL RNase (Sentra Systems, Minneapolis, USA) for 5 min at 37°C, and ﬁnally stained with 
50 µg/mL PI. Cells were subjected to ﬂow cytometric analysis of DNA content using a Becton Dickinson 
ﬂow cytometer. The percentages of cell cycle distribution were calculated by CellQuest software. 3;4
Determination of dCK activity
dCK activity, expressed in amounts of substrate converted in time per mg of total protein (pmol min-1 mg-1), 
was measured in duplicate experiments using a dCK protocol as originally described by Cheng et al. 15 with 
minor modiﬁcations described by Veuger et al. 11 [3H]-labeled Ara-C (speciﬁc activity 24 Ci mmol -1; Campro 
Scientiﬁc BV, Veenendaal, The Netherlands) was used as substrate for dCK. Speciﬁc Ara-CTP formation 
was measured using more stringent washing of the DEAE-coated paper discs with a buffer consisting of 
0.6 M HCl and 1.5 M NaCl. 
3H-thymidine and 3H-uridine incorporation assay
B-CLL cells were incubated with either medium, or 10 µM of Ara-C or ﬂudarabine in a round-bottom 
96-wells plate (0.5x106 cells/150 µL) in a humidiﬁed atmosphere at 37°C and 5% CO2. To measure DNA 
or RNA synthesis, after 4 hrs of exposure 3H-thymidine or 3H-uridine (1 µCi/well; Amersham BioSciences, 
Freiburg, Germany) was added, respectively, and the cells were cultured for an additional 16 hrs. Prior 
to harvesting, from each 3H-thymidine-incubation 4 wells were pooled (total amount of cells is 2x106/
incubation). Using an automatic microharvester cells were harvested on 96-wells Uniﬁlter type GF/C plates 
(PerkinElmer Life and Analytical Sciences, Inc., Boston, MA, USA), which speciﬁcally bind DNA and RNA. 
After drying, scintillation ﬂuid (MicroScint-O; Perkin Elmer) was added and incorporation of radioactively 
labeled precursors was determined in a liquid scintillation counter and expressed in counts per minute 
(CPM).
SDS PAGE and Western Blot analysis
Apoptosis was induced in B-CLL cells using 10-5 M Ara-C using a time range from 0 to 48 hrs of exposure. 
At each time point, whole cell lysates of 6x106 cells were obtained by freeze-thawing the cells in 100 µL 
NP40-lysisbuffer (50 mM Tris-HCl, pH 7.6, 5 mM dithiotreitol, 20% v/v glycerol, 0.5% v/v Nonidet P40, 
and 25% v/v Protease Inhibitor Cocktail (Boehringer, Mannheim, Germany). SDS PAGE and Western 
Blot analysis using PVDF membranes (Millipore Corp., Bedford, MA, USA) were performed as previously 
described. 11  Primary antibody incubations were performed for 2 hrs in 1% Ecl-blocking reagent. Cyclin 
D3 speciﬁc antibody (clone Ab-2) used for cell cycle analysis was purchased from Oncogene Research 
Products (San Diego, USA). Bcl-2 antibody (1:50,000) was from Pharmingen (San Diego, CA, USA), Bax 
(1:50,000) and Mcl-1 (1:1,000) speciﬁc antibodies were from SantaCruz Biotechnology (Santa Cruz, CA, 
USA). Caspase cleavage was detected using antibodies speciﬁc for caspase-8 (1:2,000; Pharmingen), 
caspase-9 (1:8,000; Calbiochem, San Diego, CA, USA), or cleaved caspase-3 (1:1,000; Cell Signaling 
Technology, Inc., Beverly, MA, USA). After 3 washing steps, membranes were incubated for 1 hr with 
horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (1:3,000; Promega, 
Madison, USA). β-actin expression was determined on the same blots after stripping for 30 min at 65°C 
with buffer containing 0,5% SDS using anti-β-actin clone AC-15 moAbs (1:100,000; Sigma-Aldrich).
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RESULTS
Sensitivity of B-CLL cells to various apoptotic agents
We analyzed the sensitivity of B-CLL cells to Ara-C-, deoxycytidine-, camptothecin- and 
ﬂudarabine-induced apoptosis using both 51Cr release and CFSE-based cytotoxicity 
assays. A representative result of a CFSE-based cytotoxicity assay showing lysis 
after 40 hrs of exposure is illustrated in Figure 2.1. B-CLL cells were sensitive not 
only to ﬂudarabine, but also to other chemotherapeutic agents tested including the 
S-phase-speciﬁc agent Ara-C. Deoxycytidine (dC) used as a non-speciﬁc control, did 
not induce cell death. 
Since Ara-C has been considered to be S-phase speciﬁc and B-CLL is characterized 
by the presence of mainly quiescent cells, we investigated the characteristics of 
Ara-C-mediated cell death of B-CLL cells in more detail. 
Long-term analysis of Ara-C-treated B-CLL cells using a quantitative CFSE-based 
cytotoxicity assay was performed to study the kinetics of Ara-C-mediated killing of 
B-CLL cells (Figure 2.2A). When B-CLL cells were cultured for up to 5 days in the 
absence of Ara-C, the percentage of viable B-CLL cells did not diminish the ﬁrst 
48 hrs, and only after 5 days declined from 100 to 83%, due to spontaneous apoptosis. 
CFSE intensity of the B-CLL cells was constant, showing that culturing in medium 
Figure 2.1. Susceptibility of B-CLL cells to various apoptotic agents. 
Lysis of B-CLL cells after exposure for 40 hrs to different concentrations of Ara-C, deoxycytidine (dC), 
camptothecin (Camp) and ﬂudarabine (Fluda) was determined using CFSE-based cytotoxicity assays. 
A representative result (in triplicate + SD) of 3 independent experiments is shown.
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did not induce cell proliferation. Culturing in presence of Ara-C caused a reduction 
of 50% of the cells after 48 hrs, and almost a complete deletion of B-CLL cells after 
5 days, demonstrating the susceptibility of B-CLL cells to the S-phase-speciﬁc agent 
Ara-C. 
To exclude a direct non-speciﬁc cytolytic effect of Ara-C to B-CLL cells, we investigated 
whether Ara-C-mediated cell death of B-CLL cells was characterized by PS exposure, 
an early characteristic of apoptosis. Annexin V binding and counterstaining with 
Propidium Iodide (PI) was used to distinguish between dead and early apoptotic cells. 
Figure 2.2B shows that B-CLL cells ﬁrst became annexin V positive before staining 
with PI, illustrating that these cells died via an apoptotic mechanism. 
Figure 2.2. Long-term analysis of Ara-C-mediated apoptosis of B-CLL cells. 
(A) Kinetics of Ara-C-mediated and spontaneous lysis of B-CLL cells using the CFSE-based cytotoxicity 
assay. For each time point, the percentage of surviving (CFSE+, CD45+, 7-AAD-) cells, compared to the 
medium control at day 0, is indicated. A respresentative result of 3 independent experiments is shown. 
(B) Phosphatidyl serine exposure by B-CLL cells treated for 0-96 hrs with 10-5 M Ara-C, as determined 
by FACS analysis using annexin V-FITC staining combined with PI. Dotplots are representative of 
2 independent experiments.
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Relation between Ara-C-induced apoptosis and cell cycle status of B-CLL 
cells
To investigate the relation between Ara-C-induced apoptosis and the cell cycle status 
of B-CLL cells, we exposed both resting (unmanipulated) and proliferating B-CLL 
cells (cultured for 7 days on CD40L) 12 to Ara-C for 0 to 120 hrs, and performed cell 
cycle analysis combining FITC-labeled anti-Ki-67 antibodies and Propidium Iodide 
(PI) DNA staining (Figure 2.3A). The percentages of cells in G0/G1, S or G2/M phase 
were determined based on DNA content. Double staining with Ki-67-FITC was used 
to discriminate between cells in resting G0 phase deﬁned as cells lacking expression 
of the nuclear protein Ki-67, 16;17 and cells in activated G1 phase. At day 0 of the 
experiment, resting B-CLL cells were almost all (> 98%) in G0-phase of the cell cycle, 
whereas proliferating B-CLL cells showed a cell cycle distribution of 15% of cells 
in S/G2M, 69% in G1, and only 16% in G0 phase of cell cycle. Both populations of 
B-CLL cells responded in a different way to Ara-C. Although after 48 hrs of incubation 
already 50% of primary B-CLL cells were killed, no evidence of alteration in cell 
cycle status was observed (Figure 2.3Ai), indicating that these cells were killed by 
Ara-C in G0-phase of cell cycle. In contrast, in proliferating B-CLL cells slow lysis but 
speciﬁc depletion of cells in S- and G2/M phase of the cell cycle was observed during 
exposure to Ara-C. 
Figure 2.3. Cell cycle analysis of primary and proliferating B-CLL cells after treatment with Ara-C. 
(A) Cell cycle status of (i) primary B-CLL cells and (ii) CD40L-CLL cells after treatment with Ara-C for 0, 
24, 48 or 120 hrs determined by ﬂow cytometric analysis using Ki-67-FITC and PI staining. Representative 
results of 3 independent experiments are shown. (B) Cyclin D3 expression determined by Western Blot 
analysis of primary B-CLL cells and CD40L-activated B-CLL cells (cultured for 7 days on CD40L) treated 
for 0 to 48 hrs with Ara-C. Expression patterns were similar in 2 independent experiments.
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To completely ensure that primary B-CLL cells did not leave G0-phase of the cell 
cycle before being eliminated by Ara-C, cyclin D3 protein expression, which is mainly 
found in G1 phase of the cell cycle, was analyzed (Figure 2.3B). Cyclin D3 could not 
be detected in primary and Ara-C-treated B-CLL cells, but was present in CD40L-
activated B-CLL cells exposed to Ara-C for the times indicated. These data conﬁrm 
that Ara-C used a different mechanism to kill quiescent (G0) B-CLL cells than to kill 
proliferating B-CLL cells.
Ara-C-induced apoptosis of G0-B-CLL cells is associated with inhibition of RNA 
synthesis
To study the mechanism of Ara-C-mediated apoptosis of G0-B-CLL cells, we examined 
whether Ara-C induced lysis could be blocked by dC, which is a structural analogue 
of Ara-C and the normal metabolite of DNA synthesis. As shown in Figure 2.4A, lysis 
of G0-B-CLL cells by 10
-5 M Ara-C was inhibited by dC in a dose dependent manner, 
showing complete inhibition of lysis between 3 x 10-5 M and 6 x 10-5 M dC. 
To investigate whether this inhibition of Ara-C-mediated lysis of G0-B-CLL cells 
by dC could be caused by competition for dC kinase (dCK), an enzyme involved 
in the phosphorylation of both Ara-C and dC, we investigated the capacity 
of G0-B-CLL cells to phosphorylate Ara-C, by measuring dCK activity using 
3H-labeled Ara-C as a substrate. dCK activity of G0-B-CLL cells was 81 (pmol 
min-1mg-1), illustrating that quiescent B-CLL cells show higher enzyme activity 
than expected based on their inactive state. The total amount of phosphorylated 
Ara-C (mono-, di- and triphosphate) produced in time is shown in Figure 2.4B (■). 
Speciﬁc conversion by G0-B-CLL cells of Ara-C into Ara-CTP, the active metabolite of 
Ara-C required for incorporation into DNA or RNA, was demonstrated as well (data 
not shown). Figure 2.4B further shows that increasing concentrations of dC caused 
complete inhibition of Ara-C conversion due to competition for dCK. Since both the 
phosphorylation of Ara-C in G0-B-CLL cells (Figure 2.4B) and Ara-C-induced cell 
death of G0-B-CLL cells (Figure 2.4A) could be completely blocked by increasing 
concentrations of dC, formation of Ara-CTP is likely to be important for the mechanism 
of Ara-C-mediated apoptosis of G0-B-CLL cells. 
To determine whether Ara-C affected the amounts of RNA or DNA repair synthesis 
in G0-B-CLL cells, 
3H-uridine and 3H-thymidine incorporation experiments were 
performed. G0-B-CLL cells were cultured for 20 hrs in either medium alone, or in the 
presence of Ara-C or ﬂudarabine. After 4 hrs of pre-incubation, 3H-labeled uridine or 
thymidine was added to all incubations, and incorporation into respectively RNA or 
DNA was measured after a 3H-pulse of 16 hrs. Speciﬁc 3H-thymidine incorporation 
(corrected for background) in 2 x 106 quiescent G0-B-CLL cells cultured in medium 
was only around 300 CPM (Figure 2.5A), compared to over 4000 CPM in 100,000 
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proliferating CD40L-B-CLL cells (data not shown). These low levels of speciﬁc 
3H-thymidine incorporation were blocked by both Ara-C and F-Ara-A, showing 40% 
inhibition at 10-6 M, and 60% inhibition at 10-5 M.
In contrast, RNA synthesis was much more pronounced than DNA (repair) synthesis, 
showing basal 3H-uridine incorporation of approximately 30,000 CPM in 0.5 x 106 
G0-B-CLL cells (Figure 2.5B), which was only 5-10 times lower than in proliferating 
B-CLL cells (data not shown). 3H-uridine incorporation was hardly blocked by 10-6 
M Ara-C or ﬂudarabine (8%), but 10-5 M resulted in 30% inhibition of RNA synthesis 
after 20 hrs of exposure. 
Figure 2.4. Mechanism of Ara-C-mediated killing of G0-B-CLL cells. 
(A) Competition assay using increasing amounts of dC to block Ara-C-mediated cell death of G0-B-
CLL cells after exposure for 72 hrs to 10-5 M Ara-C as determined by a CFSE-based cytotoxicity assay. 
A representative result (in triplicate) of 3 independent experiments is shown. (B) In vitro capability of 
G0-B-CLL cell extracts to convert Ara-C into its active metabolite Ara-CTP, determined by dCK activity 
measurement using 3H-labeled Ara-C as a substrate. Total amounts of 3H-labeled Ara-CMP, -CDP and 
-CTP generated in time are depicted in the ﬁgure and indicated in CPM. Increasing amounts of dC were 
added to the cell extracts to compete for dCK activity and inhibit phosphorylation of 3H-Ara-C. The graph 
shows mean values from duplicate measurements ± SD. Results are representative of 2 independent 
experiments.
Chapter 2
44
Effect of Ara-C on Bcl-2, Bax and Mcl-1 expression and caspase-activation in 
B-CLL 
One of the initiating mechanisms for drug-induced apoptosis in B-CLL cells has 
been reported to be alteration of the Bcl-2/Bax ratio, 9 either by downregulation 
of Bcl-2 or by upregulation of Bax. Moreover, downregulation of other survival 
proteins such as myeloid cell leukemia sequence 1 (Mcl-1) might contribute to 
the mechanism of Ara-C-mediated cell death of G0-CLL cells. Since exposure 
of G0-CLL cells to Ara-C resulted in decreased RNA synthesis in these cells, we 
analyzed whether this inhibition of RNA synthesis resulted in alterations in Bcl-2, 
Bax or Mcl-1 protein levels. Therefore, G0-B-CLL cells were exposed to Ara-C in 
a time range from 0 to 24 hrs, a time interval in which no cell lysis was observed 
(Figure 2.2). Bcl-2 and Bax expression levels were not signiﬁcantly altered upon 
Ara-C treatment, whereas Mcl-1 expression was decreased after 16 hrs of exposure 
to Ara-C (Figure 2.6A), suggesting that downregulation of Mcl-1 may play an important 
role in Ara-C-induced apoptosis of G0-B-CLL cells.
To reveal whether caspases were involved in the induction of Ara-C-mediated cell 
death of G0-B-CLL cells, either indirectly occurring as a consequence of cellular stress 
caused by inhibition of RNA synthesis or by downregulation of the survival protein 
Mcl-1, or directly induced by Ara-CTP via activation of the apoptosome as described 
for F-Ara-ATP, 18 caspase activation patterns were assessed in the same cell lysates 
Figure 2.5. Inhibition of RNA synthesis by Ara-C or ﬂudarabine.
G0-B-CLL cells (0.5 x 10
6/150 μL) were cultured for 20 hrs in absence or presence of 10-6 or 
10-5 M Ara-C (A) or ﬂudarabine (F). The last 16 hrs of incubation, 3H-uridine or 3H-thymidine incorporation 
was measured. To determine 3H-thymidine incorporation, prior to harvesting on Uniﬁlter plates 4 wells 
were pooled (total amount of cells is 2.0 x 106 per incubation). The data presented are mean values 
(+ SD) of triplicate 3H-uridine (A) and 3H-thymidine (B) incorporations (in CPM). Inhibition of 3H-uridine or 
3H-thymidine incorporation by Ara-C or ﬂudarabine was similar in three independent experiments.
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by Western Blot analysis (Figure 2.6B). Modest caspase-3 and -8 cleavage was 
observed after 16 hrs exposure to Ara-C, whereas caspase-9 cleavage could not be 
detected after apoptosis induction with Ara-C in a time interval from 0 to 24 hrs of 
exposure (data not shown). 
To investigate whether this modest caspase activation was required for the execution 
of Ara-C-mediated apoptosis of G0-B-CLL cells, we examined the effect of various 
caspase-inhibitors on Ara-C-induced cell death. G0-B-CLL cells were exposed to 
Ara-C in presence or absence of caspase-3, -8, -9 or the pan-caspase-inhibitor 
z-VAD-FMK, and Ara-C-induced apoptosis was determined after 48 hrs exposure 
using quantitative CFSE assays (Figure 2.6C). In the presence of 10-4 M z-VAD-FMK, 
50% inhibition of Ara-C-induced lysis was obtained (p<0.01), whereas no signiﬁcant 
effect (0-25% inhibition) was observed with caspase-3, -8 or -9 inhibitor. These data 
suggest that caspases were at least partially involved in Ara-C-induced disassembly 
of the B-CLL cells, although we could not pinpoint which speciﬁc caspase plays a key 
role in Ara-C-mediated apoptosis of G0-B-CLL cells.
Figure 2.6. Expression of apoptotic proteins and involvement of caspases in Ara-C-mediated 
apoptosis of G0-B-CLL cells.  
Cell lysates of G0-B-CLL cells were prepared after apoptosis induction with 10
-5 M Ara-C in a time course from 
0 to 24 hrs of exposure. Expression of various pro- and anti-apoptotic proteins (A) and caspase activation 
patterns (B) were determined using Western Blot analysis, and the data shown are representative for 
3 independent experiments. Active subunits of caspase-8 (p40/42) and caspase-3 (p17/19) are indicated 
with arrows; caspase-9 cleavage could not be detected (data not shown). (C) Effect of various caspase-
inhibitors (10-4 M) on Ara-C-induced apoptosis. Mean percentages of Ara-C-induced lysis (n=4) after 48 hrs 
exposure in presence or absence of speciﬁc caspase-inhibitors (caspase-3, -8, -9 inhibitor and zVAD-FMK) 
were determined using quantitative CFSE assays. Only inhibition by zVAD was signiﬁcant (p<0.01).
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DISCUSSION
Ara-C is the most important agent in the treatment of patients with acute leukemia. 
Incorporation of Ara-C into DNA is considered a key event in the mechanism of killing 
of proliferating leukemic cells. 2 We previously demonstrated speciﬁc depletion of 
leukemic cells in S- and G2/M phase of the cell cycle by Ara-C, whereas resting 
(G0) acute leukemic cells did not respond. 
3;4 We now observed unexpected lysis 
of B-CLL cells, which are mainly (>98%) in G0 phase of the cell cycle, by Ara-C, 
being independent of cell proliferation and DNA replication. In this study we analyzed 
which cellular processes were involved in Ara-C-mediated killing of G0-B-CLL cells. 
We showed that, in response to Ara-C treatment, G0-B-CLL cells died via an apoptotic 
mechanism characterized by PS exposure and caspase activation, which was not 
initiated via downregulation of Bcl-2. Furthermore, G0-B-CLL cells were able to convert 
Ara-C into Ara-CTP, and increasing concentrations of dC completely inhibited Ara-C-
mediated apoptosis of G0-B-CLL cells, indicating that phosphorylation of Ara-C is 
important for its cytotoxicity. Since unexpectedly high RNA synthesis was present in 
G0-B-CLL cells, which was blocked by Ara-C for 30%, we hypothesize that inhibition 
of RNA synthesis is an important mechanism of killing G0-B-CLL cells.
For Ara-C, only mechanisms of killing of proliferating cells have been described, such 
as inhibition of cellular DNA replication by inhibition of DNA polymerase or incorporation 
of Ara-CTP into DNA, and inhibition of DNA repair. 2 The absence of both ki-67 and 
cyclin D3 expression in Ara-C-treated B-CLL cells (Figure 2.3) revealed that Ara-C 
used a different mechanism to eliminate G0-B-CLL cells. One of the mechanisms, 
demonstrated to be important in Ara-C- in contrast to ﬂudarabine-mediated cell death 
of proliferating cells, 19 that also may play a role in quiescent cells, is inhibition of 
DNA repair synthesis. In this study, we showed that despite the quiescent stage 
of the cell cycle, B-CLL cells possessed unexpectedly high dCK activity (81 pmol 
min-1mg-1), comparable to primary healthy donor cells and AML cells (84 and 114 pmol 
min-1mg-1, respectively), 11 and that Ara-CTP could be formed. In 1986, Carson´s 
group already showed that quiescent lymphocytes break and rejoin DNA at a slow 
and balanced rate. 20 Exposure to DNA repair blocking agents such as Ara-C will 
cause an accumulation in DNA strand breaks eventually leading to apoptosis. In our 
experiments, however, basal DNA repair synthesis was hardly detectable (260-400 CPM 
in 16 hrs) in 2 x 106 G0-B-CLL-cells, whereas Seto et al. showed 
3H-thymidine 
incorporations of 2,000 CPM in 3 x 106 normal resting lymphocytes within 2 hrs of 
incubation. Huang et al. 10 found slightly higher levels of DNA repair synthesis in 
CLL cells measuring incorporation of 3H-deoxycytidine during 4 hrs (2,500 CPM in 
5 x 106 cells). Moreover, they showed that ﬂudarabine inhibited DNA repair 
synthesis in B-CLL cells (75%), but that this inhibition did not contribute to 
F-Ara-ATP-induced cytotoxicity observed in these cells. Similarly, we showed that 
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10-6 M Ara-C did result in 40% inhibition of DNA synthesis after 16 hrs (Figure 2.5A), 
but not in lysis after 48 hrs of exposure (Figure 2.1). Overall, we suppose that 
inhibition of DNA repair is less important in the mechanism of Ara-C-mediated killing of 
G0-B-CLL cells than of proliferating cells.
A potential mechanism of killing of G0-B-CLL cells by Ara-C is inhibition of RNA 
synthesis, which is also described for ﬂudarabine. 21 We demonstrated that a 
remarkable amount of RNA was synthesized within 20 hrs in G0-B-CLL cells 
(10-20% of RNA synthesis of proliferating B-CLL cells) and addition of 10-5 M Ara-C 
or ﬂudarabine for 20 hrs resulted in 30% less incorporation of 3H-uridine compared 
to control G0-B-CLL cells. Addition of 10
-6 M Ara-C hardly resulted in inhibition of 
RNA synthesis (8%, Figure 2.5B), which correlated well with lack of cytotoxicity at 
this concentration after 48 hrs (Figure 2.1). Our RNA inhibition data were in line 
with the results of the group of Huang et al. 10 showing a decrease in RNA synthesis 
of 25-50% in B-CLL cells treated for 24 hrs with 3 x 10-6-10-5 M ﬂudarabine. Although 
we showed that Ara-C treatment resulted in 30% inhibition of RNA synthesis, we did 
not clarify whether this was due to incorporation of Ara-CTP into RNA or via inhibition 
of RNA polymerase. Some studies in proliferating cells revealed that Ara-CTP was not 
incorporated into RNA, 22;23 whereas F-Ara-ATP incorporated into both RNA and DNA. 23 
Therefore, Ara-C probably inhibits RNA synthesis via inhibition of RNA polymerase, 
which was also shown by some other groups in a non-human setting. 24;25
Inhibition of gene transcription by Ara-C may reduce expression of proteins that 
are important for survival of B-CLL cells such as Bcl-2 and Mcl-1, and in this way 
lead to apoptosis of G0-B-CLL cells. Therefore, we investigated levels of Bcl-2 and 
Mcl-1 protein expression, and observed signiﬁcant downregulation of Mcl-1 but not of 
Bcl-2 upon exposure to Ara-C, as was found by several groups after chemotherapy 
treatment. 9;26
We demonstrated that caspases play a role in Ara-C-mediated apoptosis of 
G0-B-CLL cells, showing that the general caspase-inhibitor z-VAD-FMK reduced 
Ara-C-mediated cell death of G0-B-CLL cells by 50%. In contrast to our ﬁndings, other 
groups argued that caspase activation was only a secondary event of ﬂudarabine-
induced apoptosis in G0-B-CLL cells, showing that caspase inhibition only prevented 
speciﬁc manifestations of apoptosis, such as PARP cleavage and DNA fragmentation, 
but did not prevent cytotoxicity. 27-29 We speculated that caspase-activation might 
be the consequence of the 30% inhibition of RNA synthesis by Ara-C, which will 
result in major cellular stress in G0-B-CLL cells. Moreover, caspases might be 
activated in response to downregulation of the survival protein Mcl-1. An alternative 
pathway for ﬂudarabine to induce caspase activation and apoptosis, proposed by 
Genini et al., 18 is activation of the apoptosome pathway. They demonstrated that, 
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similar to dATP, F-Ara-ATP can cooperate with cytochrome C and apoptosis protein-
activating factor-1 (Apaf-1) to form an apoptosome, and directly trigger apoptosis 
via caspase-9 activation. However, if a similar mechanism plays an important role in 
Ara-CTP-induced apoptosis as well, a larger inhibition of apoptosis would be expected 
using caspase-9 inhibitor (Figure 2.6C). Moreover, this pathway is only described for 
purine analogues such as F-Ara-A and 2CdA, and not for pyrimidine analogues as 
Ara-CTP. 
In conclusion, here we provide evidence for Ara-C-mediated apoptosis of 
G0-B-CLL cells, using a different mechanism of killing than proliferating B-CLL cells 
being independent of cell proliferation and DNA replication. A potential mechanism 
of killing of resting G0-B-CLL cells by Ara-C is inhibition of RNA synthesis, either by 
direct RNA incorporation or by inhibition of RNA polymerase. This decreased RNA 
synthesis was coincided with downregulation of the survival protein Mcl-1, which may 
partly explain Ara-C-mediated apoptosis of G0-B-CLL cells.
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Role of caspase-8 in chemotherapy-induced apoptosis
ABSTRACT
Resistance of leukemic cells to chemotherapy frequently occurs in patients with 
acute leukemia, which may be caused by alterations in common apoptotic pathways. 
Controversy exists whether cytostatic agents induce the mitochondrial or death 
receptor pathway of apoptosis.  In the mitochondrial pathway cytochrome C release 
and caspase-9 activation play a central role in the induction of apoptosis, while 
formation of a Death Inducing Signaling Complex (DISC) and caspase-8 activation 
have been reported to be essential in death receptor-induced apoptosis. Here, we 
show in human derived myeloid and lymphoblastic leukemia cell lines that caspase-8 
plays a more important role than previously expected in apoptosis mediated via the 
mitochondrial pathway. We demonstrated in these malignant cells chemotherapy-
induced apoptosis independent of the death receptor pathway, since blocking this 
pathway using a retroviral construct encoding Flice inhibitory protein (FLIP) did not 
inhibit drug-induced apoptosis or caspase-8 activation, while overexpression of 
Bcl-2 completely inhibited both events. Furthermore, we showed that activation of 
caspase-8 by cytostatic agents occurred downstream from mitochondria. Since 
caspase-8 plays a central role in both death receptor- and chemotherapy-induced 
apoptosis of malignant cells from patients with acute leukemia, therapeutic strategies 
focusing at modulation and activation of caspase-8 may be successful in the treatment 
of drug-resistant malignancies.
INTRODUCTION
The treatment of choice for patients with acute leukemia is high-dose chemotherapy 
followed by allogeneic or autologous stem cell transplantation. 1 From these patients, 
approximately 70-80% will achieve complete remission. However, 50-60% of all 
patients experience a relapse of the disease. 2;3 The majority of these patients is 
resistant to further cytotoxic treatment. Resistance of leukemic cells to chemotherapy 
may be caused by overexpression of drug efﬂux pumps like P-glycoprotein or the 
multidrug-resistance protein MRP-1, 4 or of anti-apoptotic proteins, such as B cell 
lymphoma-2 (Bcl-2), 5 since overexpression of these proteins has been associated 
with poor clinical prognosis. 6-8 Functional blocks in caspase activation pathways 
are found in patients with leukemia and predict poor clinical response to induction 
chemotherapy, 9 suggesting that alterations of the intrinsic programmed cell death 
(apoptosis) pathways of the leukemic cells are also a cause of resistance to 
chemotherapy. 
Cytostatic agents initiate the mitochondrial pathway of apoptosis, also called the 
intrinsic pathway. Due to cellular stress, mitochondria membranes become permeable 
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and cytochrome c is released. In the cytosol, cytochrome c binds to pro-caspase 9 and 
apoptotic protease activating factor (Apaf-1). In this complex, called the apoptosome, 
caspase 9 is activated and in turn cleaves various effector caspases, eventually 
leading to disassembly of the cell. 10,11 
In addition to the mitochondrial pathway of apoptosis, involvement of the death 
receptor pathway in chemotherapy-induced apoptosis has been postulated by several 
investigators, after showing that several anti-cancer drugs induce upregulation of 
Fas receptor (FasR) and Fas ligand (FasL), followed by subsequent autocrine or 
paracrine induction of Fas-mediated apoptosis. 12-16 The death receptor pathway is 
initiated when death ligands, including FasL and tumor necrosis factor alpha (TNF-α), 
bind to death receptors present at the cell surface of the target cell. Upon extracellular 
triggering, trimerization of the death receptor occurs, and Fas Associated Death 
Domain (FADD) is recruited to the intracellular death domain, followed by binding 
of pro-caspase 8, also called FADD-like IL-1 converting enzyme (FLICE). 17 In this 
complex of receptor-bound FADD with pro-caspase 8, called the Death Inducing 
Signaling Complex (DISC), proteolytic cleavage of pro-caspase 8 takes place, 
initiating a caspase cascade resulting in apoptosis. 18;19
Recent patient studies showed that absence or low expression of FADD in cells from 
patients with acute myeloid leukemia is associated with resistance to chemotherapy 
treatment and poor clinical outcome. 20,21;22 Moreover, downregulation of procaspase-
8 expression, by DNA methylation as well as through gene deletion, resulted in 
several malignancies in resistance to doxorubicin-induced apoptosis. 23-25 Based on 
these results it may be hypothesized that at least part of the death-receptor signaling 
pathway is involved in resistance to chemotherapy.
In the present study, we investigated in more detail the role of the death receptor 
pathway and caspase-8 activation in chemotherapy-induced apoptosis in patient-
derived myeloid and lymphoblastic leukemia cell lines. We observed remarkable 
caspase-8 cleavage and similar amounts of caspase-8 and caspase-9 activity 
upon apoptosis induction using cytostatic agents indicating that the death-receptor 
pathway may be involved in chemotherapy-induced apoptosis of these cells. 
To examine whether this caspase-8 activation was due to activation of the death 
receptor pathway or could alternatively be involved in the mitochondrial pathway, as 
previously suggested by Wesselborg et al., 26 we introduced the anti-apoptotic proteins 
FLIP and B-cell lymphoma-2 (Bcl-2) into leukemic cell lines, to speciﬁcally inhibit 
the death receptor or mitochondrial pathway, respectively. FLIP is an enzymatically 
inactive homologue to caspase 8 and interacts with FADD, preventing pro-caspase 8 
to bind to the death domain of the death receptors. 27;28 Bcl-2 was used to speciﬁcally 
inhibit the mitochondrial pathway, since one of the mechanisms of Bcl-2 to inhibit 
apoptosis, is prevention of cytochrome c release from the mitochondria. 29;30 
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Our results show that in these human acute leukemic cells chemotherapy-induced 
apoptosis is mediated through the mitochondrial pathway and not via the death 
receptor pathway. The considerable caspase-8 activation upon chemotherapeutic 
treatment is part of the intrinsic apoptotic pathway and occurs downstream of the 
mitochondria.
 
MATERIALS AND METHODS
Cell lines and culture conditions
The human GM-CSF-dependent acute monocytic leukemia cell line AML-193 31 was obtained from 
American Type Culture Collection (ATCC) (Rockville, MD, USA). The human acute lymphoblastic leukemia 
cell line Leiden ALL-HP (ALL-HP) and the human CML-derived lymphoblastic cell line Leiden ALL-CM 
(ALL-CM) were generated in our laboratory from primary human ALL cells. Both cell lines displayed the 
karyotype of the primary malignant clone, as ALL-HP cells contained i(21)(q10) and ALL-CM cells contained 
t(9;22)(q34;q11). The cell lines displayed a precursor B immune phenotype and expressed CD10, CD19 
and CD79a (both) and CD20 (ALL-CM).
All cell lines were cultured in serum-free medium consisting of IMDM supplemented with 3 mM L-glutamine, 
50 µg/mL streptomycin, 50 U/mL penicillin (all Cambrex Bio Science, Verviers, Belgium), 0.4% human 
serum albumin (HSA) (wt/vol) (CLB, Amsterdam, The Netherlands), 20 µg/mL cholesterol (Sigma-Aldrich, 
St Louis, MO, USA), 20 µg/mL transferrin (Serva, Heidelberg, Germany), 5 x 10-5 M β-mercaptoethanol, 
and 10 µg/mL insulin (both Sigma-Aldrich). Addition of 20 ng/mL recombinant human GM-CSF (Novartis, 
Basle, Switzerland) induced persistent proliferation of the AML-193 cells. 
Apoptosis inducing agents
Apoptosis was induced with the cytostatic agents camptothecin (Alexis Corp., Lausanne, Switzerland) or 
daunorubicin (Sigma-Aldrich) using concentrations varying from 0.1 to 100 µM. Death-receptor-mediated 
apoptosis was induced using Fas agonistic antibodies (10 to 1000 ng/mL) that cause crosslinking of the 
Fas receptor (Fas Ab, 7C11; Beckman Coulter Inc., Fullerton, CA, USA), or by TRAIL (rhsKillerTRAILTM) 
(Alexis) using concentrations varying from 1 to 1000 ng/mL.
Cytotoxicity assays
Cytotoxicity was measured using 16 or 24-hr 51Cr release assays as described previously 32 or using 
CFSE-based cytotoxicity assays as described by Jedema et al., 33 with some modiﬁcations. Target cells 
were labeled with 5 µM CFSE (Molecular Probes Europe, Leiden, The Netherlands), and incubated 
overnight in a humidiﬁed atmosphere of 5% CO2 and 37°C. For the cytotoxicity assay, 25000 cells/
well (100 µL) were plated in 96-well microtiter plates (all in triplicate), and apoptosis-inducing agents 
were added in a volume of 50 µL/well. After 16 or 24 hrs of exposure, FACS analysis was performed to 
determine numbers of viable cells. To exclude dead cells from the analysis, Propidium Iodide (PI) (1 µg/mL;
Sigma) was added. To allow quantitative analysis of the viable cells, the wells were harvested, and 
transferred to FACS tubes containing 10000 Flow-Count Fluorospheres (Coulter Corporation, Miami, FL, 
USA). For each sample 3000 microbeads were acquired, facilitating the calculation of absolute numbers 
of viable (PI-) CFSE+ target cells. The percentage of speciﬁc cell death was deﬁned as: 
[(mean absolute number of viable CFSE+ target cells in control medium - absolute number of viable CFSE+ 
target cells experimental) / (mean absolute number of viable CFSE+ target cells in control medium)] x 100. 
To determine the role of caspases in chemotherapy- or death receptor-induced apoptosis, 51Cr-labeled 
target cells were pre-incubated for 2 hrs with 100 µM of irreversible cell-permeable broad-spectrum 
caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-ﬂuoromethylketone (z-VAD-FMK), caspase-3-inhibitor 
(z-DEVD-FMK), caspase-8 inhibitor (z-LETD-FMK) or caspase-9 inhibitor (z-LEHD-FMK) (all Alexis) prior 
to apoptosis induction. 
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Annexin V / PI staining
Apoptosis was determined by Annexin V and PI staining. Annexin V speciﬁcally binds to phosphatidyl 
serine (PS), a phospholipid that becomes exposed on the surface of cells undergoing apoptosis. 
Dual staining with PI enables the identiﬁcation of early apoptotic cells that have not yet lost their membrane 
integrity. 34 Cells were collected and resuspended in binding buffer (10 mM HEPES/NaOH pH 7.4, 150 mM 
NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2) at a concentration of 10
6 cells/mL. Cells were incubated 
at room temperature for 20 min with 0.1 µg/mL FITC-labeled Annexin V (Bender MedSystems, Vienna, 
Austria), washed, and resuspended in binding buffer. PI was added at a ﬁnal concentration of 1 µg/mL, and 
the cells were directly analyzed on a ﬂowcytometer. 
SDS PAGE and Western Blot analysis
Apoptosis was induced using camptothecin (50 µM) or Fas Ab (500 ng/mL for AML-193 or 100 ng/mL 
for ALL-HP cells) in a time range from 0 to 24 hrs of exposure. At each time point, whole cell lysates 
of 2 x 106 cells were obtained by freeze-thawing the cells in 100 µL NP40-lysisbuffer (50 mM Tris-HCl, 
pH 7.6, 5 mM dithiotreitol, 20% v/v glycerol, 0.5% v/v Nonidet P40, and 25% v/v Protease Inhibitor Cocktail 
(Boehringer, Mannheim, Germany). SDS PAGE and Western Blot analysis using PVDF membranes 
(Millipore Corp., Bedford, MA, USA) were performed as previously described. 35  Primary antibody 
incubations were performed for 2 hrs in 1% Ecl-blocking reagent. Caspase cleavage was detected using 
antibodies speciﬁc for caspase-8 (1:2000; BD BioSciences Pharmingen, San Diego, CA, USA), caspase-9 
(1:8000; Calbiochem, San Diego, CA, USA), or cleaved caspase-3 (1:1000; Cell Signaling Technology, 
Inc., Beverly, MA, USA). Antibodies speciﬁc for the FLAG epitope tag, used to detect introduced FLIP 
(1:1000), were purchased from Sigma. 
After 3 washing steps, membranes were incubated for 1 hr with horseradish peroxidase-conjugated anti-
rabbit or anti-mouse secondary antibodies (1:3000; Promega, Madison, USA). β-actin expression was 
determined on the same blots after stripping for 30 minutes at 65°C with buffer containing 0,5% SDS using 
anti-β-actin clone AC-15 moAbs (1:100 000; Sigma-Aldrich).
Caspase activity assay using colorimetric substrates
After apoptosis induction, for each time point 4 x 106 cells were washed and resuspended in 100 µL of 
ice-cold lysis buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 0.1% CHAPS, 1 mM DTT (freshly added), 0.1 
mM EDTA). After 5 min of incubation on ice, cells were centrifuged at 10,000 x g for 10 min at 4oC, and 
supernatants (= cell extracts) were either directly used for the assay or quickly frozen in liquid nitrogen, 
and stored at -80oC, for later use. Caspase activity assays included 50 µL of assay buffer (50 mM HEPES, 
pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10 mM DTT (freshly added), 0.1 mM EDTA and 10% glycerol), 
40 µL of cell lysate (~ 60-70 µg of protein) and 10 µL of substrate (200 µM ﬁnal concentration of DEVD-
pNA, IETD-pNA or LEHD-pNA, all purchased from Alexis). Samples were incubated at 37oC, and enzyme-
catalyzed release of p-nitroanilide was monitored for several hrs at 405 nm using a microtiter plate reader. 
Absorbance at 405 nm was plotted versus time for each sample. The slope (OD/time) was calculated for 
the initial time period over which the plot was linear, and this slope was used as a measure for caspase 
activity.
Flow cytometric analysis of intracellular Bcl-2
To determine Bcl-2 expression, cells were permeabilized at room temperature for 5 minutes using 0.25% 
saponine/PBS. After centrifugation at 1400 rpm, cells were stained for 30 min at 4°C with FITC-conjugated 
anti-Bcl-2 (Dako, Glostrup, Denmark) or IgG1-FITC isotype control (BD) MoAbs. After washing with PBS 
containing 0,8 g/L human albumin, cells were subjected to ﬂow cytometric analysis using a BD FACScan.
Construction of retroviral vectors and generation of retroviral supernatants
The complete coding region of human FLIP-long (U97074) with a FLAG tag in front of the start codon, was 
ampliﬁed from plasmid pCR3.V64 (kindly provided by Dr. J.P. Medema (Leiden University Medical Center, 
Leiden, Netherlands) already containing the long form of FLIP with a FLAG sequence at the N-terminus, 
by PCR using the forward primer 5’-tatagaagatctaccatggattacaaagacgatgac-3’ and reverse primer 5’-ta
taccgctcgagttatgtgtaggagag-3’. PCR products were sequenced to exclude mutations and were cloned 
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into the Moloney murine leukemia virus-based retrovirus vector LZRS (G. Nolan, Stanford University, 
Palo Alto, CA) containing truncated nerve growth factor receptor (ΔNGF-R) as the marker gene. 36 
The Bcl-2 construct was kindly provided by Dr. J.P. Medema, and cloned into the pLZRS vector with green 
ﬂuorescence protein (eGFP) as the marker gene. Retroviral pLZRS vectors encoding eGFP or ΔNGF-R 
alone were used as control vectors (mock) in the experiments. The pLZRS constructs were transfected 
into packaging cells φ-NX-A (G. Nolan, Stanford University, Palo Alto, CA) 36 using calcium phosphate 
(Life Technologies, Gaithersburg, MD) and retroviral supernatants were obtained as previously 
described. 37
Retroviral transduction of leukemic cells with anti-apoptotic genes
Exponentially growing AML-193, ALL-HP and ALL-CM cells were transduced with retroviral supernatants 
based on the method described by Hanenberg et al. 38 with minor modiﬁcations, 37 using recombinant 
human ﬁbronectin fragments CH-296 (RetroNectin; Takara, Otzu, Japan). ΔNGF-R expression was 
detected using a phycoerythrin (PE)-conjugated anti-human NGF-R mAb (Pharmingen).  Transduced cells 
were puriﬁed by FACS® sort based on marker gene expression using a FACSVantage (Becton Dickinson, 
Mountain View, CA), and cultured in serum free medium.  
 
RESULTS
Sensitivity of various leukemic cell lines to various apoptosis inducing agents
To determine sensitivity of various leukemic cell lines to various apoptotic stimuli, 
both 51Cr release assays (AML-193 and ALL-HP) and CFSE assays (ALL-CM) 
were performed. In Figure 3.1 representative percentages of cell lysis after 24 hrs 
of exposure to various concentrations of camptothecin (A), daunorubicin (B), Fas 
agonistic antibody (Fas Ab) (C) or TRAIL (D), are depicted for each cell line. In AML-
193 (white bars) and ALL-HP cells (grey bars), the cytostatic agents camptothecin and 
daunorubicin were equally effective in inducing apoptosis, while ALL-HP cells were 
slightly more sensitive to the death receptor triggering agents Fas Ab and TRAIL. 
ALL-CM cells (black bars) were effectively killed by chemotherapeutic agents and 
TRAIL, but not by Fas Ab due to absent Fas-receptor expression (data not shown). 
Concentrations of apoptotic agents resulting in at least 40% lysis after 24 hrs of 
exposure, indicated with an asterisk (*), were used in further experiments.
To investigate whether these leukemic cells died via an apoptotic mechanism in 
response to these different agents, we performed annexin V/PI stainings after 4, 
6, 16 and 24 hrs of exposure (partially shown in Figure 3.2). We counterstained 
the cells with Propidium Iodide (PI) to distinguish between early apoptotic and dead 
cells. These data demonstrate that chemotherapy-induced cell death was mediated 
via apoptosis in all cell lines studied, since cells became annexin V positive after 
4 hrs of treatment, while at these time points no cell death was observed (PI negative 
and no 51Cr release). Triggering of death receptors by either Fas Ab (AML-193 and 
ALL-HP) or TRAIL (ALL-CM) also resulted in the induction of apoptosis. The kinetics 
of Fas/TRAIL-induced apoptosis were slower than of chemotherapy-induced 
apoptosis, especially for ALL-HP cells, which became annexin V positive after 16 to 
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24 hrs of exposure to Fas Ab. Percentages of cell death after 24 hrs of incubation 
were comparable between the quantitative annexinV/PI analyses (using Flow-Count 
Fluorospheres; data not shown) and the 51Cr release assays (Figure 3.1). 
Caspase-8 and caspase-9 are involved in chemotherapy-induced apoptosis of 
various leukemic cell lines
To investigate the contribution of the various apoptotic pathways in chemotherapy-
induced apoptosis, we ﬁrst assessed caspases -8, -9 and -3 activation patterns 
upon apoptosis induction using camptothecin. Since other cytostatic agents such 
as daunorubicin caused similar caspase-activation patterns as campthothecin, these 
results were not shown. Figure 3.3A shows that in all cell lines rapid and substantial 
caspase-8, -9 and -3 cleavage was detected after treatment with camptothecin 
(left panel). Caspase-activation was maximal after 4 or 6 hrs of exposure to 
camptothecin in all cell lines. In AML-193 cells, the ﬁrst cleavage products of 
caspase-8 and caspase-9 were present after 2 hrs of exposure, while caspase-
3 activation was observed after 4 hrs of treatment. In ALL-HP cells, ﬁrst cleavage 
products of caspase-8, -9 and -3 were observed simultaneously after 2-4 hrs of 
exposure. Kinetics of caspase-activation was the fastest in ALL-CM cells, showing 
Figure 3.1. Sensitivity of various leukemic cell lines to various apoptotic agents. 
AML-193 (white bars), ALL-HP (grey bars) and ALL-CM cells (black bars) were exposed for 24 hrs to 
various concentrations of (A) camptothecin (Camp), (B) Daunorubicin (Dauno), (C) Fas agonistic antibody 
(Fas Ab) or (D) TRAIL. Percentages of speciﬁc lysis were determined using both 51Cr release assays 
(AML-193 and ALL-HP) and CFSE assays (ALL-CM). The data shown are representative of three 
independent experiments. Concentrations of apoptotic agents resulting in at least 40% lysis, marked with 
an asterisk (*), were used in further experiments.
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Figure 3.2. Leukemic cells die via an apoptotic mechanism in response to cytostatic agents and 
Fas Ab or TRAIL. 
AML-193, ALL-HP and ALL-CM cells were exposed for 4 or 24 hrs to camptothecin (C), and for 6 or 
24 hrs to Fas Ab (F) or TRAIL (T) in case of ALL-CM. Phosphatidyl serine exposure was determined by 
FACS analysis using annexin V-FITC staining combined with PI. Dotplots are representative of at least 
2 independent experiments.
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cleavage of all three caspases already after 2 hrs of treatment with camptothecin. 
As illustrated in AML-193 cells, the kinetics of caspase-8 activation upon triggering 
with camptothecin (left panel) was comparable to Fas Ab-induced caspase-8 activation 
(right panel), although maximal caspase-8 activation was already observed after 
2 hrs of exposure to Fas Ab.
To study the kinetics of caspase-8, caspase-9 and caspase-3 activation in more detail 
upon exposure to cytostatic agents, we performed caspase-activity assays using 
Figure 3.3. Caspase-activation patterns upon chemotherapy or death receptor-induced apoptosis 
in various leukemic cell lines. 
(A) Caspase cleavage patterns for AML-193, ALL-HP and ALL-CM cells exposed to 50 µM of camptothecin 
(Camp, left panel) for indicated periods of time, and for AML-193 cells treated with 500 ng/mL of Fas Ab 
(right panel). Cell lysates (15 μg total protein per lane) were separated by 12% SDS-PAGE. Western Blot 
analysis for caspase-8, -9 and -3 was performed as described in Materials and Methods. The migration 
position of full-length caspase-8 (Casp-8), its cleavage intermediate p40/36, full-length caspase-9 
(Casp-9), its cleavage intermediate p37/34, and the active subunits p17 and p12 of caspase-3 (Casp-3) 
are indicated. (B) Caspase activity assays in AML-193, ALL-HP and ALL-CM cells treated with 50 μM 
of camptothecin (Camp) for indicated periods of time. Cell extracts were prepared as described under 
Materials and Methods and assayed for caspase activity (in duplicate) using the colorimetric substrates 
DEVD-pNA (caspase-3-like protease), IETD-pNA (caspase-8-like protease), and LEHD-pNA (caspase-9-
like protease). Data shown are representative of 2 independent experiments.
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colorimetric caspase substrates (Figure 3.3B). These assays showed similar kinetics 
of cleavage of caspase-8 and caspase-9 substrates in all cell lines suggesting that 
both caspases are activated in the same time interval after apoptosis induction with 
camptothecin. In none of the cell lines cleavage of caspase-8 or caspase-9 substrates 
occurred earlier than cleavage of caspase-3 substrates (Figure 3.3B), suggesting 
that all three caspases were simultaneously activated. Conversion of caspase-8 and 
caspase-9 substrates was much lower than caspase-3 activity in all three cell lines. 
To determine whether both caspase-8 and caspase-9 play an important role in 
the execution pathways induced by chemotherapeutic agents the effect of speciﬁc 
caspase-inhibitors on the percentages of camptothecin and Fas Ab- or TRAIL-induced 
apoptosis was studied. Percentages of speciﬁc inhibition, deﬁned as the percentage 
of decrease in apoptosis induction in presence of speciﬁc caspase-inhibitors, were 
corrected for inhibition of spontaneous apoptosis mainly observed using the broad-
spectrum caspase-inhibitor zVAD-FMK (zVAD). Percentages of speciﬁc inhibition of 
apoptosis by zVAD, and by caspase-3, -8 and -9 inhibitor after 24 hrs of exposure 
to various apoptotic agents are shown in Figure 3.4. In general, apoptosis was most 
effectively inhibited by zVAD (black bars). As expected, caspase-8 inhibitor caused 
70-80% inhibition of death receptor-induced apoptosis by Fas Ab and TRAIL in all cell 
lines. Inhibition of death-receptor-induced apoptosis by caspase-9 inhibitor ranged 
from 20-50%.
Figure 3.4. Effect of various caspase-inhibitors on chemotherapy or death receptor-induced 
apoptosis in various leukemic cell lines. 
AML-193, ALL-HP and ALL-CM cells were exposed for 24 hrs to 50 µM camptothecin (Camp) or Fas 
agonistic antibody (Fas) (1000 ng/mL for AML-193 and 100 ng/mL for ALL-HP) in presence or absence 
of speciﬁc caspase-inhibitors (100 µM). Since ALL-CM cells were insensitive to Fas (Figure 3.1), TRAIL 
(100 ng/mL) was used to activate the death receptor pathway. Percentages of inhibition of lysis by 
the broad-spectrum caspase-inhibitor zVAD-FMK (zVAD), and by caspase-3, -8, or -9 inhibitors were 
calculated. Results are the mean percentage of inhibition by each caspase-inhibitor + SD of 3 independent 
experiments; *, p<0.05 compared to control cells without inhibitor.
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Inhibition of camptothecin-induced apoptosis by caspase-8, caspase-9 and 
caspase-3 inhibitors varied between the cell lines studied. In AML-193 and ALL-HP 
cells minimal inhibition ranging from 10 to 40% was observed, whereas in ALL-CM 
cells inhibition varied from 40 to 80%. Within each cell line only marginal differences in 
inhibition with caspase-8, caspase-9 and caspase-3 inhibitors were found. However, 
in none of the cell lines inhibition with caspase-9 inhibitor was signiﬁcant, whereas 
in AML-193 and in ALL-CM caspase-8 inhibitor signiﬁcantly inhibited camptothecin-
induced apoptosis. These data and the simultaneous activation of both caspase-8 and 
caspase-9 upon exposure to camptothecin suggested that both the death receptor 
and the mitochondrial pathway play a role in chemotherapy-induced apoptosis of 
these cell lines. 
Chemotherapy-induced apoptosis is not linked to the death receptor pathway 
but completely dependent on the mitochondrial pathway in leukemic cell lines
To investigate whether the concurrent activation of caspase-8 and caspase-9 indicated 
that both pathways play a role in chemotherapy-induced apoptosis, we introduced 
anti-apoptotic constructs into our panel of leukemic cell lines. FLIP expression was 
used to block the death receptor pathway, whereas the Bcl-2 encoding construct was 
introduced to speciﬁcally inhibit the mitochondrial pathway. Transduced cells were 
FACS sorted on the basis of ΔNGFR or GFP expression, which resulted in >90% 
pure populations. Protein expression of the transduced cell lines was determined to 
verify proper translation of the introduced anti-apoptotic constructs, which is depicted 
in Figure 3.5A for the various transduced ALL-CM cells. 
To investigate whether these anti-apoptotic constructs could prevent early-apoptotic 
processes, we analyzed annexin V expression in the different cell lines upon apoptosis 
induction with various apoptotic agents. An example is given in Figure 3.5B, in which 
ALL-HP cells transduced with mock, Bcl-2 or FLIP were exposed to camptothecin or 
Fas agonistic antibody. Increased Bcl-2 expression largely prevented phosphatidyl 
serine exposure on the cell surface after apoptosis induction with camptothecin, 
but not after treatment with Fas Ab. In contrast, enhanced FLIP expression resulted 
in speciﬁc inhibition of Fas Ab-induced apoptosis, while chemotherapy-induced 
apoptosis could not be prevented. An overview of the inhibitory effect of both elevated 
Bcl-2 and FLIP expression on the amount of chemotherapy- and death receptor-
induced apoptosis in the three different cell lines is given in Figure 3.5C. All FLIP-
transduced cell lines studied showed around 70% inhibition of lysis induced with 
Fas Ab or TRAIL, illustrating effective inhibition of the death receptor pathway by 
FLIP. In contrast, FLIP-transduced cells and mock-transduced cells were equally 
sensitive to camptothecin and daunorubicin also using other concentrations than 
shown in the ﬁgure, demonstrating that the death receptor pathway is not involved 
in chemotherapy-induced apoptosis in AML-193, ALL-HP and ALL-CM cells. 
To investigate the involvement of the mitochondrial pathway in chemotherapy-induced 
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Figure 3.5. Selective inhibition of chemotherapy-induced apoptosis by Bcl-2 and of death receptor-
induced apoptosis by FLIP in various cell lines. 
(A). Bcl-2 expression (left) of mock (light grey) and Bcl-2 (dark grey) transduced ALL-CM cells was 
determined using ﬂow cytometry. As a control, IgG1-FITC staining is shown (dotted line). FLAG-tagged 
FLIP expression (right) of WT, mock-, Bcl-2-, or FLIP-transduced ALL-CM cells is shown, as determined 
by Western Blot analysis using FLAG-tag speciﬁc antibodies. (B) The effect of elevated Bcl-2 and FLIP 
expression on apoptosis induction after treatment for 4 hrs with camptothecin (Camp) or for 24 hrs with Fas 
Ab is shown for ALL-HP cells, as determined by FACS analysis using annexin V-FITC staining combined 
with PI. Note the elevated FL-1 intensity of untreated (4 hrs medium) ALL-HP-Bcl-2 cells caused by GFP 
marker gene expression of the Bcl-2 construct. (C) The effect of increased Bcl-2 and FLIP expression 
on total cell death of various leukemic cells after exposure to various apoptotic agents. AML-193, 
ALL-HP and ALL-CM cells transduced with vector control (mock), Bcl-2, or FLIP were exposed for 24 hrs to 
camptothecin (Camp), Daunorubicin (Dauno), Fas agonistic antibody (Fas) or TRAIL using concentrations 
as indicated in Figure 3.1 (*). Because of insensitivity, ALL-CM cells were not treated with Fas. Cytotoxicity 
was determined using both 51Cr release assays (AML-193 and ALL-HP) and CFSE assays (ALL-CM). 
Percentages of inhibition by increased expression of Bcl-2 (black bars) or FLIP (white bars) on Camp-, 
Dauno-, Fas- or TRAIL- induced apoptosis were calculated, and a representative result of three independent 
experiments is shown in the ﬁgure.
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apoptosis in these cell lines, the inhibitory effect of Bcl-2 expression was determined. 
As illustrated in Figure 3.5C, Bcl-2 almost completely inhibited apoptosis induced 
by 16 to 24 hrs exposure to various cytostatic agents in AML-193 and ALL-HP cells, 
and caused 50% inhibition in ALL-CM cells, emphasizing an important role of the 
mitochondria in the execution of chemotherapy-induced apoptosis. The same results 
were found using other concentrations of cytostatic agents (data not shown).
In conclusion, despite substantial activation of caspase-8 in all 3 leukemic cell lines 
studied, chemotherapy-induced apoptosis was not executed via the death receptor 
pathway but was completely dependent on the mitochondrial pathway.
Chemotherapy-induced caspase-8 activation occurs downstream from the 
mitochondria in all leukemic cell lines studied
To verify that chemotherapy-induced caspase-8 activation was not death-receptor-
mediated, we tested the FLIP-transduced cell lines for their capacity to inhibit 
camptothecin-induced caspase-8 cleavage. Figure 3.6A shows that caspase-8 
activation upon camptothecin induction was not affected by increased expression 
of FLIP in AML-193 and ALL-HP cells, despite decreased basal expression of 
procaspase-8 in FLIP-transduced AML-193 cells compared to mock- or Bcl-2-
transduced cells. Expression of β-actin was used to conﬁrm equal protein loading. 
As a control, FLIP-transduced AML-193 and ALL-HP cells showed a complete 
block in Fas-induced caspase-8 activation compared to the mock-transduced cells 
(Figure 3.6B). These data indicate that caspase-8 activation upon camptothecin-
triggering likely occurs in the cytosol, independent of death receptors and DISC 
formation. 
To reveal whether caspase-8 cleavage occurred upstream or downstream from the 
mitochondria, the effect of Bcl-2 expression on camptothecin-induced caspase-8 
activation was assessed (Figure 3.6A). Caspase-8 cleavage was almost completely 
blocked in all Bcl-2 expressing cell lines, indicating that caspase-8 was mainly 
activated downstream from the mitochondria upon chemotherapy-induced apoptosis. 
In contrast, caspase-8 cleavage induced by Fas Ab was mainly occurring independent 
of mitochondrial activation (Figure 3.6B), since Fas-induced caspase-8 activation in 
Bcl-2-transduced cells was almost similar as in mock-transduced cells.
To conﬁrm that Bcl-2 completely inhibited caspase-8 activation after treatment with 
cytostatic agents, we performed in addition caspase-8 activity assays (Figure 3.6C). 
Although conversion of IETD-pNA substrate was low in both cell extracts of AML-193 
and ALL-HP cells treated with camptothecin, clear inhibition of caspase-8 activation 
was observed in the Bcl-2- compared to the mock- and FLIP-tranduced cell lines. 
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DISCUSSION
Chemotherapy-induced apoptosis has been considered to be induced via the 
mitochondrial pathway of apoptosis, in which cytochrome C release and caspase-9 
activation play a central role.  Some studies, however, described that chemotherapy-
induced apoptosis is mediated via the death receptor pathway, in which DISC 
Figure 3.6. Selective inhibition of chemotherapy-induced caspase-8 activation by Bcl-2 and of 
death receptor-induced caspase-8 activation by FLIP expression. 
AML-193 and ALL-HP cells transduced with vector control (mock), Bcl-2, or FLIP were exposed for 
indicated periods of time to (A) camptothecin (50 µM) or (B) Fas Ab (500 ng/mL). Cell lysates (15 µg 
total protein per lane) were separated by 12% SDS-PAGE. Western Blot analysis for caspase-8 was 
performed as described in Materials and Methods. Full-length caspase-8 and its cleavage intermediate 
p40/36 are shown in the ﬁgure (see Figure 3.3A). Equal protein loading was conﬁrmed by expression 
of β-actin. Note that increased expression of FLIP appeared to decrease procaspase-8 expression in 
AML-193 but not in ALL-HP cells, compared to mock or Bcl-2 expressing cells. (C) Caspase-8 activity 
assay in AML-193 and ALL-HP cells transduced with vector control (mock), Bcl-2, or FLIP, and treated with 
50 µM of camptothecin (Camp) for indicated periods of time. Cell extracts were prepared as described 
under Materials and Methods and assayed for caspase-8 activity (in duplicate) using the colorimetric 
substrate IETD-pNA. Data shown are mean values (+/- SD) of 2 independent experiments.
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formation and caspase-8 activation are key events. In this study, using 3 different 
cell lines derived from patients with acute leukemia, we investigated the role of the 
death receptor pathway, and in particular of caspase-8, in apoptosis induced by 
cytostatic agents. We observed that caspase-8 was rapidly cleaved upon exposure 
to camptothecin, comparable to caspase-9 and caspase-3 activation. Moreover, 
inhibition experiments using speciﬁc caspase-inhibitors revealed that camptothecin-
induced apoptosis was at least equally effectively blocked by caspase-8 as by 
caspase-9 inhibitor. To examine whether this caspase-8 activation was due to 
activation of the death receptor pathway, we compared sensitivity of mock-transduced 
leukemic cell lines with FLIP-transduced cell lines. No inhibitory effect of elevated 
expression of FLIP on camptothecin-induced apoptosis or caspase-8 activation was 
observed, whereas the effective inhibition of Fas- or TRAIL-induced apoptosis in the 
same cell lines proved functionality of the introduced retroviral construct. In contrast, 
introduction of Bcl-2 resulted in almost complete inhibition of camptothecin-mediated 
cell death in all 3 cell lines studied, showing that chemotherapy-induced apoptosis is 
completely dependent on the mitochondrial pathway. Moreover, caspase-8 activation 
was largely inhibited indicating that caspase-8 activation is occurring downstream 
from the mitochondria, independent of receptor binding or DISC formation.
Whether the death receptor pathway plays a role in anticancer drug-mediated 
cytotoxicity had been considered controversial. Several investigators showed that 
anti-cancer drugs induced upregulation of Fas receptor (FasR) and Fas ligand 
(FasL), followed by subsequent autocrine or paracrine induction of Fas-mediated 
apoptosis. 12-16 Furthermore, the Fas signaling pathway could also be activated by 
Fas trimerization in the absence of Fas-L in cells exposed to UV irradiation 39 or 
various cytostatic agents. 40 Studies by Friesen et al. indicated that extracellular 
blocking of the Fas-R resulted in inhibition of doxorubicin-induced apoptosis, 12 
while overexpression of FADD-DN did not provide protection against drug-induced 
apoptosis in Jurkat and CEM cells, 18 emphasizing the complexity of the involvement 
of the CD95 system on chemotherapy-induced apoptosis. The same group argued 
that triggering of death receptor and/or mitochondrial pathways upon drug treatment 
is cell type speciﬁc, proposing that in so-called type I cells both the receptor and the 
mitochondrial pathway are activated upon drug treatment, whereas in type II cells 
apoptosis is predominantly controlled by mitochondria. 18
Here, we demonstrate that despite considerable caspase-8 activation chemotherapy-
induced apoptosis of leukemic cells is not dependent on the death receptor pathway, 
as previously also reported by Wesselborg et al. for the human leukemic T-cell lines 
CEM and Jurkat. 26 We observed this both in an AML cell line (AML-193) and in 
two ALL cell lines (ALL-HP and ALL-CM) that closely resembled the primary ALL 
cells from which they were derived, suggesting that chemotherapy-induced apoptosis 
67
Role of caspase-8 in chemotherapy-induced apoptosis
of primary leukemic cells is also not mediated via the death receptor pathway of 
apoptosis. 
Although recent clinical studies identiﬁed low or absent expression of FADD protein in 
AML cells at diagnosis as a new independent prognostic factor for poor response to 
chemotherapy, 20 decreased FADD expression was only associated with resistance 
to chemotherapy. Therefore, it is likely that another component of the death receptor 
pathway is responsible for the poor clinical response observed in these patients. 
As illustrated in our study, retroviral introduction of FLIP into AML cells seemed 
to be coincided with downregulation of procaspase-8 (Figure 3.6A and B). 
Based on the results of this study and on other studies showing that downregulation of 
procaspase-8 expression resulted in several malignancies in resistance to doxorubicin-
induced apoptosis, 9;23-25 we suppose that defects in caspase-8 activation may 
underlie unresponsiveness of leukemic cells to chemotherapy treatment.  
In our panel of cell lines, cleavage of caspase-8 occurred predominantly downstream 
of mitochondria (Figure 3.6).  The mechanism of caspase-8 activation independently 
of death receptors and downstream of mitochondria is unknown. An early event in 
the induction of chemotherapy-induced apoptosis is the release of cytochrome C into 
the cytosol, followed by formation of the apoptosome, consisting of Apaf-1, ATP and 
procaspase-9, and subsequent cleavage of caspase-9 as the most apical caspase. 11;29 
Caspase-8 might also bind to Apaf-1, since it has been found that caspase-8 can 
interact with the Caenorhabditis elegans cell death regulator Ced-4, a homologue 
of human Apaf-1, in cell free systems. 41 The long prodomain of procaspase-8 would 
then serve as caspase recruitment domain (CARD), which can bind to the CARD 
motif of Apaf-1. Procaspase-8 would compete with procaspase-9 for binding to 
Apaf-1, which may explain the partial inhibition of camptothecin-induced apoptosis 
obtained with both caspase-8 and caspase-9 inhibitor (Figure 3.4). Procaspase-8 
might also be cleaved by active caspase-3 in an ampliﬁcation step. 42 The results 
shown in Figure 3.3 do not reveal the order of caspase activation after chemotherapy-
induced apoptosis, since in all 3 cell lines studied caspase-8, caspase-9 and caspase-
3 activation occurred almost simultaneously. Caspase-3 activity was probably higher 
than caspase-8 and caspase-9 activity (Figure 3.3B) because more effector caspases 
(casp-3) than initiator caspases (casp-8 and -9) are required to execute apoptosis.
As expected, Bcl-2 expression did not inhibit death-receptor-mediated apoptosis 
(Figure 3.5B and C). Unexpectedly, we observed inhibition of death receptor-induced 
apoptosis by caspase-9 inhibitor (Figure 3.4), which may be explained by non-speciﬁc 
inhibition by irreversible caspase-inhibitors. Therefore, we suppose that in our panel 
of cell lines apoptosis induced by extracellularly triggering of death receptors is not 
dependent on the mitochondrial pathway.
In summary, understanding the mechanisms of anticancer drug-induced apoptosis 
is of major importance for developing effective strategies in tumor therapy. 
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Since caspase-8 plays a central role in both immuno- and chemotherapy-induced 
apoptosis of malignant cells from patients with acute leukemia, and is downregulated 
in certain tumors, 23-25 therapeutic strategies focusing at modulation and activation 
of caspase-8 may sensitize drug-resistant malignancies to radiation or combination 
chemotherapy. Moreover, we assume that cross resistance of CD95 resistant cells 
to anticancer agents which is commonly observed in leukemia patients, can be 
explained by defects in a common element of both pathways, such as caspase-
8, instead of by activation of the death receptor pathway by cytostatic agents. 
To investigate this, small interfering RNA (siRNA)-mediated knockdown of caspase-
8 expression or genetic ablation in mice are preferable ways of interfering with the 
function of caspase-8 instead of inhibition assays using caspase-inhibitors.
 
CONCLUSION
In conclusion, here we show that caspase-8 plays a more important role in apoptosis of 
leukemic cells induced by cytostatic agents than previously expected. Chemotherapy-
induced apoptosis is independent of the death receptor pathway, and activation of 
caspase-8 occurs downstream from mitochondria, independently of death receptor 
triggering or DISC formation.
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ABSTRACT 
Background and objectives. Cytotoxic T lymphocytes (CTLs) may use two effector 
mechanisms to kill their target cells: perforin (PFN) and granzyme B (GrB) dependent 
granule-mediated cell death and death receptor-mediated cell death. Controversy 
exists whether in addition to PFN/GrB-mediated apoptosis death receptor-induced 
apoptosis contributes to the elimination of human tumor cells by CTLs. 
Design and Methods. Since the two CTL-mediated effector mechanisms differ 
in time required to eliminate target cells, lysis of target cells was analyzed using 
CTL clones with slow and rapid kinetics of killing derived from a patient with chronic 
myeloid leukemia (CML). To determine the involvement of the death receptor pathway, 
a retroviral construct encoding the anti-apoptotic gene FLICE inhibitory protein (FLIP) 
was introduced into these target cells. 
Results. A CTL clone capable of killing 50% of the target cells within two hrs of 
incubation primarily acted by release of PFN and GrB. In contrast, two CTL clones 
showing slower target cell killing kinetics partially used the death receptor pathway 
(~30% inhibition by FLIP).  
Interpretation and Conclusions. In conclusion, we demonstrate that the death 
receptor pathway contributes to T cell mediated cell death if not all target cells are 
destroyed by release of PFN and GrB. 
INTRODUCTION
Cytotoxic T lymphocytes (CTLs) mediate target cell death using two effector pathways: 
granule-mediated and death receptor-mediated killing. 1;2 Both pathways are activated 
by membrane T cell receptors (TCRs) recognizing target antigen. In granule-
mediated killing, TCR-triggering induces exocytosis of preformed cytotoxic granules, 
containing perforin (PFN) and a family of serine proteases termed granzymes, 3;4 of 
which granzyme B (GrB) is the most potent member. Intracellular delivery of GrB 
results in the initiation of a caspase cascade via proteolytic activation of caspase-3,
directly 5 or through a mitochondrium-dependent pathway. 6 In death receptor-
mediated killing, TCR-triggering induces surface membrane expression of apoptosis 
inducing ligands of the tumor necrosis factor (TNF) superfamily (Fas ligand (FasL), 
TNF-α, TRAIL), which cross-link death receptors expressed on the target cells. 1;7 
Upon trimerization of the death receptor, Fas Associated Death Domain (FADD) 
is recruited to the intracellular death domain, followed by engagement of pro-
caspase 8, also called FADD-like IL-1 converting enzyme (FLICE). 8 In this complex, 
procaspase-8 is proteolytically cleaved, and the active caspase-8 that is formed either 
directly cleaves effector caspases resulting in apoptosis, or activates the mitochondrial 
pathway via cleavage of Bid, a member of the pro-apoptotic Bcl2 family. 9;10
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Granule-mediated cell death has been reported to play an important role in the 
elimination of virus-infected and tumorigenic cells. 11;12 In line with this, mice with 
defects in PFN expression develop spontaneous lymphoma and have a diminished 
ability to clear many viruses or tumor cells. 13 The kinetics of granule-mediated cell 
death is very rapid, lytic concentrations of PFN induce virtually immediate cell death 
(10 min). GrB combined with sublytic concentrations of PFN also results in rapid 
target cell death (in approximately 90 min), as recently demonstrated in a mouse 
ﬁbroblast cell line. 14 
Death receptor-mediated cell death has primarily been described to be involved in 
eliminating autoreactive T cells and downsize immune responses after infection, 15-18 
as clearly demonstrated in various murine studies showing that mice genetically 
deﬁcient in Fas (lpr) or Fas ligand (gld) develop lymphoproliferative disorders. 19;20 
In other murine studies, Fas/FasL-mediated killing has also been reported to play a role 
in elimination of virus-infected cells. 21-23 Kinetics of death receptor-induced apoptosis 
are slow compared to PFN-GrB-mediated cell death, 24;25 which was underlined by 
a study of Shresta et al, who showed in a murine model that apoptosis induced by 
GrB-/- CTL was delayed for 4 hrs compared to lysis by GrB+/+ CTL. 26 In the human 
setting it is largely unknown whether besides secretion of PFN and GrB, cytotoxic 
T cells also use the death receptor pathway to kill virus-infected or tumor cells. 
In the current study, we investigated the role of the death receptor pathway in CTL-
mediated cell death of human target cells. Because of the differences in kinetics 
of cell death between granule-induced and death receptor-induced cell death, we 
used not only rapidly lysing CTL but also T cell clones displaying slow kinetics of 
killing that have been isolated from a patient with chronic myeloid leukemia (CML) 
at the time of clinical response to donor lymphocyte infusion. We investigated the 
involvement of the death receptor pathway in CTL-mediated lysis by introduction into 
EBV transformed B cells (EBV-LCL target cells) of a retroviral construct encoding 
the anti-apoptotic gene FLICE inhibitory protein (FLIP), which is an enzymatically 
inactive homologue to caspase 8 and interacts with FADD, preventing pro-caspase 8 
to bind to the death domain of the death receptors. 27;28 In this study we demonstrate 
that leukemia-reactive T-cell clones at least partially use the death receptor pathway 
to kill their target cells. 
MATERIALS AND METHODS
Cells and culture conditions
HY-A1 is a CD8+ HLA-A1-restricted anti-HY T cell clone isolated from a patient with a bone marrow 
rejection, recognizing a peptide derived from the DFFRY protein. 29 B57-2 and C6-2 are two mHag-speciﬁc 
CD8+ leukemia-reactive T cell clones isolated from a CML patient (JTO) at the time of clinical response 
to donor lymphocyte infusion (DLI). 30 These clones are HLA-B57- and Cw-6-restricted, respectively, and 
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recognize EBV-LCL derived from the patient. The T cell clones were cultured in IMDM supplemented with 
3 mM L-glutamine, 50 µg/mL streptomycin, 50 U/mL penicillin, 5% pooled human serum, 5% FBS, and 
100 IU/mL IL-2 (Chiron, Amsterdam, the Netherlands), and stimulated every 2 weeks with a mixture of 
irradiated allogeneic peripheral blood mononuclear cells, 800 ng/mL phytohemagglutinin (PHA, Murex 
Biotech Limited, Dartford, UK), and 120 IU/mL IL-2.
EBV-LCL were cultured in IMDM supplemented with 10% fetal bovine serum (FBS), 3 mM L-glutamine, 
50 µg/mL streptomycin and 50 U/mL penicillin (all Cambrex Bio Science, Verviers, Belgium).
CFSE cytotoxicity assay
Cytotoxicity was measured using CFSE (carboxyﬂuorescein diacetate succinimidyl ester) -based 
cytotoxicity assays as described by Jedema et al. 31 Target cells were labeled with 5 µM CFSE (Molecular 
Probes Europe, Leiden, The Netherlands), and incubated overnight in a humidiﬁed atmosphere of 5% CO2 
and 37°C. For the cytotoxicity assay, 5,000 target cells/well (50 µL) were plated in 96-well microtiter plates 
(all in triplicate), and 5,000 effector T cells were added in a volume of 100 µL/well. After 2, 5 and 24 hrs 
of coculture, FACS analysis was performed to determine numbers of viable target cells. To exclude dead 
cells from the analysis, propidium iodide (PI) (1 µg/mL; Sigma-Aldrich, St Louis, MO, USA) was added. 
To allow quantitative analysis of the viable cells, the wells were harvested, and transferred to FACS tubes 
containing 10,000 Flow-Count Fluorospheres (Coulter Corporation, Miami, FL, USA). For each sample 
3,000 microbeads were acquired, facilitating the calculation of absolute numbers of viable (PI-) CFSE+ 
target cells. The percentage of speciﬁc cell death was deﬁned as: 
[(mean absolute number of viable CFSE+ target cells in control medium - absolute number of viable CFSE+ 
target cells experimental) / (mean absolute number of viable CFSE+ target cells in control medium)] x 100. 
Activation of the death-receptor pathway
Death-receptor-mediated apoptosis was induced with Fas agonistic antibodies (10 to 1000 ng/mL) that 
cause crosslinking of the Fas receptor (Fas Ab, 7C11; Beckman Coulter Inc., Fullerton, CA, USA), or with 
recombinant human TRAIL (rhsKillerTRAILTM) (Alexis Corp., Lausanne, Switzerland). 
Generation of retroviral constructs and transduction of EBV-LCL cells
The complete coding region of human FLIP-long (U97074) with a FLAG tag in front of the start codon 
was ampliﬁed from plasmid pCR3.V64 (kindly provided by Dr. J.P. Miedema (Leiden University Medical 
Center, Leiden, The Netherlands)) by PCR using the forward primer 5’-tatagaagatctaccatggattacaaagacg
atgac-3’ and the reverse primer 5’-tataccgctcgagttatgtgtaggagag-3’. FLAG-FLIP encoding PCR products 
were cloned into the Moloney murine leukemia virus-based retrovirus vector LZRS (G. Nolan, Stanford 
University, Palo Alto, CA) containing truncated nerve growth factor receptor (∆NGF-R) as the marker gene. 32 
Retroviral pLZRS vector encoding ∆NGF-R alone was used as a control vector (mock) in the experiments. 
Generation of retroviral supernatant and retroviral transduction of EBV-LCL were performed as previously 
described. 33 Transduced cells were puriﬁed by FACS® sort based on marker gene expression using a 
FACSVantage (Becton Dickinson, Mountain View, CA, USA).  
SDS PAGE and Western Blot analysis
Cell lysates of 2 x 106 cells were obtained by freeze-thawing the cells in 100 µL NP40-lysisbuffer 
(50 mM Tris-HCl, pH 7.6, 5 mM DTT, 20% v/v glycerol, 0.5% v/v Nonidet P40, and 25% v/v Protease 
Inhibitor Cocktail (Boehringer, Mannheim, Germany). SDS PAGE and Western Blot analysis using 
PVDF membranes (Millipore Corp., Bedford, MA, USA) were performed as previously described. 34 
Primary antibody incubations were performed for 2 hrs in 1% Ecl-blocking reagent. Horseradish peroxidase 
(HRP) -conjugated antibodies speciﬁc for the FLAG epitope tag (Sigma) were used to detect introduced 
FLIP (1:1,000) . 
Statistical analysis
Statistical analysis was performed using a two-paired Student’s t-test to calculate whether lysis in WT-
EBV-JTO cells signiﬁcantly differed from lysis observed in EBV-JTO cells stably expressing FLIP. 
Differences were considered statistically signiﬁcant when p values were ≤ 0.05.
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Intracellular Perforin and Granzyme B analysis
20,000 T cells were stimulated for 2 hrs with 20,000 speciﬁc (EBV-JTO) or a-speciﬁc (EBV-JY) target cells. 
To discriminate between effector and target cells, T cells were stained with CD8 speciﬁc antibodies (BD, 
San Jose, CA, USA). Cells were ﬁxed and permeabilized using Fix Buffer I and Perm/Wash Buffer I (both 
BD), respectively, according to the manufacturer’s protocol. Intracellular amounts of PFN and GrB present 
in the T cells were determined by ﬂow cytometry using PFN (1:20) and GrB (1:20) speciﬁc antibodies (BD). 
IgG antibodies were used to correct for background staining. The differences in PFN and GrB staining 
(∆MFI) after speciﬁc and a-speciﬁc stimulation of the T cells reﬂect the amounts of PFN and GrB released 
by the different T cell clones within 2 hrs of speciﬁc stimulation with EBV-JTO.
RESULTS
mHag-restricted CTL clones show different killing kinetics towards the same 
EBV-LCL
We examined 3 different CTL clones for their capacity to kill EBV-LCL from patient 
JTO (EBV-JTO). Percentages of speciﬁc lysis of EBV-JTO cells were determined 
after 2, 5 and 24 hrs of coculturing with the T cell clones using the CFSE-based 
cytotoxicity assay. CTL clone HY-A1 showed very fast kinetics of killing, resulting in 
50% of target cell lysis after 2 hrs of incubation and maximal lysis (90%) after 24 hrs 
(Figure 4.1). CTL clone B57-2 showed 15% of lysis after 2 hrs, almost 40% after 5 
hrs, and 70% after 24 hrs of incubation, which we classiﬁed as intermediate killing 
kinetics. CTL clone C6-2 caused no EBV-JTO-speciﬁc cell death after 2 and 5 hrs, but 
50% lysis after overnight incubation, which we regarded slow killing kinetics.
Figure 4.1. Kinetics of minor Ag-restricted CTL-mediated killing of EBV-JTO cells. 
EBV-LCL cells from patient JTO (EBV-JTO) were exposed for 2, 5, and 24 hrs to the HLA-A1-restricted 
CTL clone HY-A1, the B57-restricted CTL clone B57-2 and the Cw6-restricted CTL clone C6-2, at an E/T 
ratio of 1/1. Percentages of speciﬁc lysis were determined using CFSE-based cytotoxicity assays, and 
the mean percentages of 3 (HY-A1), 5 (B57-2) and 7 (C6-2) independent experiments are indicated in the 
ﬁgure. 
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Kinetics of Fas-mediated cell death of EBV-JTO cells 
To study the kinetics of death-receptor-mediated apoptosis in EBV-JTO cells, we 
performed cytotoxicity experiments in time using various concentrations of Fas 
Ab or TRAIL to activate the death receptor pathway. The EBV-JTO cells did not 
respond to various concentrations of TRAIL (data not shown) suggesting that the 
target cells do not express the receptor for TRAIL. As shown in Figure 4.2, in the ﬁrst 
2 hrs of exposure to Fas Ab, no lysis was observed. After 5 hrs of exposure, high 
concentrations of Fas Ab (≥500 ng/mL) caused 20-30% apoptosis of EBV-JTO cells, 
whereas hardly any (0-10%) target cells died in response to low concentrations of 
Fas Ab (≤100 ng/mL). Exposure to Fas Ab for 24 hrs resulted in 60% apoptosis at 
high concentrations, and also signiﬁcant cell death (~40%) at low concentrations 
(100 ng/mL) of Fas Ab (Figure 4.2). These data show a correlation between the 
concentration of Fas Ab and the rate of Fas-induced apoptosis.
Elevated FLIP expression efﬁciently inhibits the death receptor pathway
To study the role of the death-receptor pathway in CTL-mediated apoptosis, we 
introduced a retroviral construct into EBV-JTO target cells encoding the anti-
apoptotic gene FLICE inhibitory protein (FLIP), which speciﬁcally blocks death-
receptor-induced apoptosis. As a control, target cells were also transduced 
with empty vector (mock). Transduced EBV-JTO cells were FACS sorted on 
the basis of NGFR expression, which resulted in >90% pure populations. 
Protein expression of the transduced cell lines was determined to verify proper 
Figure 4.2. Kinetics of Fas Ab-induced cell death of EBV-JTO cells.
Mean percentages of lysis, as determined by CFSE-based or 51Cr-release cytotoxicity assays, obtained 
in 4 independent experiments are shown. Percentages of lysis after 2, 5 or 24 hrs exposure to various 
concentrations of Fas Ab (Fas) are represented by dashed black lines, solid black lines, or solid grey lines, 
respectively. 
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translation of the introduced FLIP-encoding construct, as depicted in Figure 4.3A. 
To test the functionality of the FLIP construct, wildtype (WT), mock- and FLIP-
transduced EBV-JTO cell lines were exposed for 5 or 24 hrs to Fas Ab, and cell death 
was determined using the CFSE-based cytotoxicity assay (Figure 4.3B). Enhanced 
FLIP expression resulted in approximately 80% inhibition of lysis induced with Fas 
Ab, both after 5 and 24 hrs of exposure, compared to WT and mock-transduced EBV-
JTO cells, illustrating effective inhibition of the death receptor pathway by FLIP. 
Involvement of the death-receptor pathway in CTL-mediated killing of EBV-JTO 
cells 
To determine the importance of the death receptor pathway in the execution 
mechanisms of the different T cell clones, we tested WT, mock and FLIP expressing 
EBV-JTO cells for their sensitivity to CTL clones HY-A1, B57-2 and C6-2 (described 
in Figure 4.1). Speciﬁc lysis was determined after 2, 5 and 24 hrs of incubation 
with the CTL clones. Lysis of the WT and mock-transduced EBV-JTO cells was 
identical (data not shown). In our experiments we therefore compared the lysis of 
FLIP-transduced EBV-JTO cells with the lysis of WT-EBV-JTO cells (Figure 4.4). 
Expression of FLIP did not signiﬁcantly affect the lysis of the EBV-LCL by HY-
A1, as shown in Figure 4.4A. Moreover, the majority of the target cells were killed 
within 2 hrs of exposure, in which Fas-mediated apoptosis hardly takes place 
(Figure 4.2), suggesting that HY-A1-induced cell death of EBV-JTO is mainly directly 
PFN or PFN/GrB-mediated. 
Figure 4.3. Functionality of EBV-JTO cells transduced with the anti-apoptotic gene FLIP.
A. FLIP protein expression of WT, mock-, and FLIP transduced EBV-JTO cells as determined by Western 
Blot analysis. B. Effective inhibition of Fas-induced apoptosis in EBV-JTO cells stably expressing FLIP. 
WT, mock-, and FLIP-transduced EBV-JTO cells were exposed to Fas Ab (500 ng/mL), and cytotoxicity 
was determined after 5 and 24 hrs of exposure using a CFSE-based assay. Mean percentages of lysis 
(+SD) of 3 independent experiments are shown. 
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As illustrated in Figure 4.4B, FLIP did not inhibit B57-2-induced lysis of the 
EBV-LCL in the ﬁrst two hrs of incubation, which correlates with the absence of Fas-
induced cell death in this time interval (Figure 4.2). In the time intervals where Fas-
induced apoptosis theoretically plays a role (based on the results of Figure 4.2), an 
inhibitory effect of FLIP was observed. Signiﬁcantly lower percentages of lysis of the 
FLIP expressing EBV-JTO compared to the WT EBV-JTO cell line (mean inhibition 
of 27±19%, p=0.05) were observed between 2 and 5 hrs of exposure to CTL clone 
B57-2. Similar results were found in the time interval from 5 to 24 hrs. These data 
show that the death receptor pathway plays a role in the execution mechanisms used 
by CTL clone B57-2. 
Figure 4.4. The effect of enhanced FLIP expression on CTL-mediated target cell death.
Both wildtype (WT) and EBV-JTO cells stably expressing FLIP were exposed to CTL clones HY-A1 (A), 
B57-2 (B) and C6-2 (C), At an E/T ratio of 1:1. Percentages of speciﬁc lysis were determined after 2, 
5 and 24 hrs of exposure using CFSE-based cytotoxicity assays. In the ﬁgures, lysis is compared between 
WT and FLIP-expressing cell lines, and is shown in 3 time-intervals: lysis from 0 to 2 hrs, lysis from 2 to 
5 hrs, and lysis from 5 to 24 hrs of exposure. Concerning clone C6-2, lysis in the intervals 0-2 hrs and 
2-5 hrs was negligible and is not shown in the ﬁgure. Single experiments are represented in the ﬁgure by 
grey lines (n=3 for HY-A1, n=5 for B57-2 and n=7 for C6-2). Mean percentages of lysis of these independent 
experiments are indicated with a bold black line. Statistical analysis was performed, and p-values are 
shown in the ﬁgures. Lysis in EBV-JTO-FLIP was signiﬁcantly lower than lysis in EBV-JTO WT if p-values 
were ≤0.05. * means that lysis was signiﬁcantly higher in the FLIP-expressing cells than in the WT cells. 
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Clone C6-2 was not capable of lysing EBV-JTO cells in the ﬁrst 5 hrs of incubation 
(Figure 4.1). In the time interval from 5 to 24 hrs, 50% target cell death was observed, 
which was even higher than with clone B57-2 in the same time interval (35%). 
To investigate whether this lysis was caused by activation of the death receptor 
pathway in the target cell, we tested the effect of FLIP on C6-2-induced cell death 
after 24 hrs of coculture. As depicted in Figure 4.4C, inhibition of the death receptor 
pathway by FLIP resulted in signiﬁcantly decreased cell death (p=0.001) compared 
to WT EBV-JTO cells (mean % inhibition = 36 ± 14).
Involvement of PFN/GrB release in CTL-mediated killing of EBV-JTO target 
cells
To investigate whether CTL HY-A1 which showed very fast kinetics of killing indeed 
rapidly secreted high levels of PFN and/or GrB, intracellular PFN and GrB stainings 
were performed. The amounts of PFN and GrB present in the three CTL clones 
after 2 hrs stimulation with an irrelevant target cell (JY) compared to the speciﬁc 
target JTO were determined. We suppose that upon recognition of a speciﬁc target 
cell, the CTL will release PFN and GrB, resulting in lower amounts of intracellular 
PFN and GrB. The differences in PFN and GrB staining (∆MFI) after speciﬁc and 
a-speciﬁc stimulation of the T cells were calculated, and are shown in Figure 4.5A 
and B, respectively. These ∆MFI values reﬂect the amounts of PFN and GrB released 
by the different T cell clones within 2 hrs of speciﬁc stimulation with EBV-JTO.
Figure 4.5. CTL-induced PFN and GrB release.
CTL clones HY-A1, B57-2, and C6-2 were stimulated for 2 hrs with the speciﬁc target EBV-JTO or with an 
irrelevant target EBV-JY. Intracellular levels of PFN and GrB were determined in the various CD8+ T cells 
by ﬂow cytometry (n=2). MFI values were corrected for background staining using control IgG antibodies. 
The differences in PFN (A) and GrB (B) staining (∆MFI) after speciﬁc and a-speciﬁc stimulation of the 
T cells were calculated, and are shown in the ﬁgures. These ∆MFI values reﬂect the amounts of PFN and 
GrB released by the different T cell clones within 2 hrs of speciﬁc stimulation with EBV-JTO.
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In line with our assumption, we found that intracellular levels of both PFN and GrB 
in HY-A1 cytotoxic T cells were lower after 2 hrs of stimulation with EBV-JTO cells 
compared to coculture with EBV-JY cells, suggesting that HY-A1 released both 
PFN and GrB in this time-interval. Compared to the other two CTL clones HY-A1 
secreted the highest amount of PFN, which may explain why JTO cells are killed 
within 2 hrs by HY-A1 but not or barely by B57-2 or C6-2. All three clones secreted 
remarkable amounts of GrB within 2 hrs of coculture with EBV-JTO, but without PFN 
this apparently does not lead to apoptosis of the target cell.
DISCUSSION
In this study, we investigated the role of the death receptor pathway in CTL-mediated 
cell death of human target cells. To determine the contribution of this slow execution 
mechanism, we introduced the anti-apoptotic protein FLIP, a speciﬁc inhibitor of 
the death receptor pathway. We used CTL clones isolated from a patient with CML 
that showed slow (C6-2, Figure 4.1), intermediate (B57-2) and fast (HY-A1) kinetics 
of killing EBV-LCL target cells. Concerning the rapidly lysing CTL clone HY-A1 no 
involvement of the death receptor pathway could be demonstrated (Figure 4.4A). 
Since 50% of target cells was already killed within 2 hrs of exposure, a time-interval 
in which HY-A1 was shown to release PFN and GrB, whereas control experiments 
indicated that Fas-induced apoptosis did not occur during this time-interval 
(Figure 4.2), we argued that this CTL clone mainly acted by secretion of PFN and 
GrB. In contrast, the EBV-LCL target cells were at least partially killed via the death 
receptor pathway upon exposure to the other two T cell clones (B57-2 and C6-2), 
suggesting that this pathway is important in the execution mechanism of a T cell if not 
all target cells have been destroyed by release of PFN/GrB. 
Although cytotoxic T cells can mediate target cell death via different effector 
mechanisms, it is still questionable whether CTL clones preferentially use secretion of 
PFN and GrB or also use death ligands to kill human tumor cells. 15-18 11;12 Since kinetics 
of death receptor-induced apoptosis are slow compared to PFN-GrB-mediated cell 
death, we analyzed CTL-mediated target cell death in different time intervals (0-2 hrs, 
2-5 hrs, and 5-24 hrs). We could not use the standard 51Chromium release assay, 35 
because this assay is hampered by spontaneous release of 51Cr, making it impossible 
to analyze cell death in EBV-LCL for longer than 4-10 hrs of incubation. Therefore we 
used a CFSE-based cytotoxicity assay which can be used for longer time periods. 
Results obtained with the CFSE assay have been demonstrated to correlate well with 
the results obtained in the conventional 51Cr release assay in 4-hrs incubations. 31 
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To study the contribution of the death receptor pathway in T-cell-mediated target cell 
death, we introduced the anti-apoptotic gene FLIP into the target cell via retroviral 
transduction, and demonstrated that enhanced expression of FLIP caused almost 
complete inhibition of Fas-induced apoptosis (Figure 4.3B). The inhibitory effect 
of FLIP was variable when target cell death was induced with the different CTL 
clones. No inhibition was achieved when EBV-JTO cells were exposed to the very 
rapidly killing CTL HY-A1. Already 40-50% of target cells were killed within 2 hrs of 
incubation which was coincided with PFN and GrB release by HY-A1 (Figure 4.5). 
Although besides PFN also high amounts of GrB were released by CTL HY-A1 after 
2 hrs incubation with EBV-JTO, we hypothesize that these target cells may be killed 
via a PFN-dependent mechanism of cell death, since PFN has been shown to induce 
direct lysis of the target cell. 36;37 Although most of these studies were performed 
in vitro using non-physiological concentrations, Simon et al. illustrated in a murine 
study, in which CTLs were used that lacked both GrA and GrB, the in vivo importance 
of direct PFN-induced lysis. 38 We observed that the death receptor pathway plays 
at least a partial role in the effector mechanism of the CTL that killed its EBV-LCL 
target cells after 5 hrs of exposure (B57-2) and of the CTL being cytotoxic only after 
24 hrs of incubation (C6-2). This suggests that this pathway is important at a later 
time point after T cell-target cell interaction if not all cells have been destroyed by 
immediate release of PFN/GrB. 
Two of the three T cell clones used in this study (B57-2 and C6-2) were isolated from 
a patient (JTO) during the clinical response after the second DLI. 39 Analysis of the 
reactivity of the different CTL clones against different subsets of bone marrow (BM) 
cells from the patient revealed that B57-2 lysed only monocytic cells of the patient, 
whereas C6-2 was capable of lysing both monocytic and mature myeloid cells 
(40, data not shown). The authors showed that resting B and T cells and immature CD34-
positive cells representing BM progenitor cells were not or only marginally recognized 
by these T-cell clones. The T-cell clone HY-A1 recognized all target cell populations. 
Since both B57-2 and C6-2 CTL clones were capable of rapidly killing monocytes of 
patient JTO (41, data not shown), we postulate that the differential kinetics of killing 
EBV-LCL of the same patient by these two CTL clones may be caused by differences 
in the strength of interaction between effector and target cell. We hypothesize that 
Cw6-restricted CTL clones recognize minor antigens highly expressed on monocytes, 
but poorly expressed on EBV-LCL from the patient resulting in a low avidity interaction 
between TCR and MHC/peptide complex. In case of a low avidity interaction between 
TCR and MHC/peptide complex, the CTL probably releases only low amounts of PFN 
and GrB, as illustrated for C6-2 in Figure 4.5, but may still activate the death receptor 
pathway, causing slow elimination of the target cell. The strength of triggering of the 
Fas-receptor on the target cell may determine the kinetics of the apoptosis induction, 
as was also illustrated by the correlation between the concentration of Fas Ab used to 
induce target cell death, and the rate of Fas-mediated apoptosis (see Figure 4.2). 
83
CTL-induced Fas-mediated apoptosis
In conclusion, in this study we demonstrate that not only PFN/GrB release but also 
the death receptor pathway plays a role in the execution mechanism of cytotoxic 
T cells derived from a patient with CML. 
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SHORT REPORT
Patients with leukemia and other hematological malignancies can be successfully 
treated with chemotherapy followed by allogeneic hematopoietic stem cell 
transplantation. Chemotherapy mainly kills malignant cells via activation of the 
mitochondrial pathway of apoptosis, but has also been described to activate the 
death receptor pathway of apoptosis. 1 After allogeneic stem cell transplantation 
natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) can mediate target cell 
death using two different effector mechanisms: perforin (PFN) and granzyme B (GrB) 
dependent granule-mediated cell death and death receptor-mediated apoptosis. 2
Malignant cells protect themselves from chemotherapy- and CTL-induced apoptosis 
using several escape mechanisms including upregulation of anti-apoptotic proteins 
such as B cell lymphoma-2 (Bcl-2), FLICE (caspase-8) Inhibitory Protein (FLIP) and 
serine protease inhibitor-9 (PI-9).  Bcl-2 is a speciﬁc inhibitor of the mitochondrial 
pathway of apoptosis, and overexpression has been shown to be an adverse prognostic 
factor for outcome of chemotherapeutic interventions. 3 FLIP, an enzymatically inactive 
homologue to caspase-8, has been shown to efﬁciently block the death receptor 
pathway of apoptosis, and enhanced FLIP expression has been associated with 
poor clinical outcome after treatment with chemotherapy and immunotherapy. 4 PI-9, 
a protein that speciﬁcally binds to GrB,  was shown to efﬁciently inhibit PFN/GrB-
mediated apoptosis in both in vitro and in vivo studies, 5 and is considered to be a 
speciﬁc prognostic marker for outcome of cellular immunotherapy. 6 However, due to 
the similarity between PI-9 and the viral serpin cytokine response modiﬁer A (CrmA), 
an efﬁcient inhibitor of Fas-mediated and to a lesser extent of GrB-induced cell death, 7 
we hypothesized that PI-9 may also protect cells against Fas-mediated apoptosis, 
and hence may be less speciﬁc for certain immunological processes than expected. 
In this study, we therefore examined the effect of enhanced PI-9 expression on Fas-
induced apoptosis. 
Both EBV-transformed B cells (EBV-JTO) and Jurkat J16 target cells were transduced 
with retroviral constructs encoding FLIP or PI-9. Transduced cells were puriﬁed (>95%) 
on basis of NGFR or GFP marker gene expression using cell sorting. Wildtype (WT) 
and enhanced FLIP- or PI-9 expressing EBV-JTO and Jurkat cells were exposed to 
various concentrations of Fas agonistic antibody (Fas Ab, 7C11; Beckman Coulter 
Inc., Fullerton, CA, USA), and cell death was determined after 5 and 24 hrs of 
exposure using a CFSE-based cytotoxicity assay. Fas Ab titration curves for both EBV-
JTO and Jurkat cells are shown in Figure 5.1A. EBV-JTO cells were less sensitive 
to Fas Ab treatment than Jurkat cells, since maximal lysis of EBV-JTO cells after 
5 hrs of exposure was 30% using 500 ng/mL of Fas Ab, whereas 10 ng/mL of Fas Ab 
was sufﬁcient to kill 30% of Jurkat cells. The IC50 value for EBV-JTO cells after 5 and 
24 hrs of exposure was approximately 100 ng/mL of Fas Ab, while IC50 values for Jurkat 
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Figure 5.1. Effect of FLIP and PI-9 expression on Fas- and camptothecin (Camp)-induced 
apoptosis. 
(A) Fas Ab titration curves for EBV-JTO (left panel) and Jurkat (right panel) cells after 5 and 24 hrs of 
exposure. The IC50 value for EBV-JTO was 100 ng/mL of Fas Ab; IC50 values for Jurkat were 10 and 
1 ng/mL of Fas Ab after 5 and 24 hrs of exposure, respectively. (B) Percentages of inhibition of Fas-
induced apoptosis by FLIP and PI-9 after 5 hrs (left panel) and 24 hrs (right panel) of exposure of EBV-
JTO and Jurkat cells. Percentages of lysis were determined with CFSE-based cytotoxicity assays using 
IC50 concentrations and concentrations of Fas Ab causing maximal lysis of EBV-JTO and Jurkat cells. 
Data shown are mean values (+SD) of 9 (EBV-JTO) or 4 (Jurkat) independent experiments. NA; not 
applicable, lysis in WT < 10%. (C) Percentages of inhibition of Camp-induced apoptosis by FLIP and PI-9 after 
24 hrs of exposure of EBV-JTO and Jurkat cells. Lysis was 83% and 88% in wild type EBV-JTO and Jurkat 
cells, respectively, using 10-5 M Camp. Data shown are mean values (+SD) of 2 (EBV-JTO) or 4 (Jurkat) 
independent experiments.
‡  p > 0.05; inhibition was considered signiﬁcant if p ≤ 0.05.
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cells after 5 and 24 hrs of exposure were 10 and 1 ng/mL of Fas Ab, respectively. 
Percentages of inhibition of Fas-induced apoptosis by FLIP and PI-9 after 5 hrs 
(left panel) and 24 hrs (right panel) of exposure are shown in Figure 5.1B. FLIP 
expression resulted in efﬁcient and signiﬁcant (p<0.05) inhibition of Fas-mediated 
apoptosis in EBV-JTO cells (75-90%), while the inhibitory effect of the same construct 
was less pronounced in Jurkat cells (30-50%). Unexpectedly, PI-9 also caused 40-
70% and 20-30% inhibition of Fas-induced apoptosis in EBV-JTO and Jurkat cells, 
respectively. The lower the concentration of Fas Ab used, the higher the inhibitory 
effect of both FLIP and PI-9 we observed. 
To ensure that introduction of PI-9 did not render EBV-JTO and Jurkat cells into 
less responsive cells in general, we exposed the WT, FLIP- or PI-9-transduced cell 
lines to various concentrations of the cytostatic agent camptothecin (Alexis Corp., 
Lausanne, Switzerland). Camptothecin-induced cell death was not inhibited by FLIP 
or PI-9 in both cell lines (Figure 5.1C). Moreover, upregulation of PI-9 in EBV-JTO 
cells did not inﬂuence lysis caused by other chemotherapeutic agents such as Ara-C 
or daunorubicin (data not shown).  
We demonstrated that in both EBV-JTO and Jurkat cells, PI-9 signiﬁcantly inhibited 
Fas-induced apoptosis. This is in contrast with results from other groups showing that 
PI-9 selectively inhibits GrB-mediated apoptosis without affecting Fas-induced cell 
death in Jurkat cells. 8;9 We showed that the inhibition of Fas-induced cell death by 
PI-9 was much more pronounced in EBV-JTO cells than in Jurkat cells, suggesting 
that the inhibitory effect of PI-9 on Fas-induced apoptosis is dependent on the cell 
line studied. Jurkat cells are so-called type II cells, in which Fas-induced apoptosis 
is partially executed via the mitochondria through caspase-8-mediated cleavage 
of BH3-interacting-domain death agonist (Bid), a member of the pro-apoptotic 
B-cell lymphoma 2 (Bcl-2) family. 1 This explains the partial inhibition of Fas-induced 
apoptosis we observed in Jurkat cells by FLIP and also by Bcl-2 (data not shown). 
In EBV-JTO cells, Fas-induced apoptosis was completely mediated via the death 
receptor pathway, since FLIP expression almost completely inhibited Fas-induced 
apoptosis (Figure 5.1B). 
It is not known at what level PI-9 interferes with the death receptor pathway. 
We speculate that PI-9 perturbs the death receptor pathway downstream from 
caspase-8 activation. Fas-induced apoptosis in Jurkat cells will be less affected by 
this intervention, since apoptosis can still be executed via the mitochondrial bypass. 
Bird et al. demonstrated that PI-9 poorly inhibited caspase-8 activation in vitro (10%), 
but efﬁciently blocked activation of caspase-4 (70%), and to a less extent (35%) of 
caspase-10. 8 Caspase-4 has a thus far unknown function, but intervention of Fas-
induced apoptosis by PI-9 may occur at the level of caspase-10, since this protein 
has been reported to play a role in the death receptor pathway of apoptosis. 10
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In conclusion, here we demonstrate that PI-9 interferes with the Fas cell death 
pathway, and hence is less speciﬁc for the PFN/GrB pathway than previously reported. 
Consequently, poor clinical outcomes associated with elevated PI-9 levels may not 
automatically implicate disruption of T-cell-induced PFN/GrB-mediated apoptosis, 
but can also be the result of blockade of the death receptor pathway which may affect 
chemotherapy treatment.
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ABSTRACT
Background and objectives. Cytotoxic T lymphocytes (CTL) are considered to 
selectively kill target cells via granule-mediated or death-receptor-induced apoptosis 
after T cell receptor (TCR) dependent recognition of a speciﬁc peptide presented in 
the context of the correct HLA molecules. In this study, we examined a CTL-mediated 
mechanism of killing target cells which is non Major Histocompatibility Complex 
(MHC)-restricted and independent of TCR-triggering. 
Design and Methods. We investigated lysis of various HLA-A2 positive and negative 
target cells derived from patients with acute lymphoblastic leukemia (ALL) by HLA-
A2-restricted CTL clones via MHC-restricted and non MHC-restricted interactions. We 
studied the involvement of granule-mediated and death-receptor-induced apoptosis 
using blocking studies with ethylene glycol tetraacetic acid (EGTA) and introduction 
of caspase-8 (FLICE) like inhibitory protein (FLIP) overexpression in the different 
target cells, respectively. 
Results. We showed that HLA-A2-restricted T cell clones killed HLA-A2-expressing 
target cells via classical TCR/MHC-dependent interactions resulting in 40-70% lysis 
after 4 hours of incubation (E/T ratio = 10/1). As a consequence of this speciﬁc TCR 
triggering, the T cells downregulated their expression of TCR and CD8 and produced 
interferon (IFN)-γ. This MHC-restricted target cell death was completely inhibited by 
pre-incubating the T cells with EGTA. In addition to MHC-restricted target cell death 
at the same E/T ratio the CTL clones exerted non MHC-restricted target cell death 
(10-30%) after 10 hours of coculture, which was not accompanied by IFN-γ release 
and TCR downregulation, and could be speciﬁcally inhibited by blocking the death-
receptor pathway by overexpression of FLIP in the target cells. 
Interpretation and Conclusions. In conclusion, we demonstrate that CTLs can 
mediate target cell death via a MHC-restricted and non-restricted interaction. 
MHC-restricted lysis is mediated via the perforin (PFN)/Granzyme B (GrB) pathway 
of killing, whereas non MHC-restricted cell death is mediated via the death receptor 
pathway of killing. 
 
INTRODUCTION
T cell receptors (TCR) of cytotoxic CD8+ T cells recognize a complex consisting of 
class I Major Histocompatibility Complex (MHC) molecules and antigenic peptides, 
mainly derived from intracellular processing of endogenously synthesized proteins. 1 
In response to TCR-dependent recognition of target antigen, cytotoxic T lymphocytes 
(CTLs) potentially use two effector pathways to mediate target cell death: granule-
mediated and death receptor-mediated killing. 2;3 In granule-mediated killing, 
TCR-triggering of the T cell induces exocytosis of preformed cytotoxic granules, 
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containing perforin (PFN) and various granzymes including granzyme B (GrB). 4;5 
Intracellular delivery of GrB into the target cell results in apoptosis via direct proteolytic 
activation of caspase-3 or via induction of the mitochondrial pathway of apoptosis. 5 
In death receptor-mediated killing, TCR-triggering induces expression of death ligands 
(Fas ligand (FasL), tumor necrosis factor (TNF)-α, TNF-related apoptosis inducing 
ligand (TRAIL)) on the T-cell membrane, which cross-link death receptors expressed 
on the target cells. 2;6 Upon trimerization of the death receptor, a signaling cascade is 
initiated in which caspase-8, also called Fas Associated Death Domain (FADD)-like 
IL-1 converting enzyme (FLICE), 7 plays a vital role, eventually leading to apoptosis. 8;9 
Granule-mediated cell death has been reported to play an important role in the 
elimination of virus-infected cells and malignant cells. 10;11 In contrast, death receptor-
mediated cell death has primarily been described to be involved in eliminating 
autoreactive T cells and in downsizing of immune responses after infections. 12-15 
After clearance of an infection, the surplus of T cells has to be deleted to prevent 
collateral damage. Since activated T cells express both death receptors and death 
ligands, neighboring T cells are able to kill each other via induction of death-receptor-
induced apoptosis, a process leading to termination of the immune response. 
To prevent that the T cells kill each other while the infection is still present, this process 
has been reported to only take place in the absence of a speciﬁc TCR/MHC-peptide 
interaction. 16 As long as the cytotoxic T cells are actively engaged via a speciﬁc 
TCR/MHC-peptide interaction, several survival mechanisms have been described 
that protect them from Fas-mediated deletion. 16-18 
Exocytosis of preformed cytotoxic granules by CD8+ T cells is only induced after 
speciﬁc activation of the TCR by the appropriate MHC/peptide complex. This speciﬁc 
triggering of the TCR will lead to internalization of the TCR complex, 19 and in addition 
to cytokine production by the activated T cell. 20;21 In contrast, death-receptor-induced 
apoptosis is not directly dependent on TCR/MHC interaction. 22 Previously, we 
observed that in addition to killing via speciﬁc TCR-mediated recognition of target 
antigen in the context of the appropriate HLA, in vitro CD8+ CTL frequently exert 
non MHC-restricted crossreactivity against B cell malignancies including acute 
lymphoblastic leukemia (ALL). 23 Non MHC-restricted target cell lysis has also 
been reported by other groups. Von Geldern et al. showed that besides a classical 
MHC-restricted mode of killing, the same CTLs can display an NK-like non MHC-
restricted activity towards targets, dependent on the functional status of the T cell. 24 
The group of Reisner reported on TCR-independent cell death of B-cell lineage 
chronic lymphocytic leukemia (B-CLL) cells by allogeneic anti-third-party CTLs, 
although the mechanism of killing of the B-CLL cells was not completely elucidated. 25 
We hypothesized that this non MHC-restricted lysis may be mediated via a similar 
mechanism of killing as used for the removal of T cells after clearance of an infection. 
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We postulate that activated (death ligand expressing) CTLs may kill death receptor-
expressing (neighboring) target cells irrespective of their TCR/MHC speciﬁcity. In the 
absence of speciﬁc TCR triggering this effector-target interaction will not result in 
downregulation of the TCR or its co-receptor CD8, neither in IFN-γ release by the 
T cell.  
In this study, we investigated the recognition of various HLA-A2 positive and 
negative ALL target cells by HLA-A2-restricted CTL clones via MHC-restricted 
and non MHC-restricted interactions. To investigate the involvement of the TCR 
in the recognition of these different target cells, we measured TCR and CD8 
downregulation and IFN-γ production by the T cells. We studied whether MHC-
restricted and non MHC-restricted effector-target interactions resulted in induction 
of different apoptotic pathways in the target cells. Our results demonstrate that 
T cells can mediate target cell death of ALL cells via two distinct mechanisms. MHC-
restricted lysis is mediated via the PFN/GrB pathway of killing, whereas non MHC-
restricted cell death is mediated via the death receptor pathway of killing. 
 
MATERIALS AND METHODS
Cells and culture conditions
The human acute lymphoblastic leukemia cell lines Leiden ALL-HP (ALL-HP) and Leiden ALL-KW 
(ALL-KW), and the human CML-derived lymphoblastic cell line Leiden ALL-CM (ALL-CM) were 
generated in our laboratory from primary human ALL cells, and kindly provided by Dr. B.A. Nijmeijer. 
These cell lines were phenotypically and karyotypically similar to the primary malignant clone. ALL cell 
lines were cultured in serum-free medium consisting of IMDM supplemented with 3 mM L-glutamine, 
50 µg/mL streptomycin, 50 U/mL penicillin (all Cambrex Bio Science, Verviers, Belgium), 0.4% human 
serum albumin (HSA) (wt/vol) (CLB, Amsterdam, The Netherlands), 20 µg/mL cholesterol (Sigma-Aldrich, 
St Louis, MO, USA), 20 μg/mL transferrin (Serva, Heidelberg, Germany), 5 x 10-5 M β-mercaptoethanol, 
and 10 µg/mL insulin (both Sigma-Aldrich). 
EBV-LCL were cultured in IMDM supplemented with 10% fetal bovine serum (FBS), 3 mM L-glutamine, 
50 µg/mL streptomycin and 50 U/mL penicillin (all Cambrex Bio Science, Verviers, Belgium).
HA1.83 26 and HA2.27 27 are CD8+ HLA-A*0201-restricted T cell clones recognizing the minor 
histocompatibility antigens HA-1 and HA-2, respectively. MBM-15 is a CD8+ HLA-A2-restricted 
alloreactive T cell clone. 28 The T cell clones were cultured in IMDM supplemented with 3 mM L-glutamine, 
50 μg/mL streptomycin, 50 U/mL penicillin, 5% pooled human serum, 5% FBS, and 100 IU/mL IL-2 (Chiron, 
Amsterdam, the Netherlands), and stimulated every 1-2 weeks with a mixture of irradiated allogeneic 
peripheral blood mononuclear cells and 800 ng/mL phytohemagglutinin (PHA, Murex Biotech Limited, 
Dartford, UK).
Cytotoxicity assay and various blocking strategies
Cytotoxicity was measured using 51Cr release assays as described previously. 29 Effector cells and target 
cells were incubated at an E/T ratio of 10/1. For exogenous peptide loading, 51Cr-labeled target cells 
were pulsed with 1 µM peptide for 1 hr at 37°C in 100 µL. The following peptides were used in this study: 
HA-1 (VLHDDLLEA) and HA-2 (YIGEVLVSV). After labeling, excess of peptide was washed away, and the 
target cells were added to the effector cells.
Blocking of Ca2+-dependent PFN/GrB-mediated cytotoxicity was performed by preincubation of the effector 
T cells with 5 mM EGTA (Sigma-Aldrich) for 30 min at 37 oC, prior to addition of the 51Cr-labeled target 
cells. 
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Death-receptor-mediated apoptosis was induced with recombinant human TRAIL (rhsKillerTRAILTM) 
(Alexis Corp., Lausanne, Switzerland) using concentrations from 10 to 100 ng/mL. To determine the role 
of various caspase-8 in CTL-or TRAIL-induced cell death, 51Cr-labeled target cells were pre-incubated for 
1 hr with 100 µM of irreversible cell-permeable caspase-8 inhibitor (z-LETD-FMK) (both Alexis) prior to 
addition of effector T cells.
TCR downregulation
For analysis of TCR and CD8 downregulation, 20,000 T cells were stimulated with 20,000 target cells. 
These incubations were performed in medium containing low concentrations of IL-2 (30 instead of 
100 IU/mL) to prevent spontaneous activation of T cells by high amounts of IL-2. After 5 hrs, reactions 
were stopped by placing the samples on ice, and FACS analysis was performed in duplicate using 
PECy5-labeled TCRαβ (clone BMA031, Immunotech, Marseille, France) and APC-labeled CD8α (clone 
3B5, Caltag, Burlingame, CA) speciﬁc antibodies. TCR and CD8 surface expression on the T cells after 
incubation with non-stimulator (HLA-disparate) cells was set as 100%. Percentages of downregulation 
were calculated as follows: 
% of downregulation (stimulator) = [1-(mean MFI stimulator / mean MFI non-stimulator)] * 100.
IFN-γ production
For analysis of IFN-γ production, 5,000 T cells were stimulated with 30,000 stimulator cells. After 24 hrs, 
supernatant was harvested, and the concentration of IFN-γ was measured in duplicate by standard ELISA 
(CLB, Amsterdam, The Netherlands).
Generation of retroviral constructs and transduction of target cells
FLAG-tagged FLICE inhibitory protein (FLIP) encoding PCR products were generated as described 
previously, 30 and cloned into the Moloney murine leukemia virus-based retrovirus vector LZRS (G. Nolan, 
Stanford University, Palo Alto, CA) containing the truncated nerve growth factor receptor (∆NGF-R) as the 
marker gene. 31 Retroviral pLZRS vector encoding ∆NGF-R alone was used as a control vector (mocκ) 
in the experiments. Generation of retroviral supernatant and retroviral transduction of target cells were 
performed as previously described. 28 FLIP-transduced cells were puriﬁed by cell sorting using NGFR-
speciﬁc antibodies (BD BioSciences, San Diego, CA, USA). 
 
RESULTS
MHC-restricted and non MHC-restricted CTL-mediated target cell death
We examined the HLA-A*0201-restricted CTL clones HA1.83 and HA2.27 recognizing 
the minor histocompatibility antigens HA-1 and HA-2, respectively, as well as 
the alloreactive HLA-A2-restricted CTL MBM-15 for their capacity to kill various 
HLA-A*0201 positive and negative target cells. Percentages of lysis were determined 
after 4 and 10 hrs of coculture using standard 51Cr release assays, and are shown 
in Figures 6.1A and B, respectively. After 4 hrs of incubation the HLA-A*0201 and 
HA-1 and HA-2 expressing cell lines ALL-CM and EBV-BDV were recognized by all 
three CTL clones resulting in 40-70% of lysis (Figure 6.1A). EBV-Z cells expressing 
HLA-A*0201 but not the minor antigens HA-1 and HA-2 were killed by MBM-15. 
Speciﬁc lysis by the CTL clones HA1.83 and HA2.27 was observed after exogenously 
pulsing with speciﬁc peptides (EBV-Z + pep). HLA-A*02 negative target cells 
(ALL-KW) were not killed by any of the three CTL clones. HA-1 and HA-2 positive 
target cells expressing the HLA-A2 subtype variant HLA-A*0205 (ALL-HP) were not 
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recognized by HA1.83 and HA2.27, whereas 30% of speciﬁc lysis of these cells was 
observed after 4 hrs of coculture with the alloreactive CTL MBM-15, illustrating that 
this CTL clone can also recognize other HLA-A2 subtype variants. These data show 
that after 4 hrs of incubation CTL clones only display speciﬁc MHC-restricted target 
cell death, and are not reactive with HLA-disparate or mHag negative target cells. 
In contrast, after 10 hrs of incubation, in addition to MHC-restricted target cell death 
all three HLA-A*02-restricted CTL clones showed lysis of HLA-A*02 negative target 
cells, varying from 10 to 30%. These data suggest that T cell clones are not only 
capable of lysing target cells via a speciﬁc TCR-MHC/peptide interaction, but also via 
a non MHC-restricted mechanism.
Figure 6.1. HLA-A*0201 speciﬁc CTLs mediate target cell death via a MHC-restricted and non MHC-
restricted interaction. 
Percentages of lysis were determined after 4 hrs (A) and 10 hrs (B) of incubation of different 
HLA-A*0201 positive and negative target cells with the HA-1 and HA-2 speciﬁc CTL clones HA1.83 and 
HA2.27 and the alloreactive CTL MBM-15, at an E/T ratio of 10/1. Results are representative of 3 or 
more independent experiments. EBV-Z is a HLA-A*0201+ HA-1- HA-2- target cell. EBV-Z +pep indicates 
EBV-Z exogenously loaded with HA-1 and HA-2 peptide. 
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Differential TCR involvement and T cell activation in MHC-restricted and non 
MHC-restricted target cell recognition
One of the hallmarks of TCR-dependent effector-target interaction is internalization 
of the TCR-MHC/peptide complex by the T cell resulting in decreased expression 
of the TCR and its co-receptor CD8 on the membrane of the T cell. To investigate 
whether TCR triggering is involved in the recognition of non MHC-restricted target 
cells, the T cell clones HA2.27 and MBM-15 were cocultured for 5 hrs with the same 
HLA-A*0201 positive and negative target cells as mentioned in Figure 6.1. 
FACS analysis showed that expression levels of TCRαβ and CD8 on HLA-A2-
restricted CTLs were similar after culturing for 5 hrs in medium alone or in presence 
of HLA-A2 negative ALL-KW cells (data not shown). Therefore, the HLA-A2 
negative ALL-KW cells were used in these experiments as non-stimulator cells. 
The percentages of TCR and CD8 downregulation were calculated as described 
in the Materials and Methods section, and representative results are shown in 
Figure 6.2A and B, respectively. Downregulation of both TCRαβ and CD8 was 
only observed in HA2.27 when stimulated with the HLA-A*0201+ HA-2+ target cells 
ALL-CM and EBV-BDV, or with the HLA-A*0201+ HA-2- EBV-Z target cells exogenously 
loaded with HA-2 peptide. In contrast, MBM-15 also internalized its TCR complex 
when stimulated with the HLA-A*0205 expressing cell line ALL-HP, which correlated 
with the lysis found with the same T cell clone, as shown in Figure 6.1. 
Because TCR triggering will result in T cell activation and concomitant cytokine 
release, we also determined IFN-γ production by HA2.27 and MBM-15 after stimulation 
with the same target cells for 24 hrs. As shown in Figure 6.2C, no IFN-γ production 
was found by the T cells without antigen-speciﬁc stimulation. HA2.27 produced high 
amounts of IFN-γ (1500-2500 pg/mL) in case of TCR/MHC speciﬁc interactions 
(ALL-CM, EBV-BDV and EBV-Z loaded with HA-2 peptide), whereas no IFN-γ release 
was measured after stimulation with ALL-KW (HLA-A2-), ALL-HP (HLA-A*0205) or 
EBV-Z (HLA-A*0201+ HA-2-) cells. MBM-15 produced IFN-γ in response to both 
HLA-A*0201 and HLA-A*0205 expressing target cells but not to the HLA-A2 negative 
cell line ALL-KW. 
In conclusion, these data show that T cell clones may kill target cells via a non 
MHC-restricted mechanism, which is not accompanied by downregulation of the 
TCR complex or by IFN-γ production. Apparently, in contrast to TCR/MHC-speciﬁc 
recognition TCR triggering is not involved in CTL-induced cell death of non MHC-
restricted target cells.
CTL-induced MHC-restricted and non MHC-restricted target cell death are 
executed via induction of two distinct effector pathways 
To investigate whether MHC-restricted and non MHC-restricted CTL-mediated target 
cell death were induced via activation of differential effector pathways, we selectively 
blocked the two main potential effector pathways, and examined the inhibitory effect 
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on CTL-mediated lysis of ALL-CM (A*0201+) versus ALL-HP (A*0205+) target cells. 
ALL-HP target cells were used instead of ALL-KW cells since both MHC-restricted 
and non MHC-restricted cell death could be analyzed in this cell line using the CTL 
clones MBM-15, and HA1.83 or HA2.27, respectively.
Figure 6.2. Non MHC-restricted effector-target interactions do not result in internalization of the 
TCR complex or in CTL-mediated IFN-γ production. 
The HLA-A*0201-restricted HA-2 speciﬁc CTL HA2.27 and the HLA-A2 speciﬁc alloreactive CTL 
MBM-15 were stimulated with various HLA-A*0201 positive and negative target cells. After 5 hrs, 
expression levels of TCRαβ and CD8 were determined by FACS analysis, and percentages of TCR (A) 
and CD8 (B) downregulation were calculated as described in the Materials and Methods. ALL-KW cells 
were used as non-stimulator cells. After 24 hrs, IFN-γ production (pg/mL; in triplicate + SD) was measured 
using standard ELISA reactions (C). 
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PFN/GrB-mediated lysis was blocked by incubating CTLs with the Ca2+-chelator 
EGTA, which has been reported to efﬁciently inhibit all secretion pathways in the 
T cell. 32 Death-receptor-induced apoptosis was inhibited by introduction of a retroviral 
construct encoding FLIP, an efﬁcient inhibitor of death-receptor-induced apoptosis, 33
into ALL-HP and ALL-CM target cells (more than 90% pure populations after 
enrichment using cell sorting). Death-receptor-induced apoptosis was previously 
shown to be efﬁciently inhibited in these FLIP-expressing ALL cell lines. 30 
Previous studies showed that granule-induced and death-receptor-mediated 
apoptosis differ in time required to eliminate target cells. PFN/GrB-mediated target 
cell death can already take place within 2 hrs of incubation, whereas death-receptor-
Figure 6.3. CTL-induced MHC-restricted and non MHC-restricted target cell death are mediated via 
activation of two distinct effector pathways. 
The effect of enhanced expression of the anti-apoptotic protein FLIP or addition of EGTA on the kinetics 
of lysis of (A) ALL-CM (HLA-A*0201+) and (B) ALL-HP (HLA-A*0205+) target cells by various CTLs was 
studied. Percentages of lysis of WT or FLIP-expressing ALL-CM (▲) and ALL-HP (●) cells by CTL clones 
HA1.83, HA2.27 and MBM-15 (E/T ratio = 10/1) in presence or absence of 5 mM EGTA were determined 
after 2, 5 and 10 hrs of incubation using standard 51Cr release assays. Results are representative of at 
least 3 independent experiments.
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mediated apoptosis was observed after 5-24 hrs of coculture. 34 Therefore, in these 
experiments speciﬁc lysis was determined after 2, 5 and 10 hrs of incubation with 
HA1.83, HA2.27, or MBM-15. Kinetics of cell death of the HLA-A*0201+ ALL-CM 
(▲) and HLA-A*0205+ ALL-HP (●) cells by the three T cell clones are shown in 
Figure 6.3A and B, respectively. All three CTL clones showed rapid kinetics of killing 
HLA-A*0201 positive ALL-CM cells (25% lysis within 2 hrs), suggesting a granule-
dependent mechanism of killing. In line with this, expression of FLIP had no effect 
on lysis of ALL-CM cells by the three CTL clones, whereas blocking experiments 
with EGTA showed almost complete inhibition of CTL-induced lysis of ALL-CM cells. 
These data indicate that MHC-restricted CTL-induced cell death of ALL-CM cells is 
mainly directly PFN or PFN/GrB-mediated.
Kinetics of lysis of ALL-HP cells by MBM-15 (Figure 6.3B) was comparable to ALL-
CM cells. This lysis was efﬁciently inhibited by EGTA, while overexpression of 
FLIP in the target cell had no effect, again illustrating the involvement of PFN/GrB 
in MHC-restricted cell death. CTL clones HA2.27 and HA1.83 were not capable of 
lysing ALL-HP cells in the ﬁrst 5 hrs of incubation, as also shown in Figure 6.1A. 
In the time interval from 5 to 10 hrs, up to 30% target cell death was observed. 
This lysis of ALL-HP cells was completely inhibited by overexpression of FLIP, while 
no inhibition was observed using EGTA, illustrating that non MHC-restricted lysis 
was mediated via the death receptor pathway of apoptosis. Noteworthy, the same 
minor percentages of non MHC-restricted, death-receptor-mediated apoptosis by 
the three T cell clones could be observed in the HLA-A*0201 positive ALL-CM cells 
(Figure 6.3A), since EGTA was not able to completely inhibit CTL-induced cell death 
between 5 and 10 hrs of incubation (dashed lines).
Since caspase-8 activation is essential in death-receptor-mediated apoptosis, we 
assessed the role of this caspase in HA2.27-induced cell death of ALL-HP and ALL-
CM cells using a speciﬁc caspase-8 inhibitor (Figure 6.4). As a control, the effect 
of caspase-8 inhibitor on TRAIL-induced apoptosis was determined. TRAIL-induced 
apoptosis was blocked in both cell lines by caspase-8 inhibitor (zLETD-FMK). HA2.27-
induced cell death of ALL-HP cells but not of ALL-CM cells was efﬁciently blocked 
with caspase-8 inhibitor, illustrating the importance of the death-receptor pathway in 
non MHC-restricted but not in MHC-restricted target cell death.
DISCUSSION
Cytotoxic T cells are considered to selectively kill target cells after recognition of a 
speciﬁc MHC-peptide complex by their TCR. As a consequence of activation via their 
TCR, the T cells will internalize the TCR complex, 19 and produce IFN-γ. 20;21 Here, we 
demonstrate another mechanism of target cell killing which is non MHC-restricted. 
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The CD8+ T cells killed these target cells in a non MHC-restricted manner, did not 
show TCR down regulation, and produced no IFN-γ, indicating that target recognition 
was TCR-independent. We showed that HLA-peptide speciﬁc lysis of target cells was 
almost completely mediated via granule-mediated cell death, whereas non MHC-
restricted target cell death was exclusively mediated via the death-receptor pathway 
(Figure 6.3). 
Arditti et al. showed that anti-third-party CTLs were capable of efﬁciently killing 
B-CLL cells but not AML blasts in a non MHC-restricted manner via a TCR-independent 
mechanism of killing. 25 Since we here demonstrate a similar phenomenon in ALL cells 
and EBV-LCL, CTL-induced non MHC-restricted killing may be speciﬁcally occurring 
in B cells. Although the same group observed an upregulation of CD95/FasR in the 
B-CLL cells after coculturing with anti-third party CTLs, they also showed that 
blocking experiments using CD95 antibodies did not inhibit B-CLL-killing by these 
anti-third-party CTLs. Therefore, they concluded that the killing was not mediated via 
Fas-induced apoptosis. However, the killing they observed may still have been death-
receptor-mediated, since we also did not obtain inhibition of non MHC-restricted 
target cell death using CD95 blocking antibodies (data not shown). In contrast, 
complete inhibition was observed when FLIP expression was enhanced in the target 
Figure 6.4. The role of caspase-8 in non MHC-restricted target cell death. 
ALL-CM and ALL-HP cells were exposed for 20 hrs to 100 ng/mL TRAIL or to the CTL clone HA2.27 at an 
E/T ratio of 10/1, in presence or absence of the caspase-8 inhibitor z-LETD-FMK (10-4 M). Target cell death 
was determined using 51Cr release assays. 
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cell, suggesting that other death ligands such as TNF or TRAIL may be involved in 
the mechanism of non MHC-restricted killing by the CTLs.
In our study, T cells were activated using irradiated feeder cells, PHA and IL-2, which 
will result in the upregulation of death ligands on the T cell membrane and an increase 
in expression of intracellular levels of perforin and granzymes. One to two weeks 
after stimulation these activated T cells were brought into close contact with peptide/
MHC disparate target cells (in a 96-wells round-bottom plate) in absence of speciﬁc 
peptide/MHC expressing targets. Since death-receptor-induced apoptosis itself is 
not directly dependent on TCR/MHC interaction, 22 we hypothesized that all death 
receptor-expressing target cells may be responsive to these death ligand-expressing 
T cells. This may explain the lysis of HLA-A*0201 negative target cells by activated 
HLA-A*0201-restricted T cells shown in Figure 6.1. 
In addition to recognition of HLA-A*0201, the HLA-A2-restricted alloreactive CTL 
clone MBM-15 showed reactivity to the HLA-A*0205 expressing cell line ALL-HP. 
Lysis of ALL-HP cells by MBM-15 was already observed after 2-5 hrs of incubation 
(Figures 6.1A and 6.3B), showing similar kinetics of cell death as observed in the HLA-
A*0201 expressing cell line ALL-CM. FACS analysis revealed that after stimulation with 
ALL-HP, the expression of membrane-bound TCRαβ and CD8 was downregulated, 
suggesting internalization of the TCR complex by MBM-15. Furthermore, MBM-
15-mediated cell death of ALL-HP cells was accompanied by release of IFN-γ 
(Figure 6.2), which is characteristic of classical TCR-dependent recognition of 
target cells. 21 In contrast, lysis of ALL-HP cells by the HLA-A*0201-restricted CTL 
clones HA1.83 and HA2.27 was only observed after 10 hrs of coculture and was not 
coincided with TCR downregulation and IFN-γ release, which we assume to be non 
MHC-restricted CTL-induced target cell death.
In this study we demonstrated that non MHC-restricted target cell death was mediated 
via the death receptor pathway of apoptosis. In vivo, this mechanism of cell death 
has been described to play a role in the regulation of an immune response. 12-15 
After clearance of an infection the surplus of activated cytotoxic effector T cells is 
deleted via a TCR/MHC-peptide-independent death-receptor-mediated apoptosis 
mechanism 16 to prevent collateral damage caused by a cytokine storm. However, 
non MHC-restricted target cell death may also result in collateral damage since 
in presence of speciﬁc target cells, CD8+ murine T cells have been reported to kill 
non MHC-restricted bystander cells via a Fas ligand/Fas-based mechanism. 35;36 
We suppose that the destructive effect of this bystander lysis will probably be 
minimal, because: 1) bystander lysis can only happen temporarily: when all MHC-
restricted target cells have been killed, the TCR-MHC speciﬁc interaction is lost and 
the cytotoxic T cells will kill each other via death-receptor-induced apoptosis; 2) only 
death-receptor expressing bystander cells will be killed.
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In conclusion, here we show that CTLs can mediate target cell death via a MHC-
restricted and a non MHC-restricted interaction. TCR/MHC-speciﬁc interactions 
between target and effector cell led to PFN/GrB-induced cell death of the target cell, 
while non MHC-restricted interactions between effector and target cells activated the 
death receptor pathway in the target cell. 
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SUMMARY
Failure of therapy due to acquired resistance is one of the major problems in the 
treatment of patients with acute leukemia. Initially, most patients respond well to 
induction chemotherapy usually consisting of a combination of cytostatic agents 
including daunorubicin, vincristine, methotrexate, and cytarabine (Ara-C), 1-3 leading 
to 70-80% complete remissions (CR). However, despite aggressive induction and 
consolidation therapy, relapses of the disease frequently occur (50-60%) resulting 
in low overall 5-year survival rates of patients with acute myeloid leukemia (AML) 
and acute lymphoblastic leukemia (ALL). 4;5 Those patients who relapse more than 
one year after diagnosis have a good chance to achieve a second remission after 
administration of the original induction regimen, or at least one of similar intensity. 
The most effective post-remission therapy, however, is high-dose chemotherapy and 
total body irradiation followed by allogeneic or autologous stem cell transplantation 
(SCT), using stem cells from a (partially) HLA-matched donor or from the patient, 
respectively. SCT can be considered as a rescue procedure to achieve immunologic 
reconstitution in patients of whom both malignant and normal hematopoiesis were 
destroyed. The advantage of allogeneic SCT (followed by donor lymphocyte infusions 
(DLI) at relapse) is that besides causing immunologic reconstitution the donor T cells 
in the graft may recognize and attack the residual leukemic cells, leading to a graft-
versus-leukemia (GVL) effect. 
Patients who never achieve a CR or who experience a relapse within 6 months 
(during treatment) are considered to be resistant to further cytotoxic treatment. 
Various mechanisms may underlie this resistance, including expression of drug 
efﬂux pumps, 6-8 and cell cycle status of the leukemic cell. 9;10 Another cause for the 
unresponsiveness of leukemic cells to chemotherapy has been shown to be defects 
in the apoptotic machinery of these leukemic cells. 11-17 
Cytostatic agents (chemotherapy) and donor-derived T lymphocytes (cellular 
immunotherapy) kill leukemic cells via induction of apoptosis in the target cell. 
Aberrations in common apoptotic pathways may therefore cause unresponsiveness 
to both forms of therapy, as has been observed in some patients. Other patients are 
resistant to chemotherapy but do respond to DLI, indicating that these patients may 
have defects in chemotherapy-speciﬁc pathways. Assessment of potential defects 
in apoptotic pathways is only possible when the functional apoptotic pathways are 
unraveled in more detail.  Although general therapy-induced apoptotic pathways 
have been described (Figure 7.1), actual apoptotic mechanisms are mostly much 
more complicated than shown in this ﬁgure. This thesis emphasizes the complexity 
of the apoptotic pathways that are induced in leukemic cells after treatment with 
conventional cytostatic drugs or with cytotoxic T cells. Moreover, several controversies 
that still exist in the ﬁeld of apoptosis research are highlighted in this thesis, and at 
least partially unraveled. 
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The cell cycle status of leukemic cells affects their sensitivity to chemotherapy, since 
most chemotherapeutic agents speciﬁcally act on proliferating (S or G2/M phase) or at 
least activated (G1) cells, while quiescent (G0) cells are considered to be unresponsive. 
Incorporation of Ara-C into DNA, a process speciﬁcally occurring during S-phase of 
the cell cycle, is assumed to be a key event in the mechanism of killing of proliferating 
leukemic cells. 19 Chapter 2 describes the unexpected potential of Ara-C to cause 
apoptosis, characterized by phosphatidyl serine exposure on the cell membrane 
and caspase activation, in resting (>98% in G0) primary B cells derived from four 
previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL). Cell 
cycle analysis combined with long-term analysis of cell death using CFSE-based 
cytotoxicity assays conﬁrmed that these non-proliferating B-CLL cells were killed by 
Ara-C in G0 phase of the cell cycle. 
Since inhibition of DNA incorporation was not the mechanism of action of Ara-C in 
G0-B-CLL cells, other cellular processes must be involved. We demonstrated that 
increasing concentrations of deoxycytidine (dC) blocked both the formation of Ara-
CTP and Ara-C-induced cell death of G0-B-CLL cells. dC is a structural analogue of 
Ara-C and the normal metabolite of both RNA and DNA synthesis. In contrast to DNA 
(repair) synthesis which was hardly detectable, unexpectedly high RNA synthesis 
was present in G0-B-CLL cells. This RNA synthesis was blocked by Ara-C for 30%, 
suggesting that inhibition of RNA synthesis is a potential mechanism of killing resting 
Figure 7.1. Apoptotic pathways induced by chemotherapy or (cellular) immunotherapy (partly 
adapted from Siegel 18).
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G0-B-CLL cells by Ara-C. B-CLL cells are characterized by high expression levels 
of B-cell lymphoma-2 (Bcl-2) protein, which causes the prolonged survival of these 
malignant cells. 20 One of the initiating mechanisms for drug-induced apoptosis in 
B-CLL cells has been reported to be alteration of the expression levels of pro- or anti-
apoptotic proteins (Bcl-2/Bax ratio 21;22). Therefore, we analyzed whether addition of 
Ara-C resulted in alterations in Bcl-2, Bax or Mcl-1 protein levels. We showed that 
the survival protein Mcl-1 was downregulated in response to Ara-C, which may be a 
consequence of the decreased RNA synthesis. In conclusion, both downregulation of 
RNA synthesis and Mcl-1 expression appear to contribute to the mechanism of action 
of Ara-C in G0-B-CLL cells.
Besides investigating the mechanisms that are involved in chemotherapy-induced 
apoptosis of resting leukemic cells, it is very important to gain more insight into the 
apoptotic pathways induced by cytostatic agents in proliferating leukemic cells, since 
resistance of leukemic cells to chemotherapy-induced apoptosis frequently occurs 
in patients with acute leukemia. One of the controversial topics in chemotherapy-
induced apoptosis is the pathway via which cell death is initiated. Treatment with 
chemotherapy may lead to speciﬁc activation of the mitochondrial pathway, in which 
cytochrome C release and caspase-9 activation have been reported to play a central 
role. (Figure 7.1) 23,24 Alternatively or perhaps additionally it may activate the death 
receptor pathway of apoptosis, in which formation of a Death Inducing Signaling 
Complex (DISC) and caspase-8 (FLICE) activation are key events. 25 In Chapter 3 of 
this thesis, the role of the death receptor pathway in chemotherapy-induced apoptosis 
of human derived myeloid and lymphoblastic leukemia cell lines is described. 
The rapid and substantial activation of caspase-8 that we observed after treatment 
with camptothecin, combined with the effective inhibition of chemotherapy-induced 
apoptosis by caspase-8 inhibitor, strongly suggested involvement of the death-
receptor pathway in apoptosis induced by cytostatic agents. This assumption was 
examined by introducing retroviral constructs encoding Bcl-2 or FLICE inhibitory 
protein (FLIP) into the target cells, and subsequently analyzing the sensitivity of 
these cell lines for various cytostatic drugs. Enhanced Bcl-2 expression was used 
to speciﬁcally block the mitochondrial pathway, whereas FLIP selectively prevented 
death-receptor-induced apoptosis. No inhibitory effect of elevated expression of FLIP 
on camptothecin-induced apoptosis or caspase-8 activation was observed, while 
introduction of Bcl-2 resulted in almost complete inhibition of camptothecin-mediated 
cell death and caspase-8 activation in all three cell lines studied, indicating that in 
these cell lines chemotherapy-induced apoptosis is completely dependent on the 
mitochondrial pathway. Moreover, caspase-8 apparently plays a central role in both 
death receptor- and chemotherapy-induced apoptosis of malignant cells from patients 
with acute leukemia. 
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Not only controversy existed about the role of the death receptor pathway in 
chemotherapy-induced apoptosis, the involvement of this pathway in the elimination 
of leukemic cells by cytotoxic T lymphocytes (CTLs) was also largely unclear. In 
Chapter 4 we studied whether in addition to cell death mediated by perforin (PFN) and 
granzyme B (GrB) death receptor-induced apoptosis contributes to the elimination of 
human tumor cells by CTLs. In most studies that have been published, CTL-mediated 
target cell death was only analyzed after 4 hrs of interaction between target and 
effector cell. Since death-receptor-mediated apoptosis is slow compared to PFN/GrB-
induced cell death, in this study we used T cell clones with slow and rapid kinetics of 
killing derived from a patient with chronic myeloid leukemia (CML), and analyzed cell 
death in various time intervals. The three CTL clones used in this study all recognized 
primary CML cells from the patient. Because for these types of studies insufﬁcient 
leukemic cells can be isolated from the patient, EBV-LCL from the patient were used 
as target cells in this study. To determine the involvement of the death receptor 
pathway, a retroviral construct encoding FLIP was introduced into these target cells. 
A CTL clone capable of killing 50% of the target cells within 2 hrs of incubation 
primarily acted by release of PFN and GrB (no inhibition by FLIP was observed). 
In contrast, two CTL clones showing slower target cell killing kinetics partially used the 
death receptor pathway (~30% inhibition by FLIP). Thus, not only PFN/GrB release 
but also the death receptor pathway can play a role in the execution mechanism of 
cytotoxic T cells.
Whereas the anti-apoptotic protein FLIP speciﬁcally blocks the death-receptor 
pathway of apoptosis, proteinase inhibitor-9 (PI-9) has been reported to be a speciﬁc 
inhibitor of GrB-induced cell death, 26-28 and should therefore not affect Fas-induced 
apoptosis. However, in Chapter 5, we demonstrate that PI-9 is less speciﬁc than 
previously expected. Two different cell lines transduced with retroviral constructs 
encoding FLIP or PI-9 together with their wild type counterparts were exposed for 5 
or 24 hrs to Fas apoptosis-inducing antibodies. In both types of cell lines we showed 
substantial and signiﬁcant inhibition of Fas-induced apoptosis by enhanced PI-9 
expression, although the levels of inhibition were lower than in the FLIP-expressing 
cell lines. PI-9 did not affect chemotherapy-induced apoptosis, showing that PI-9 
interferes with the death receptor pathway but not with the mitochondrial pathway. 
Cytotoxic T cells are considered to selectively kill target cells after speciﬁc TCR-
mediated recognition of target antigen in the context of the appropriate HLA. 
In Chapter 6, we describe another T cell-mediated mechanism of killing target cells 
which is non MHC-restricted and is independent of TCR-triggering. HLA-A2-restricted 
CTL clones showed cytolytic activity to HLA-A2-expressing target cells via classical 
TCR/MHC-dependent interactions resulting in 40-70% lysis after 4 hrs of incubation. 
As a consequence of this speciﬁc TCR triggering, the T cells internalized their 
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TCRs, and produced interferon (IFN)-γ. This MHC-restricted target cell death was 
completely inhibited by pre-incubating the T cells with the calcium chelator EGTA, 
which inhibits all secretion pathways of the CTL, showing that the lysis was mediated 
by PFN and/or GrB. In addition the same CTL clones exerted non MHC-restricted 
target cell death (10-30%) after 10 hrs of coculture, which was not accompanied by 
TCR downregulation and IFN-γ release. This lysis could be speciﬁcally blocked by 
FLIP expression in the target cells, demonstrating death-receptor-induced apoptosis. 
A similar non MHC-restricted mechanism of killing is used for the removal of the 
surplus of T cells after clearance of an infection to prevent collateral damage. 29
The results presented in this thesis emphasize the complexity of the mechanisms 
involved in apoptosis induction in leukemic cells after treatment with chemotherapy 
or cellular immunotherapy.
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Background
Defects in the apoptotic machinery of leukemic cells have been shown to cause 
resistance of these cells to chemotherapy and/or cellular immunotherapy. 11-17 
Apoptosis is induced and regulated by a complex network of proteins that are 
connected via various signal transduction cascades. Although the exact pathways 
are not precisely known, induction of apoptosis eventually leads to death of the 
target cell. In the last decades a lot of research has been performed on many 
aspects of apoptosis by different research groups. General proposed mechanisms 
of chemo- and immunotherapy-induced apoptosis have been composed from the 
separate results of these experiments, leading to the simpliﬁed model presented in 
Figure 7.1. One major problem of this model is that it is composed of results of so 
many different experiments, and therefore a “general” mechanism actually does not 
exist. In addition, not all mechanisms of apoptosis are completely unraveled and still 
many controversies exist, which are highlighted in this thesis.
The paradoxic mechanism of action of cytostatic agents like Ara-C
One of the inconsistencies of chemotherapy treatment is the mechanism of action of 
cytostatic drugs like Ara-C. Like other chemotherapeutic agents Ara-C is supposed 
to exert its action preferably in cycling cells. 30-32 Incorporation of Ara-C into DNA, 
a process speciﬁcally occurring during S-phase of the cell cycle, and leading to 
termination of DNA synthesis, is assumed to be a key event in the mechanism of killing 
of proliferating leukemic cells. 19 In addition, Ara-C inhibits DNA repair by blocking 
topoisomerase I-mediated DNA religation. 33 The unexpected killing by Ara-C of 
cells not in proliferation or active phase of the cell cycle, as demonstrated in 
chapter 2 of this  thesis for G0-B-CLL cells, revealed that Ara-C also induces apoptosis 
via other mechanisms of action. Although this observation was not expected, a similar 
phenomenon is seen in patients with acute leukemia treated with chemotherapy, since 
not only the rapidly dividing leukemic blasts, but also normal resting B and T lymphocytes 
are frequently killed by the cytostatic drugs. It is intriguing why these G0 cells are 
killed, while in former studies speciﬁc deletion of cycling cells was demonstrated. 10;33 
In chapter 2, we additionally studied B-CLL cells that were stimulated with CD40L. 
Culturing of B-CLL cells for 7 days on irradiated mouse ﬁbroblasts expressing human 
CD40L induced proliferation in these B-CLL cells resulting in the following cell cycle 
distribution: 15% S/G2M, 69% G1, and 16% G0. These cells were less responsive to 
Ara-C than primary B-CLL cells, but after 48 to 72 hrs of incubation speciﬁc deletion 
of cells from the S-phase of the cell cycle was observed, suggesting that these CD40 
stimulated B-CLL cells behaved more or less like normal proliferating cells. The G0 
cells that were left in this CD40L-stimulated population were unresponsive to Ara-C 
like other G0 cells in proliferating cell lines. Apparently, these CD40L-stimulated “G0” 
cells are not identical to primary B-CLL cells. 
117
Summary and General Discussion
It was demonstrated in chapter 2 that both downregulation of RNA synthesis and 
Mcl-1 expression appear to contribute to the mechanism of action of Ara-C in 
G0-B-CLL cells. Enhanced expression levels of Bcl-2 but perhaps also of Mcl-1 cause 
the prolonged survival observed in B-CLL cells. 20 Nowadays, clinical studies are 
ongoing to investigate the potential of Bcl-2 antisense oligonucleotides (Oblimersen) 
in the treatment of B-CLL. 34 Based on the results of chapter 2, Mcl-1 may be another 
interesting target to downregulate. This hypothesis has to be evaluated in in vitro 
studies aimed at speciﬁc downmodulation of this gene in B-CLL cells, for instance by 
siRNA or antisense RNA strategies. 
The ﬁndings described in chapter 2 will probably not directly imply a clinical application 
for Ara-C in the treatment of B-CLL, especially since combination therapy using a 
combination of ﬂudarabine and Ara-C was not more effective than treatment with 
ﬂudarabine alone. 35 However, the unexpected potential of Ara-C, which has been 
considered to be S-phase speciﬁc, to kill G0-B-CLL cells makes it likely that other 
nucleotide analogues such as gemcitabine or clofarabine may be effective in killing 
B-CLL cells as well.
The controversial role of the death receptor pathway in chemotherapy-induced 
apoptosis
Cytostatic agents have been reported to induce apoptosis via the mitochondrial 
pathway. 23,24 However, involvement of the death receptor pathway in chemotherapy-
induced apoptosis has also been shown by some investigators who reported that 
activation of the death receptor pathway by chemotherapy occurred via extracellular 
triggering of death receptors due to drug-induced upregulation of Fas receptor and 
ligand leading to autocrine or paracrine induction of Fas-mediated apoptosis. 36-40 
In the study described in chapter 3, chemotherapy-induced apoptosis in AML and 
ALL leukemic cell lines was shown to be completely mediated via the mitochondrial 
pathway. Although AML and ALL cell lines were used in this study instead of 
primary leukemic cells, we suppose that especially the ALL cell lines resemble the 
primary ALL cells, and that the results can be extrapolated to the clinical situation. 
The death receptor pathway was not involved, although one of the key regulators 
of this pathway, namely caspase-8, likely played an important role in the execution 
of the leukemic cells by chemotherapy as well. This unexpected involvement of 
caspase-8 in mitochondria-mediated apoptosis makes it likely that in some former 
studies in which chemotherapy-induced caspase-8 activation was found incorrect 
involvement of the death receptor pathway has been concluded. 
The group of Fulda postulated that the pathway of chemotherapy-induced apoptosis 
is cell-type dependent. 41 In so-called type I cells both the death receptor and the 
mitochondrial pathway were activated upon drug treatment, whereas in type II cells 
selective induction of the mitochondrial pathway was demonstrated. According to 
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this theory, AML and ALL cells are categorized as type II cells. Fulda et al. also 
proposed that type II cells are characterized by the fact that Fas-induced apoptosis 
is enhanced via a mitochondrial bypass (see Figure 7.1). 42 In our studies, however, 
apoptosis induced by Fas agonistic antibodies or TRAIL was completely mediated 
by the death receptor pathway, since complete inhibition of Fas-induced apoptosis 
was found in cells overexpressing FLIP while no inhibition was observed in cells with 
Bcl-2 overexpression. Apparently, the classiﬁcation of cells is more complicated than 
a distinction into type I and II cells as suggested by the group of Fulda.
The impact of common elements involved in different apoptotic cascades
An important ﬁnding of this study was that, apparently, caspase-8 plays a central 
role in both death receptor- and chemotherapy-induced apoptosis of malignant cells 
from patients with acute leukemia. To investigate this theory in more detail, additional 
studies should be performed in which caspase-8 expression is downregulated in 
leukemic cells, for instance via a siRNA-based protocol, and subsequently the effect 
of this knockdown on sensitivity to chemotherapy is analyzed. If these data are in line 
with our theory this may have implications for therapy. It is known that caspase-8 is 
downregulated in certain tumors. 15;43;44 Therefore, therapeutic strategies focusing at 
modulation and activation of caspase-8 may sensitize drug-resistant malignancies to 
chemotherapy. However in practice this will be complicated, since caspase-8 is also 
present in normal healthy cells, which will also be destroyed when caspase-8 is not 
speciﬁcally targeted in malignant cells. On the other hand, regular chemotherapy also 
destroys normal hematopoiesis which may be restored by allogeneic SCT.
The existence of common important elements in the mitochondrial and the death 
receptor pathway may also explain the synergistic effect observed using combination 
therapies. Various studies have reported on increased sensitivity of cancer cells to Fas 
or TRAIL when patients were simultaneously treated with low dose chemotherapy. 45;46 
This cotreatment with chemotherapy may cause upregulation of death receptors, 46 
but additionally it may activate common apoptotic elements such as caspase-3 45;47 or 
caspase-8, which later on facilitates TRAIL-induced apoptosis. 
Cross resistance of Fas/TRAIL resistant cells to anticancer agents which is commonly 
observed in leukemia patients, can also partly be explained by defects in a common 
element of both pathways, 48 such as caspase-8. When defects in common elements 
of the two pathways are detected in a patient with leukemia this may be important 
in further treatment stratiﬁcation. Moreover, if CTL-induced target cell death 
is also largely mediated via the death receptor pathway, defects in for instance 
caspase-8 may also cause decreased responsiveness to cellular immunotherapy in 
these patients. 
119
Summary and General Discussion
The inﬂuence of effector-target interactions on the kinetics and the execution 
pathway of CTL-induced target cell death
In response to recognition of target antigen by their membrane TCRs, CTLs 
potentially use two pathways for lysis of target cells. 49;50 Cell lysis occurs either via 
a rapid PFN/GrB-mediated mechanism of cell death (<90 min) 51, or alternatively, via 
activation of the death receptor pathway in the target cell 50;52;53 causing relatively 
slow elimination of this target cell (>4 hrs) 54 as also demonstrated in chapters 4 
and 6 of this thesis. It is largely unknown how these pathways are activated. 
Since cytotoxic T lymphocytes can use secretion of perforin (PFN) and granzyme B 
(GrB) to kill their target cells, why would they in addition have the potential to induce 
death receptor-mediated apoptosis? Virus-infected and tumorigenic cells have indeed 
been reported to be predominantly eliminated via rapid granule-mediated cell death. 
55;56 Death receptor-mediated cell death, in contrast, primarily has been described to 
be involved in eliminating autoreactive T cells and downsize immune responses after 
infection. 57-60 In chapter 4 another role of the death receptor pathway is described, 
namely, execution of human target cells by cytotoxic T cells if not all target cells have 
been destroyed by release of PFN/GrB. In addition the death receptor pathway has 
also been shown to be involved in CTL-induced non MHC-restricted target cell death 
(Chapter 6).  
Based on the results described in chapters 4 and 6, we hypothesize that the strength 
of interaction between target and effector cell determines the kinetics of target cell 
death and perhaps also the pathway of cell death. More speciﬁcally, we assume 
that weak effector-target interactions may be sufﬁcient to induce the death receptor 
pathway of apoptosis, but cannot or only marginally lead to the release of PFN/GrB. 
In Chapter 4 was shown that the T cell clone C6-2 slowly killed EBV-LCL derived 
from a patient with leukemia. The same CTL was previously shown to be capable 
of rapidly killing monocytes of the same patient, 61 indicating that the execution 
machinery of the T cell is intact. Since the EBV-LCL could be killed within 4 hrs by 
another CTL clone (HY-A1), the observed differences in kinetics of killing are also 
not caused by any defects in one of the apoptotic mechanisms of the target cell. 
Therefore, more likely they are caused by differences in effector-target interaction, 
for instance due to variant levels of peptide presentation by the HLA molecules on 
the different target cells. Probably, the Cw6-restricted CTL clones recognize minor 
antigens highly expressed on monocytes but poorly expressed on EBV-LCL from the 
patient resulting in a low avidity interaction between TCR and MHC/peptide complex. 
The low amounts of PFN that were released are assumed to be a consequence of 
this weak interaction, as well as the fact that target cell death was at least partially 
executed via the death receptor pathway (Chapter 4).
The results shown in Chapter 6 also support the hypothesis that low avidity effector-
target interactions only lead to death-receptor-induced apoptosis of target cells, while 
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strong effector-target interactions mainly induce PFN/GrB-induced target cell death. 
In addition to MHC-restricted target cell death, CD8+ T cells were demonstrated to be 
capable of killing target cells in a non MHC-restricted manner. For the latter mechanism 
of lysis the TCR was not involved, implying a low avidity effector-target interaction. 
This non MHC-restricted target cell death was demonstrated to be completely 
mediated via activation of the death receptor pathway in the target cell. In contrast, 
in case of a strong effector-target cell interaction, as involved in TCR-dependent 
MHC-restricted recognition of target cells, the same cytotoxic T cells used PFN/GrB 
release as the main execution mechanism to induce rapid target cell death.
Why weak effector-target interactions can lead to activation of the death receptor 
pathway, but not to the release of PFN and GrB remains largely unknown. A model 
has been proposed assuming that after ligand binding the TCR complex has to 
undergo a number of modiﬁcations, including clustering of receptors, tyrosine 
phosphorylation steps and SH2 interactions, before a signal can be transmitted. 62 
The requirement for these modiﬁcations results in a temporal lag between ligand 
binding and receptor signaling. At each step of this cascade the MHC/peptide-TCR 
complex may dissociate making it very unlikely that low-avidity MHC/peptide-TCR 
complexes can ever assemble the ﬁnal signaling complex resulting in release of 
PFN and granzymes. However, a sufﬁciently high density of low-afﬁnity MHC/peptide 
complexes can support the early steps of the process and lead to a distinct (partial) 
signaling pathway resulting in death-receptor-mediated apoptosis. 
This model is supported by some murine studies demonstrating that interaction of 
CTLs with target cells exogenously loaded with single-amino-acid variants of the 
optimal MHC-binding peptide resulted in Fas-mediated target cell death while PFN/
GrB-mediated cell lysis was absent. 63-65 When the same less-than-optimal peptides 
were endogenously processed, using a virus-based infection model, CTL-mediated 
cell death was completely absent. In Chapter 6 similar results were described 
showing that the HLA-A*0205 expressing cell line ALL-HP was not killed within 4 hrs 
by the HLA-A*0201-restricted T cell clone HA2.27 (Figure 6.1). Unpublished results 
of our group revealed that exogenous loading of this HLA-A*0205 positive cell line 
with high concentrations of HA-2 peptide resulted in rapid PFN/GrB-mediated cell 
death by CTL HA2.27. By artiﬁcially offering more speciﬁc MHC/peptide complexes 
to the TCR, the avidity of the MHC/peptide-TCR complex is apparently sufﬁciently 
enhanced to overcome a certain threshold of TCR triggering and making PFN/GrB 
release possible. In conclusion, small differences in avidity of MHC/peptide-TCR 
complexes can highly affect recognition by that speciﬁc TCR and determine which 
effector mechanisms can be used by the T cell.
From a physiological point of view it is not surprising that weak effector-target 
interactions could not lead to the release of PFN/GrB. Misdirected effector molecules 
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would cause a lot of damage to neighboring tissues. In the complex selection 
mechanism taking place in the thymus to delete potentially self-reactive T cells, it 
is important, however, that weak interactions can lead to death-receptor-mediated 
apoptosis. 
Overexpression of anti-apoptotic genes as a method to study the role of 
different apoptotic pathways
Enhancing the expression of FLIP has been demonstrated to be an effective method 
to block the death receptor pathway in different leukemic cell lines (Chapters 3 
and 4 of this thesis). PI-9 is considered to be an efﬁcient and selective inhibitor of 
Granzyme B. Retroviral introduction of PI-9, FLIP, or both constructs into a target cell 
would therefore provide an elegant approach to study all effector mechanisms of a 
CTL. However, in chapter 5 it was demonstrated that overexpression of PI-9 inhibited 
Fas-induced apoptosis. Apparently, proteins that are supposed to act speciﬁcally 
in a certain pathway may interfere in other pathways, which may lead to incorrect 
conclusions. 
Retroviral transfer of PI-9 can thus not be used to study CTL-induced PFN/GrB-
mediated target cell death. Alternative strategies to evaluate the role of PFN and 
GrB in CTL-mediated cytotoxicity may be measuring PFN/GrB release using ﬂow 
cytometry (as shown in chapter 4) or performing inhibition experiments using EGTA 
(chapter 6) or concanamycin A (CMA). The Ca2+-chelator EGTA efﬁciently inhibits 
all (Ca2+-dependent) secretion pathways in the T cell, 66 while CMA is an inhibitor of 
vacuolar type H+-ATPase that inhibits PFN-based cytotoxicity, mostly by accelerated 
degradation of PFN caused by an increase in the pH of lytic granules. 67
The inhibitory effect of PI-9 on Fas-induced cell death was much more pronounced in 
one of the two cell lines studied. We speculate that this may be caused by differential 
usage of Fas-cell death pathways by the two cell lines studied. In the earlier mentioned 
type I cells, Fas-induced apoptosis is completely dependent on the death-receptor 
pathway. In these cells the highest inhibition by PI-9 was observed. In type II cells in 
contrast, Fas-induced apoptosis is partly mediated via the mitochondrial pathway of 
apoptosis. Dependent on the site of interference of PI-9 in the apoptotic cascade, the 
inhibitory effect may differ between type I and II cell lines. This may also explain why 
this inhibitory effect was not observed by other groups that only studied one or two 
(type II) cell lines. 
Conclusion
In conclusion, the results described in this thesis demonstrate that apoptosis induction 
in leukemic cells after treatment with chemotherapy or (cellular) immunotherapy is very 
complex and frequently dependent on the target cell studied, and on the interaction 
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between target and effector cell. It was shown that G0 cells derived from patients with 
B-CLL compared to G0 cells from patients with acute leukemia responded differently 
to Ara-C treatment, which may be partially explained by the different mechanisms of 
action exerted by Ara-C. In this thesis the role of the death receptor pathway in both 
chemotherapy-induced and CTL-induced apoptosis of leukemic cells was unraveled 
in more detail, at least in the cell lines that were studied. Considering future strategies 
in the treatment of leukemia, it will be worthwhile to focus on the investigation 
and development of agents that restore normal or therapy-induced apoptosis in 
resistant leukemic cells. These agents should be combined with conventional 
treatment modalities. For B-CLL, already a number of agents are under investigation 
which target not only Bcl-2, but also other anti-apoptotic proteins in CLL cells. 
Other attractive targets are proteins that are common in multiple apoptotic pathways, 
for instance caspase-8. Defects in caspase-8 or other common caspases like caspase-
3 may cause multiple drug resistance and also cross resistance to immunotherapeutic 
interventions. Modulation or activation of these proteins will sensitize the leukemic 
cell simultaneously to all these forms of therapy.
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SAMENVATTING
Hematopoiese en leukemie
De normale aanmaak van bloedcellen, hematopoiese genaamd, vindt plaats in 
het beenmerg (BM). Hier bevinden zich hematopoietische stamcellen (HSC) die 
via verschillende differentiatiestappen uit kunnen rijpen tot verschillende types 
bloedcellen, zoals rode bloedcellen (erythrocyten), bloedplaatjes (thrombocyten) en 
veschillende soorten witte bloedcellen (leukocyten, o.a. lymfocyten en granulocyten). 
Rode bloedcellen zijn belangrijk voor het zuurstoftransport naar de weefsels, 
bloedplaatjes zijn betrokken bij de bloedstolling en witte bloedcellen spelen een 
belangrijke rol in de afweer tegen verschillende ziekteverwekkers.
Tijdens het differentiatieproces van onrijpe voorlopercellen naar rijpe witte bloedcellen 
kunnen er mutaties optreden, wat uiteindelijk kan leiden tot een ongeremde en 
ongecontroleerde groei van getransformeerde witte bloedcellen die niet meer verder 
kunnen uitrijpen. Deze populatie cellen hoopt zich op in het BM totdat op een gegeven 
moment het BM vol is en de maligne cellen in het bloed terechtkomen. Wanneer dit 
het geval is, spreekt men van leukemie. Door de ophoping van leukemiecellen in het 
BM wordt de aanmaak van normale bloedcellen verstoord, wat leidt tot symptomen 
als moeheid, bleekheid, blauwe plekken, bloedingen en infecties. Er bestaan 
verschillende vormen van leukemie, afhankelijk van in welke uitrijpingslijn en in welk 
stadium de transformatie tot leukemiecel heeft plaatsgevonden. De meest bekende 
vormen van leukemie zijn acute myeloide leukemie (AML), acute lymfatische leukemie 
(ALL), chronische myeloide leukemie (CML) en chronische lymfatische leukemie 
(CLL). 
Behandeling van leukemie
De behandeling van leukemie hangt erg af van het type leukemie. CLL komt vooral 
voor bij oudere mensen en heeft een relatief mild verloop. Vaak wordt pas in een 
later stadium van de ziekte begonnen met therapie, die dan meestal bestaat uit 
verschillende combinaties van chemotherapie en eventueel Rituximab. Rituximab is 
een antistof gericht tegen het CD20 molecuul dat speciﬁek op het membraan van 
B cellen, dus ook op B-CLL cellen, voorkomt, waardoor alleen B cellen door Rituximab 
vernietigd worden.
CML is een stamcelziekte die wordt veroorzaakt door een translocatie tussen 
chromosoom 9 en 22, waardoor een stukje van chromosoom 9 van plaats wisselt 
met een stukje van chromosoom 22. Zowel op chromosoom 9 als op chromosoom 
22 breekt het chromosoom midden in een gen. Op chromosoom 9 is dat het 
ABL-gen en op chromosoom 22 is dat het BCR-gen. Door de translocatie onstaat het 
fusiegen BCR-ABL op chromosoom 22, wat leidt tot de vorming van het fusie-eiwit 
BCR-ABL. Het BCR-ABL eiwit is verantwoordelijk voor de sterke groei en abnormale 
ontwikkeling van witte bloedcellen. Behandeling van CML in de chronische fase 
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is tegenwoordig speciﬁek gericht op remming van de tyrosine kinase activiteit van 
het BCR-ABL fusie-eiwit door middel van het geneesmiddel Imatinib. Door deze 
relatief nieuwe aanpak met Imatinib is de overlevingskans van patiënten met CML de 
laatste jaren ﬂink verbeterd (van 50% naar 90% overleving, 5 jaar na behandeling). 
Toch reageert een deel van de patiënten niet goed op deze behandeling (o.a. door 
resistentie tegen Imatinib). Bij het merendeel van deze patiënten gaat de CML 
uiteindelijk over van een chronische naar een acute fase, de zogenaamde CML in 
blastencrisis, die dan vervolgens als een acute leukemie behandeld wordt.
De behandeling van acute leukemie richt zich op het zo volledig mogelijk vernietigen 
van de leukemiecellen, voornamelijk met behulp van chemotherapie en bestraling. 
De meest effectieve  behandeling tegen acute leukemie (bij volwassenen) is hoge 
dosis chemotherapie en totale lichaamsbestraling gevolgd door allogene of autologe 
stamceltransplantatie (SCT), waarbij respectievelijk gebruik wordt gemaakt van 
stamcellen van een (gedeeltelijk) HLA-gematchte donor (vaak een broer of zus) 
of van de patiënt zelf. SCT is nodig om weer een normale bloedcelaanmaak op 
gang te brengen in deze patiënten van wie zowel de kwaadaardige als de normale 
hematopoiese vernietigd zijn (door de chemotherapie en de bestraling). Het voordeel 
van allogene SCT is dat naast het herstellen van de hematopoiese tevens een 
gunstig effect op de eventueel resterende leukemiecellen verkregen kan worden, 
het zogenaamde graft-versus-leukemia (GVL) effect. Dit GVL effect berust op 
de reactiviteit van de aanwezige T cellen in het transplantaat die nog resterende 
leukemiecellen van de patiënt kunnen herkennen en vernietigen. Met het doel om 
nogmaals een GVL effect te verkrijgen, worden soms na de allogene SCT opnieuw 
lymfocyten van dezelfde donor gegeven, de zogenaamde donor lymfocyten infusies 
(DLI).
Resistentie
Eén van de belangrijkste problemen in de behandeling van patiënten met acute 
leukemie is resistentie (aangeboren of verworven) van de leukemiecellen waardoor de 
therapie niet (meer) aanslaat. In eerste instantie reageren de meeste patiënten goed 
op inductie chemotherapie die gewoonlijk bestaat uit een combinatie van cytostatica 
zoals daunorubicine, vincristine, methotrexaat en cytarabine (Ara-C). In 70-80% 
van de patiënten leidt dit tot een complete remissie (er worden geen leukemiecellen 
meer gedetecteerd). Ondanks agressieve inductie- en consolidatietherapie treedt in 
50-60% van de patiënten een recidief van de ziekte op, waardoor de genezingskans 
van patiënten met AML of ALL klein is. De patiënten die na meer dan een jaar na 
diagnose recidiveren hebben een goede kans om in een tweede remissie te komen 
na behandeling met de originele inductietherapie, of een protocol van vergelijkbare 
intensiteit. 
Patiënten die nooit in complete remissie geraken of al snel een recidief krijgen 
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reageren meestal niet meer op verdere behandeling met dezelfde cytostatica als 
ze in eerste instantie hebben gekregen. Deze resistentie kan door verschillende 
mechanismen veroorzaakt worden, zoals het opreguleren door de leukemiecellen 
van bepaalde eiwitten, drug efﬂux pompen genaamd, waardoor de cytostatica weer 
naar buiten gepompt worden voordat ze de cel vernietigd hebben. Verder is de fase 
van de celcyclus waarin de leukemiecel zich bevindt op moment van blootstelling aan 
de chemotherapie belangrijk, omdat cellen in rust minder gevoelig zijn dan cellen die 
aan het delen zijn. Een andere oorzaak waardoor leukemiecellen resistent kunnen zijn 
tegen chemotherapie zijn defecten in de eiwitten die betrokken zijn in de cascade die 
uiteindelijk leidt tot apoptose van de leukemiecel. Dit laatste resistentiemechanisme 
is de directe aanleiding voor het in dit proefschrift beschreven onderzoek.
Apoptose en morfologie
Apoptose, of geprogrammeerde celdood, is een mechanisme om op een 
gecontroleerde manier ongewenste cellen uit het lichaam te verwijderen, in 
tegenstelling tot necrose, waarbij de cel plotseling dood gaat en de celinhoud vrij 
komt in het omringende weefsel wat leidt tot ongewenste ontstekingsreacties. 
Apoptose speelt een belangrijke rol tijdens de ontwikkeling van een embryo, 
maar is ook essentieel voor bijvoorbeeld  de opbouw van een goed functionerend 
immuunsysteem. Als het mechanisme van apoptose ontregeld raakt, wordt de balans 
tussen celdeling en celdood verstoort, wat kan leiden tot auto-immuunziektes, neuro-
degeneratieve aandoeningen en kanker.
Apoptose verloopt via een gereguleerd proces dat via een aantal stappen uiteindelijk 
leidt tot de dood van de cel. Tijdens het apoptoseproces zijn er verschillende fases 
te onderscheiden, waarbij de morfologie van de cel constant veranderd. Eerst krimpt 
de cel en krijgt het chromatine (DNA en eiwitten in de celkern) een compactere 
structuur. Tijdens deze fase gaat ook de symmetrie van de celmembraan verloren 
waardoor phosphatidylserine zichtbaar wordt op het celoppervlak. Vervolgens 
komen er uitstulpingen in het celmembraan waardoor de cel zijn ronde vorm verliest. 
In de volgende stappen condenseert het chromatine verder en vindt DNA fragmentatie 
plaats. Uiteindelijk splitst de cel zich in fragmenten die apoptotische lichaampjes 
worden genoemd. Deze celfragmenten worden door macrofagen opgeruimd zodat 
er geen ontstekingsreacties ontstaan.
Regulatie van apoptose door caspases
Het gehele apoptotische proces wordt gereguleerd door bepaalde eiwitten, de 
zogenaamde cysteine-afhankelijke aspartaat-speciﬁeke proteases, ofwel caspases. 
Caspases hebben zowel een rol in de inductie van apoptose (initiator caspases, zoals 
caspase-2, -8, -9 en -10) als in de executiefase van apoptose (caspase-3, -6 en -7). 
Caspases komen in de cel voor als inactieve procaspases. Na activatie wordt door 
middel van een aantal klievingsstappen een actief caspase gevormd bestaande uit 
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twee grote en twee kleine domeinen. Actieve caspases kunnen speciﬁek bepaalde 
substraten binden en knippen het doormidden na een aspartaat groep. Tot de 
caspasesubstraten behoren zowel apoptose-regulerende eiwitten als structurele 
eiwitten.
Intrinsieke en extrinsieke apoptoseroute
Caspases kunnen zowel via een intrinsieke als via een extrinsieke apoptoseroute 
geactiveerd worden. Deze routes worden schematisch beschreven in Figuur 7.1. 
In de intrinsieke route, ook wel mitochondriële route genoemd, wordt apoptose van 
binnen uit de target cel geïnitieerd. Deze route wordt geactiveerd als mitochondriën 
(celstructuren die zorgen voor de energievoorziening in de cel) doorlaatbaar worden 
onder invloed van bepaalde stressfactoren, waardoor pro-apoptotische eiwitten zoals 
cytochroom C in het cytoplasma terecht komen. Cytochroom C bindt vervolgens aan 
twee eiwitten: Apaf-1 en procaspase-9. In dit complex, een apoptosoom genaamd, 
wordt procaspase-9 geactiveerd. Caspase-9 kan op zijn beurt allerlei andere 
caspases activeren, waaronder de effector caspase-3, wat uiteindelijk resulteert in 
de dood van de cel.
Apoptose kan ook van buiten de target cel geïnduceerd worden (extrinsieke route) 
door binding van zogenaamde death liganden (bijvoorbeeld Fas ligand) aan death 
receptoren (bijvoorbeeld de Fas receptor) die aanwezig zijn op de celmembraan 
van de target cel. Death receptoren bestaan uit een gedeelte dat zich buiten de cel 
bevindt, een gedeelte dat door de celmembraan steekt en een gedeelte dat zich 
in de cel bevindt. Door de binding aan de buitenkant van de cel wordt de death-
receptor-geïnduceerde apoptose route, kortweg death-receptor route, in de target 
cel aangezet. De death liganden die voor de activatie van de death receptor route 
zorgen, bevinden zich o.a. op de celmembraan van cytotoxische T cellen. Na activatie 
worden drie death receptoren naar elkaar toe getrokken (trimerisatie). Hierdoor kan 
het eiwit FADD aan het intracellulaire domein van de death receptoren binden en 
wordt procaspase-8 aangetrokken. Samen vormen deze eiwitten het zogenaamde 
“death-inducing signaling complex” (DISC). In dit complex wordt procaspase-8 
geactiveerd. Actief caspase-8 kan vervolgens of direct caspase-3 activeren, of via 
een ander eiwit de mitochondriële route activeren. Beide routes leiden uiteindelijk tot 
apoptose van de target cel.
STUDIES UIT DIT PROEFSCHRIFT
Cytostatica (chemotherapie) en T lymphocyten afkomstig van de donor (cellulaire 
immunotherapie) maken leukemiecellen dood via inductie van apoptose. Afwijkingen 
in gemeenschappelijke apoptoseroutes zouden dus ongevoeligheid tegen beide 
vormen van therapie kunnen veroorzaken, zoals waargenomen wordt in sommige 
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patiënten. Andere patiënten zijn resistent tegen chemotherapie, maar reageren 
nog wel op DLI, wat aangeeft dat deze patiënten waarschijnlijk defecten hebben in 
chemotherapie-speciﬁeke routes. Het is slechts mogelijk om potentiële afwijkingen in 
apoptoseroutes in patiënten aan te tonen als er meer inzicht verkregen wordt in hoe 
normale functionele apoptoseroutes eruit zien. Alhoewel er wel algemene therapie-
geïnduceerde apoptoseroutes beschreven zijn (Figuur 7.1), zijn de werkelijke 
apoptoseroutes die door therapie aangezet worden vaak veel complexer dan in 
dit ﬁguur wordt weergegeven. In dit proefschrift wordt benadrukt hoe complex de 
apoptoseroutes zijn die in leukemiecellen worden geïnduceerd na behandeling met 
traditionele cytostatica of met cytotoxische T cellen (cellulaire immunotherapie). 
Bovendien worden verschillende tegenstrijdigheden die nog steeds bestaan op het 
gebied van apoptose belicht en verder uitgezocht.
Het paradoxale werkingsmechanisme van Ara-C
Om zichzelf te vermeerderen doorloopt een cel een bepaalde celcyclus, die bestaat 
uit verschillende fases. In de G1 (“gap 1”) fase vindt cytoplasmagroei plaats en 
bereidt de cel zich voor om zijn DNA te vermeerderen door bepaalde enzymen aan te 
maken. In de S (“synthese”) fase verdubbelt de cel zijn DNA zodat bij de uiteindelijke 
deling beide dochtercellen precies hetzelfde DNA mee krijgen. In de G2 (“gap 2”) fase 
controleert de cel of al het DNA inderdaad netjes gedupliceerd is en bereidt de cel 
zich voor op een celdeling. In de M (“mitose”) fase vindt de feitelijke celdeling plaats 
waardoor uiteindelijk twee identieke dochtercellen ontstaan. In de beide gap fases 
bevinden zich belangrijke controlepunten. Op deze momenten wordt besloten of de 
cel door kan gaan met zijn cyclus of in apoptose moet gaan als het niet verantwoord is 
om de deling verder door te zetten. Tijdens de G1 fase bestaat er ook de mogelijkheid 
voor de cel om in rust te gaan (G0-fase) en (voorlopig) niet meer door te gaan met 
prolifereren.
De meeste cytostatica induceren DNA schade en hebben alleen een effect op cellen 
die actief bezig zijn om hun DNA te vermeerderen en in deling te gaan, terwijl cellen 
in rust (G0) beschouwd worden als ongevoelig. Inbouw van Ara-C in het DNA, een 
proces dat speciﬁek plaatsvindt tijdens de S-fase van de celcyclus, wordt beschouwd 
als het belangrijkste werkingsmechanisme van Ara-C om proliferende cellen dood te 
maken. In hoofdstuk 2 beschrijven we de onverwachte bevinding van het vermogen 
van Ara-C om ook apoptose te induceren in rustende (meer dan 98% van de cellen 
zit in G0) primaire B cellen afkomstig van vier tot dan toe onbehandelde patiënten 
met chronische lymfatische B-cel leukemie (B-CLL). Experimenteel werd in deze 
B-CLL cellen na behandeling met Ara-C zowel expressie van phosphatidyl serine 
aan de buitenkant van de celmembraan als caspase-activatie, twee belangrijke 
eigenschappen van apoptose, aangetoond. Met behulp van celcyclus analyse in 
combinatie met lange termijn analyse van celdood met behulp van CFSE-gebaseerde 
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cytotoxiciteitsassays konden we bevestigen dat deze niet-prolifererende B-CLL cellen 
door Ara-C in de G0-fase van de celcyclus zijn gedood.
Aangezien remming van DNA synthese niet het werkingsmechanisme van Ara-C 
in deze G0-B-CLL cellen kan zijn geweest, moeten er andere cellulaire processen 
betrokken zijn. In deze studie hebben we aangetoond dat oplopende concentraties 
van deoxycytidine (dC), een structurele analoog van Ara-C en tevens de normale 
bouwsteen van zowel RNA als DNA synthese, zowel de vorming van Ara-CTP als 
Ara-C-geïnduceerde celdood van G0-B-CLL cellen remden. In tegenstelling tot DNA 
(repair) synthese welke nauwelijks detecteerbaar was, werd een onverwacht hoge 
RNA synthese gevonden in G0-B-CLL cellen. Deze RNA synthese werd voor 30% 
geremd door Ara-C, wat suggereert dat remming van RNA synthese een mogelijk 
werkingsmechanisme van Ara-C in rustende G0-B-CLL cellen is. B-CLL cellen 
worden gekenmerkt door hoge expressie niveaus van het eiwit B-cel lymphoma-2 
(Bcl-2), dat een langere overleving van deze maligne cellen veroorzaakt. In eerdere 
studies is reeds aangetoond dat verandering van de expressie levels van pro-of anti-
apoptotische eiwitten (met name de Bcl-2/Bax ratio) drug-geïnduceerde apoptose 
in B-CLL cellen kan initiëren. Daarom hebben we geanalyseerd of blootstelling aan 
Ara-C de eiwitniveaus van Bcl-2, Bax of Mcl-1 in B-CLL cellen veranderde. We vonden 
dat Mcl-1 expressie door Ara-C behandeling werd gedownreguleerd, wat een gevolg 
van de verminderde RNA synthese in deze cellen zou kunnen zijn. Concluderend 
kunnen we zeggen dat zowel de remming van RNA synthese als de downregulatie 
van het anti-apoptotische eiwit Mcl-1 kunnen bijdragen aan het werkingsmechanisme 
van Ara-C in G0-B-CLL cellen.
De rol van de death receptor route in chemotherapie-geïnduceerde apoptose
Naast het onderzoeken van de mechanismen die betrokken zijn bij chemotherapie-
geïnduceerde apoptose van rustende leukemiecellen, is het erg belangrijk om meer 
inzicht te verkrijgen in de apoptoseroutes die worden geïnduceerd door cytostatica 
in prolifererende leukemiecellen, aangezien resistentie van leukemiecellen 
tegen chemotherapie-geïnduceerde apoptose vaak optreedt in patiënten met 
acute leukemie. Eén van de tegenstrijdige onderwerpen op het gebied van 
chemotherapie-geïnduceerde apoptose is via welke route celdood geïnitieerd wordt. 
Behandeling met chemotherapie kan enerzijds leiden tot speciﬁeke activatie van 
de mitochondriële route, waarin uitscheiding van cytochroom C en caspase-9 een 
centrale rol spelen. Een alternatieve of misschien additionele route die tot apoptose 
leidt en die door chemotherapie aangezet zou kunnen worden is de “death receptor” 
route, waarin vorming van de DISC en caspase-8 (FLICE) activatie belangrijke 
gebeurtenissen zijn (zie Figuur 7.1). In hoofdstuk 3 van dit proefschrift beschrijven 
we de rol die de death receptor route speelt in chemotherapie-geïnduceerde apoptose 
van humane cellijnen die gemaakt zijn uit AML of ALL cellen van patiënten. De snelle 
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en aanzienlijke activatie van caspase-8 die we waarnamen na behandeling met de 
drug camptothecine, gecombineerd met de effectieve remming van chemotherapie-
geïnduceerde apoptose door commerciële caspase-8 remmers, wekten sterk de 
suggestie dat de death receptor route betrokken is in door cytostatica geïnduceerde 
apoptose. Deze veronderstelling werd onderzocht door Bcl-2 en FLICE inhibitory 
protein (FLIP) tot overexpressie te brengen in de cellijnen met behulp van retrovitrale 
constructen, en vervolgens de gevoeligheid van deze cellijnen voor verschillende 
cytostatica te testen. Verhoogde expressie van Bcl-2 werd gebruikt om speciﬁek 
de mitochondriële route te remmen, terwijl door middel van FLIP expressie juist 
selectief death receptor-geïnduceerde apoptose  kon worden geblokkeerd. 
FLIP overexpressie gaf geen remmend efect op camptothecine-geïnduceerde 
apoptose of caspase-8 activatie. Verhoogde Bcl-2 expressie, daarentegen, 
resulteerde in een bijna complete remming van camptothecine-gemedieerde celdood 
en caspase-8 activatie in alle drie cellijnen die we bestudeerd hebben. Deze resultaten 
geven aan dat chemotherapie-geïnduceerde apoptose in deze cellijnen compleet 
afhankelijk is van de mitochondriële route. Bovendien konden we uit deze studie 
opmaken dat caspase-8 blijkbaar een centrale rol speelt in zowel death receptor- als 
chemotherapie-geïnduceerde apoptose van maligne cellen afkomstig van patiënten 
met acute leukemie.
De rol van de death-receptor route in CTL-geïnduceerde target celdood
Er bestond niet alleen veel controversie over de rol van de death-receptor route 
in chemotherapie-geïnduceerde celdood, het was ook grotendeels onduidelijk 
in hoeverre deze route bijdraagt aan de eliminatie van leukemische cellen door 
cytotoxische T lymfocyten (CTL). In hoofdstuk 4 hebben we onderzocht of CTL naast 
het uitscheiden van perforine (PFN) en granzyme B (GrB) tevens gebruik maken van 
hun death receptors om tumorcellen dood te maken. In de meeste studies die tot 
nu toe gepubliceerd zijn, werd alleen naar hele snelle CTL-gemedieerde celdood 
gekeken die binnen 4 uur na interactie tussen de tumor cel en de T cel optreedt. Omdat 
death-receptor gemedieerde apoptose langzaam verloopt in verhouding tot PFN/GrB 
geïnduceerde celdood, hebben we in deze studie T celklonen gebruikt die hun target 
cellen of snel of langzaam om zeep hielpen (snelle en langzame kinetiek van “killen”), 
en vervolgens gedurende verschillende tijdsintervallen de celdood bestudeerd. 
Deze CTL klonen waren afkomstig uit een patiënt met CML en herkenden allemaal 
primaire CML cellen van de patiënt. Omdat voor dit soort studies niet voldoende 
leukemische cellen uit de patiënt verkregen kunnen worden, werden EBV-
getransformeerde B-cellen (EBV-LCL) van de patiënt als target cellen in onze 
studies gebruikt.  Om de rol van de death-receptor route te bestuderen, werd FLIP 
tot overexpressie gebracht in deze target cellen. Een CTL kloon die 50% van de 
target cellen doodde binnen 2 uur, bleek hoofdzakelijk te werken door PFN en GrB 
uit te scheiden. Er werd in dit geval ook geen remming door FLIP gevonden. De twee 
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T celklonen die een langzamere kinetiek van killen lieten zien, bleken in ieder geval 
gedeeltelijk hun target cellen via de death-receptor route dood te maken aangezien 
ongeveer 30% remming met FLIP werd gevonden. Hieruit konden we concluderen 
dat cytotoxische T cellen niet alleen uitstoot van hun granulae, maar ook de death-
receptor route gebruiken om hun target cellen te vernietigen.
PI-9 remt niet alleen GrB- maar ook Fas-geïnduceerde apoptose
Zoals het anti-apoptotische eiwit FLIP speciﬁek de death-receptor gemedieerde 
apoptoseroute blokkeert, zo was beschreven dat proteinase inhibitor-9 (PI-9) een 
specieke remmer is van GrB-geïnduceerde celdood en geen effect zou hebben op 
Fas-gemedieerde apoptose. Echter, in hoofdstuk 5 laten we zien dat PI-9 een minder 
speciﬁeke remmer is dan door andere onderzoekers werd gerapporteerd. Voor onze 
studie hebben we twee verschillende soorten cellijnen getransduceerd met retrovirale 
constructen die codeerden voor FLIP of PI-9.  Vervolgens werd zowel in de wildtype 
als in de FLIP- of PI-9 getransduceerde cellijnen de Fas-receptor geactiveerd met 
behulp van antilichamen die Fas-geïnduceerde apoptose veroorzaken. In beide 
types cellijnen konden we een aanzienlijke remming van Fas-geïnduceerde apoptose 
door verhoogde PI-9 expressie aantonen, hoewel de remming minder was dan in 
de cellijnen die FLIP tot overexpressie brachten. PI-9 expressie had geen effect op 
chemotherapie-geïnduceerde apoptose, wat aangeeft dat PI-9 interfereert met de 
death-receptor route maar niet met de mitochondriële route van apoptose. Uit deze 
resultaten kunnen we concluderen dat het niet mogelijk is om door middel van PI-9 
overexpressie speciﬁek GrB-geïnduceerde apoptose te bestuderen.
TCR-afhankelijke en onafhankelijke target celdood
Cytotoxische T cellen worden verondersteld hun target cellen selectief te doden, 
nadat ze met hun TCR speciﬁek een bepaald antigen in de context van het juiste HLA 
molecuul hebben herkend. In hoofdstuk 6 beschrijven we een ander mechanisme 
dat door T cellen gebruikt kan worden om target cellen te vernietigen. Dit mechanisme 
is niet afhankelijk van het juiste HLA en triggering van de TCR is geen vereiste.
In dit hoofdstuk laten we zien dat HLA-A2 gerestricteerde CTL klonen cytolytische 
activiteit vertoonden tegen target cellen die HLA-A2 tot expressie brachten, wat 
resulteerde in 40-70% lysis na 4 uur incubatie. Als gevolg van deze klassieke TCR-
MHC/peptide interactie, werd de TCR geactiveerd en vervolgens geïnternaliseerd, 
en produceerden de T cellen IFN-γ. Deze MHC-gerestricteerde target celdood werd 
compleet geremd door de T cellen te pre-incuberen met EGTA. EGTA vangt Ca2+ 
weg, waardoor alle Ca2+-afhankelijke processen, dus ook secretieroutes, geremd 
worden. Deze resultaten laten zien dat TCR/MHC-afhankelijke celdood compleet 
verloopt via uitscheiding van PFN en/of GrB, aangezien de death-receptor route niet 
afhankelijk is van calcium.
Naast de klasieke manier om hun target celllen te doden, lieten dezelfde 
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T celklonen ook nog MHC-onafhankelijke lysis van target cellen zien (10-30%) na 10 
uur incubatie. Dit mechanisme van T cel-gemedieerde celdood ging niet gepaard met 
TCR downregulatie en resulteerde bovendien niet in IFN-γ productie door de T cel. 
Verder toonden we aan dat deze lysis verliep via de death-receptor route, 
aangezien FLIP overexpressie een complete remming van deze lysis tot gevolg 
had. Een vergelijkbaar niet-MHC gerestricteerd eliminatiemechanisme wordt 
gebruikt om na aﬂoop van een immuunrespons als gevolg van bijvoorbeeld een 
infectie het overschot aan T cellen op te ruimen, zodat geen bijkomende schade 
optreedt. 
Conclusie
De resultaten die in dit proefschrift beschreven worden, benadrukken hoe complex 
de mechanismes zijn die geïnduceerd worden in leukemiecellen na behandeling met 
chemotherapie of cellulaire immunotherapie. Tevens wordt duidelijk dat het type cel dat 
bestudeerd wordt en de mate van interactie tussen target en effector cel grotendeels 
bepalen welke apoptoseroute aangezet worden. Zo zagen we bijvoorbeeld dat 
G0 cellen die afkomstig waren van een patiënt met B-CLL anders reageerden op 
behandeling met Ara-C dan G0 cellen van een patiënt met acute leukemie.
Verder werd in dit proefschrift de rol van de death-receptor route in zowel 
chemotherapie- als CTL-geïnduceerde apoptose van leukemiecellen verder 
opgehelderd, tenminste wat betreft de cellijnen die we bestudeerd hebben. 
Het is de moeite waard om toekomstige strategieën voor de behandeling van 
leukemie te richten op de ontwikkeling van nieuwe middelen die de normale of 
therapie-geïnduceerde apoptose kunnen herstellen in resistente leukemiecellen. 
Voor de behandeling van B-CLL valt bijvoorbeeld te denken aan remmers van anti-
apoptotische eiwitten zoals Bcl-2 en ook Mcl-1, waarvan al een aantal in ontwikkeling 
zijn. Deze middelen zouden dan gecombineerd moeten worden met conventionele 
behandelingsmethoden. Andere aantrekkelijke “target”eiwitten zijn eiwitten 
die betrokken zijn in meerdere apoptoseroutes, zoals bijvoorbeeld caspase-8. 
Defecten in caspase-8 of in andere gemeenschappelijke caspases zoals caspase-3 
zouden resistentie tegen verschillende cytostatica (multiple drug resistance) maar ook 
resistentie tegen immunotherapie kunnen veroorzaken. Wanneer juist een dergelijk 
eiwit gemoduleerd of geactiveerd zou  kunnen worden, zou de leukemiecel in één 
keer gevoelig kunnen worden voor al deze vormen van therapie.
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LIST OF ABBREVIATIONS
7-AAD  7-amino-actinomycin D
Ab  antibody
ALL  acute lymphoblastic leukemia
AML  acute myeloid leukemia
Apaf-1  apoptosis inducing factor-1
Ara-C  cytosine arabinoside; cytarabine
Ara-CTP Ara-C triphosphate
Bak  Bcl-2 antagonist/killer
Bax  Bcl-2 associated X protein
Bcl-2  B-cell lymphoma 2
Bid  BH3-interacting domain death agonist
BM  bone marrow
Camp  camptothecin
CARD  caspase recruitment domain
CFSE  carboxyﬂuorescein diacetate succinimidyl ester
CLL  chronic lymphocytic leukemia
CML  chronic myeloid leukemia
CML-AP CML-accelerated phase
CML-BP CML blast phase
CML-CP CML chronic phase
CR  complete remission
CTL  cytotoxic T lymphocyte
Dauno  daunorubicin
dC  deoxycytidine
DD  death domain
DED  death effector domain
DFS  disease free survival
DISC  death inducing signaling complex
DLI  donor lymphocyte infusion
DNA  deoxyribonucleic acid
EBV  Eppstein Barr virus
EGTA  ethylene glycol tetraacetic acid
E/T  effector/target
FADD  Fas-associated death domain
FasL  Fas ligand
FasR  Fas receptor
FLICE  FADD-like IL-1 converting enzyme
FLIP  FLICE-like inhibitory protein
GrB  granzyme B
List of Abbreviations
138
GVHD  graft versus host disease
GVL  graft versus leukemia
HLA  human leukocyte antigen
HSC  hematopoietic stem cell
IAP  inhibitor of apoptosis
IFN  interferon
Mcl-1  myeloid cell leukemia sequence 1
mHag  minor histocompatibility antigen
MHC  major histocompatibility complex
MRD  minimal residual disease
NGFR  nerve growth factor receptor
NK  natural killer
PFN  perforin
PI  propidium iodide
PI-9  proteinase inhibitor 9
PR  partial response
PS  phosphatidylserine
RNA  ribonucleic acid
siRNA  small interfering RNA
SCT  stem cell transplantation
TCR  T cell receptor
TNF  tumor necrosis factor
TRAIL  TNF-related apoptosis inducing ligand
z-VAD-FMK N-benzyloxycarbonyl-Val-Ala-Asp-ﬂuoromethylketone
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Hoera, het is zover, mijn proefschrift is af! En zoals zo vaak het geval is, bleken ook 
nu de laatste loodjes het zwaarst te wegen. Omdat dit boekje niet tot stand zou zijn 
gekomen zonder de hulp van anderen, maak ik graag van de gelegenheid gebruik 
om op deze plaats een aantal mensen te bedanken.
Allereerst alle collega’s van de Experimentele Hematologie: met zijn allen maken 
jullie de afdeling een erg plezierige plek om te werken! De analisten wil ik bedanken 
voor het zo goed laten functioneren van het lab en voor het draaien van alle beurten 
en achterwachten. Hier plukken wij maar al te vaak (en graag) de vruchten van! Dan 
wil ik nog graag in het bijzonder de analisten bedanken die mij geholpen hebben bij 
diverse experimenten, zoals Linda, Willy, Edith, Simone, Ellie, Renate, Menno en 
Michel.
Ook de dames van het secretariaat verdienen een compliment voor het verrichten 
van allerlei hand- en spandiensten, bedankt!
Dan de WP’ers: ik heb erg genoten van alle wetenschappelijke en niet-
wetenschappelijke discussies! Vooral de verschillende congresbezoeken (in het 
bijzonder de ASH) vond ik erg geslaagd. Nog even een speciaal woordje voor de 
AIO’s van “mijn lichting”, Lars, Geert en Marleen, ik vond het erg ﬁjn om zo nu en 
dan bij en mét jullie stoom af te blazen! Het schept toch een band als je in hetzelfde 
schuitje zit. Ik wens jullie nog veel succes met het afronden van jullie proefschrift 
(komt goed!) en heel veel plezier met jullie nieuwe banen.
Verder nog een speciaal woord van dank voor Linda Wammes. Linda, jij bent ruim 
een half jaar als stagiaire Biomedische Wetenschappen werkzaam geweest op mijn 
project en ik moet zeggen dat dit mij erg goed bevallen is! Behalve dat jouw data in 
een artikel zijn verwerkt, wat natuurlijk super is, vond ik het ook nog eens erg gezellig 
om met jou samen te werken. Je bent inmiddels zelf AIO en ik weet zeker dat jou een 
mooie carrière staat te wachten.
En dan Edith: jij bent misschien wel de meest sociale collega van de Hematologie. 
Ik ben dan ook erg blij dat je deze dag mijn paranimf wilt zijn! Zonder mopperen heb 
je diverse keren ’s avonds laat nog je ﬁets gepakt om op de onmogelijkste tijden 
chroom te gaan oogsten, ik heb me daar best schuldig over gevoeld! Verder hebben 
we samen menig uurtje doorgebracht in kamer 51 en omdat de experimenten altijd 
uitliepen (kwestie van plannen?) hebben we aardig wat LUMC maaltijden geproefd. 
Niet altijd even lekker, maar wel altijd erg gezellig!
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Nieuwe collega’s van de Immunologie, ook jullie wil ik hier graag nog even noemen. 
Ik ben erg blij dat ik na mijn tijd in Leiden opnieuw op een erg leuke plek ben terecht 
gekomen. De dames van het secretariaat, in het bijzonder Wendy en Marcia, wil ik 
bedanken voor het lay-outen van mijn boekje, top dat jullie dat voor me wilden doen. 
Tar van Os, hartelijk dank voor de hulp bij de voorkant van mijn proefschrift.
Dan ben ik nu aanbeland bij de mensen van buiten het lab. Vrienden van korfbal, ik 
vond het erg ﬁjn om ook tijdens de drukste periodes van mijn promotietijd mijn hoofd 
even lekker leeg te kunnen maken door een fanatieke training of wedstrijd. En nu.... 
is het tijd voor een feestje!
Margreet en Nieko, onze vriendschap vind ik erg bijzonder. Wij als “Friezen om utens” 
hebben toch op één of andere manier een speciale band. Ik hoop dat we ook in de 
toekomst met zijn vieren nog vele leuke dingen gaan doen. Margreet, ik ben er trots 
op dat jij deze dag als paranimf naast me wilt staan! 
Ook nog even een woord van dank richting Nieko’s vader: meneer De Jong, bedankt 
dat u in uw vrije tijd op spinnen hebt willen jagen, dankzij uw fotografeerkunst heb ik 
nu een mooi web op de voorkant!
Tot slot mijn familie, bedankt voor jullie interesse in mijn onderzoek en vooral ook 
voor alle leuke aﬂeiding naast het werk. Jullie snapten waarschijnlijk vaak niet waar 
ik nou precies mee bezig was en waarom het zo lang moest duren, maar toch bleven 
jullie geïnteresseerd vragen hoe het ging met de “studie”. 
Lieve heit en mem, aan jullie ben ik veel verschuldigd. Jullie hebben me altijd 
gemotiveerd om verder te studeren en het voelt zeker goed om te weten dat jullie 
altijd trots op me zullen zijn!
Als allerlaatste, lieve Oebele, het moet voor jou toch zo nu en dan echt niet zo leuk 
geweest zijn als ik al weer een weekend moest werken, maar toch heb je me altijd 
gesteund! Mijn dank daarvoor is niet in woorden uit te drukken, maar het ﬁjne is dat 
dat ook niet hoeft!
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